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Noma, also known as cancrum oris, is a gangrenous infection of the oral cavity, which causes 
widespread orofacial destruction. If untreated, noma has a reported 90% mortality rate within weeks 
after the onset of first symptoms. Noma progresses through distinct stages defined by the World 
Health Organisation (WHO); Stage 0: simple gingivitis; Stage 1: acute necrotizing gingivitis; Stage 
2: oedema; Stage 3: gangrene; Stage 4: scarring. Stage 5: sequelae. It is unclear how many patients 
with the early stages of noma will progress to the later stages of disease. Treatment in the early 
reversible stages with antibiotics, wound debridement and nutritional support greatly reduces 
morbidity and mortality.  Acute noma is most often reported in children aged between two and five 
years. Many patients who survive the acute stages of the disease suffer into adulthood with 
disfigurement and disability of varying degrees.  Noma is thought to be most prevalent in 
developing countries in Africa and Asia. Estimates for noma prevalence and incidence vary.  In 
1998, the WHO estimated an annual incidence of 140,000 cases of acute noma and 770,000 noma 
survivors living with sequelae.  Two Nigerian studies estimated the burden of disease ranged from 
seven cases per 1,000 children aged between one and 16 years (2003) to 6.4 per 1,000 children 
(2003).  A study from 2019 estimated the period prevalence of noma from 2010 to 2018 was 1.6 
per 100,000 population at risk in Nigeria.  These estimates are based on expert opinion, number of 
hospital admissions and retrospectively collected hospital-based data and it is unclear which stages 
of noma were included.  Risk factors for the disease include poor oral hygiene, malnutrition, co-
morbidities and low socioeconomic status. Despite its ancient history (reported by Hippocrates (460 
- 370 BC)), noma-related literature remains mainly confined to case reports and case series. 
 
By employing both qualitative and quantitative methods, we sought to examine the biopsychosocial 
features of noma, its epidemiology and treatment in northwest Nigeria in order to inform advocacy 
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and prevention efforts.   The three overarching objectives to fulfil this aim were to assess the 
distribution of noma among children in northwest Nigeria; identify factors associated with noma 
(including factors influencing health-seeking behaviour and risk factors for the development of 
noma) and gain an understanding of the biomedical and non-biomedical care provided to noma 
patients in this setting.  The knowledge gained through this thesis will support the assessment of 




We conducted a scoping literature review, three quantitative studies (risk factors, outcomes, 
prevalence) and two qualitative studies (language and beliefs and traditional healing practices) in 
northwest Nigeria.  Data were collected from patient caretakers at the Noma Children’s Hospital, 
hospital staff, children and traditional healers in villages within Sokoto and Kebbi States.  Data 
collection methods included quantitative surveys, oral screenings, anthropometric measurements, 
quality of life questionnaires, qualitative in-depth interviews and focus group discussions. 
Consenting adult respondents answered questionnaires and participated in interviews, and where 
applicable, data was collected from assenting children.  Quantitative analyses included descriptive 
statistics as well as univariable and multivariable risk factor analyses.  Qualitative data was 
manually coded and analysed thematically. 
 
Findings 
We included 74 cases (noma patients presenting at the hospital in the year preceding data collection) 
and 222 controls (both median age of five years (inter-quartile range 3, 15 years)) in the risk factor 
study.  Vaccination coverage for polio and measles was below 7% in both cases and controls. The 
multivariable analysis identified the child being fed pap every day (adjusted odds ratio (aOR) 9.8; 
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95% confidence interval (CI 1.5, 62.7) as a risk factor. The mother being the primary caretaker 
(aOR 0.08; CI 0.01, 0.5) and the caretaker being married (aOR 0.006; CI 0.0006, 0.5) were 
protective factors. 
 
Of the 37 patients with noma sequelae included in the outcomes study, 21 (56.8%) were male and 
22 (62.9%) were aged six years or older.  Fifteen patients (40.5%) had two to three surgeries. The 
most frequently used surgical procedure was a deltopectoral flap (n=16 patients; 43.2%). Trismus 
was released in 12 patients (32.4%), of these; none had a normal mouth opening at the follow-up 
visit. Despite this finding, all respondents reported that the surgery had improved their quality of 
life. 
 
In the cross-sectional study assessing the prevalence of all stages of noma, we included 3,499 
households and 7,122 children aged <15 years; 4,239 (59.8%) were aged 0 to 5 years. Simple 
gingivitis was identified in 3.1% (n=181; CI 2.6-3.8), acute necrotizing gingivitis in 0.1% (n=10; 
CI 0.1-0.3), and oedema in 0.05% (n=3; CI 0.02-0.2).  No cases of late-stage noma were detected. 
 
Naming of the disease differed between caretakers and healthcare workers in the language and 
beliefs study.  Beliefs about the causes of noma were varied (spirits, animals, insects, previous 
infections).  Noma patient caretakers spoke of the mental health strain due to stigmatization as a 
key issue.  Difficulty in accessing care was evident.  A lack of trust in the health system was 
mentioned as a barrier to care.  
 
Traditional healers offered specialised forms of care for specific conditions and referral guidance.  
They viewed the stages of noma as different conditions with individualised remedies and were 




Social conditions and childhood feeding practices are associated with the occurrence of noma in 
northwest Nigeria.  This thesis has shown that following their last surgical intervention, noma 
patients do experience some improvements in their quality of life, but continue to face functional 
challenges that inhibit their daily life. We found many, widely distributed, early-stage noma cases 
in northwest Nigeria indicating a large population at risk of progressing to the later stages of disease.  
Caretaker and practitioner perspectives may enlighten efforts to improve case finding, and to 
understand barriers to accessing health care.  Differences in disease naming illustrated the 
difference in beliefs about the disease.  Traditional healers could play a crucial role in the early 
detection of noma and the health-seeking decision-making process of patients. Intervention 
programmes should include traditional healers through training and referral partnerships.  
 
In conclusion, this thesis provides a unique view of the biopsychosocial features, epidemiology and 
treatment options for noma in northwest Nigeria.   Noma is a disease, which is indicative of a weak 
health system and socio-economic environments of extreme deprivation.  Intervention programmes 
should include widespread health system improvements that could address a host of risk factors for 
noma, and simultaneously other childhood diseases.  These include increasing access to quality 
health care (including vaccinations), ensuring effective referral mechanisms, predominantly in rural 
areas, and the creation of a robust surveillance network.  Health financing initiatives would need to 
be paired with these improvements.  Nutritional programs aimed at caretakers of young children 
and community-based oral health initiatives could be effective mechanisms to curb the number of 
noma cases. Awareness-building initiatives targeting healthcare workers and community members 




The combined findings of this thesis highlight the neglected nature of noma and make a strong case 
for placing noma on the WHO neglected tropical diseases list.  This initiative could foster awareness 
among policy-makers and governments and direct much needed funding to facilitate further 






Thank you to my mentor Annick who took me under her wing from thousands of kilometres away, 
and since that one e-mail exchange in 2016, has completely transformed my life. This thesis is as 
much yours as it is mine. You have taught me to be patient, resilient and hardworking. I will forever 
be grateful for the opportunities you have granted to me.  Thank you for showing me compassion 
during the difficult times, and for always demanding the best from me. I will always look up to you 
and will cherish the lessons you have taught me.   
 
Thank you Ushma for being willing to take on a topic that very few people know about.  Thank you 
for your input, I have enjoyed our talks and your guidance.  
 
To Mary-Ann who fought against tough odds to get this PhD off the ground, thank you for your 
belief in me as a researcher, and in noma as a worthwhile topic for the University of Cape Town 
(UCT) to explore. 
 
Thank you to Eleanor Conner for proofreading and editing the thesis, for welcoming me into your 
family and helping me through this process.  
 
Thank you to Amanda Edwards for your support and friendship throughout the years and for 
offering your guidance on this thesis, your input was invaluable. 
 
I would like to thank all of the respondents, the noma patients, noma caretakers, hospital staff and 
traditional healers who agreed to be a part of these studies.  Thank you for welcoming us into your 
homes.  Your shared insights and knowledge have been vital in helping us better understand noma.  
vii 
 
Thank you to Médecins Sans Frontières (MSF), for having a bold dream, and for unrelentingly 
trying to make things better for people in difficult conditions. Your support for these research 
projects and the noma patients is abundant and I feel extremely blessed to have worked for such a 
strong and caring organisation.  Funding for all data collection and dissemination came from MSF.  
Without this wonderful organization, none of this work would have been possible. A special thank 
you to Karla Bil and Cono Ariti for guiding me along this journey. To the MSF Noma Team, Mani, 
Prosper, Moses, Ponman, Mr Sam, Nura, Vera, Betty, Alex, Allen, Ruth and Michael you made 
every day enjoyable and I am so thankful to you for the kindness, care and respect you show the 
patients.  
 
A special thank you to Modupe Juliana Oyemakinde whose kindness and tenacity made the projects 
included in this thesis a success, I will always treasure our special friendship.  A heartfelt thank you 
to the co-authors and the study team for all their hard work and dedication to these projects.  I am 
grateful to have had the chance to meet and work with you, and now call you friends: Amina 
Abubakar, Linda Torhee, Victoria Agboarumi, Hassana Abdullahi, Christiana Abuka, Jiya Hassan 
Abdulmalite, Hussaina Bala, Paschal Aneke, Christiana Peter, Betty Nwokocha, Aliyu Muhammad, 
Aisha Abubakar, Maryam Abdulmu-min Imam, Sarah John, Gladys Simon, Buhari Ahmed, 
Maryam Adeola, Maryam Suleiman, Emmanuel Ameh, Nafisa Abubakar, Victoria Egba, Angela 
Udie, Adaeze Ihechi Anyanwu,Eunice Yakuba, Shafaatu Muhammad Bala, Hussiena Mohammed, 
Farida Ahmed, Ryan Winters, Dr Taiwo and Dave Shaye.  Thank you to Wendy Smith for your 
help sourcing articles for the literature review.  To Dr Ade and Dr Shafiu, thank you for always 
being interested in the research projects and for operating on all the cleft patients we found during 




Thank you to the funders who supported the dissemination of these findings.  Funding for 
attendance and presentation at the European Congress on Tropical Medicine and International 
Health came from the UCT Travel Grant and the MSF Travel Grant.    UCT provided funding for 
the student through the Doctoral Research Scholarship and the VC Scholarship.  
 
This thesis is dedicated to my family.  Thank you to my husband Paul for always being interested 
in my work and for understanding my long absences, thank you for making me smile each day. 
Thank you to my mum who has, throughout my life, been a strong source of support, who taught 
me to be compassionate and to always have a dream to work towards.  To the baby we lost during 
this process, you are with me each day. To my dad who would have so enjoyed being a part of this 






This thesis is presented in fulfilment of the requirements for the degree of Doctor of Philosophy in 
the Division of Public Health Medicine, School of Public Health and Family Medicine, Faculty of 
Health Sciences, University of Cape Town.  The work included in this thesis is original research 
and has not, in whole or in part, been submitted for another degree at this or any other university. 
The contents of this thesis are entirely the work of the candidate, or, in the case of multi-authored 
published papers, constitutes work for which the candidate was the lead author. This thesis includes 
published manuscripts, as per general provision 6.7 in the General Rules for the Degree of Doctor 
of Philosophy of the University of Cape Town.  
 
I confirm that I have been granted permission by the University of Cape Town’s Doctoral Degrees 
Board to include the following publications in my PhD thesis, and where co-authorships are 
involved, my co-authors have agreed that I may include the publications.  The following 
manuscripts are included in the thesis and are presented as self-contained chapters in the following 
order: 
 
1. Language and beliefs in relation to noma: a qualitative study, northwest Nigeria. Farley E, 
Lenglet A, Abubakar A, Bil K, Fotso A, Oluyide B, Tirima S, Mehta U, Stringer B.  
Published in PLoS Neglected Tropical Diseases in 2020. 
https://doi.org/10.1371/journal.pntd.00067972 
 
2. Risk factors for diagnosed noma in northwest Nigeria: A case-control study, 2017. Farley 
E, Lenglet A, Ariti C, Jiya NM, Adetunji AS, van der Kam S, Bil K.  




3. ‘I treat it but I don’t know what this disease is’: a qualitative study on noma (cancrum 
oris) and traditional healing in northwest Nigeria. Farley E, Bala HM, Lenglet A, Mehta 
U, Abubakar N, Samuel J, de Jong A, Bil K, Oluyide B, Fotso A, Stringer B, Cuesta JG, 
Venables E. 
 Published in International Health in 2019. https://doi.org/10.1093/inthealth/ihz066 
 
4. Outcomes at 18 months of 37 noma (cancrum oris) cases surgically treated at the Noma 
Children’s Hospital, Sokoto, Nigeria. Farley E, Amirtharajah M, Winters R,  Taiwo A, 
Oyemakinde M, Fotso A, Torhee L, Mehta U, Bil K, Lenglet A.  
 Published in Transactions of the Royal Society of Tropical Medicine and Hygiene in 
2020. https://doi:10.1093/trstmh/traa061 
 
5. Prevalence of noma in northwest Nigeria: cross -sectional study. Farley E, Juliana O, 
Schuurmans J, Ariti C, Saleh F, Uzoigwe G, Bil K, Oluyide B, Fotso A, Amirtharajah M, 
Vynke J, Brechard R, Adetunji A,  Ritmeijer K, van der Kam S, Baratti-Mayer D, Mehta 
U, Isah S, Ihekweazu C, Lenglet A. 
Published in BMJ Global Health in 2020. https://doi:10.1136/bmjgh-2019-002141 
 
All analyses are based on data collected as part of ongoing MSF operational research on noma. The 
candidate was employed as an epidemiologist with MSF working on this project from 2017 (and is 
still working in this role for the organisation).  The PhD candidate, in consultation with her 
supervisors, developed the independent concepts for the projects presented in this PhD theses. The 
candidate was the lead author on all protocols, led data collection teams in Nigeria, prepared the 
datasets for analysis, conducted all analyses, and was the lead author of the manuscripts.  Co-
authors reviewed and approved the manuscripts and the PhD candidate reviewed co-author 
xi 
comments and integrated them into the manuscripts prior to submission.  The contribution of the 
candidate to each manuscript is outlined at the start of each chapter. 
The candidate had three supervisors, two from UCT (primary UCT supervisor Dr Ushma Mehta, 
UCT co-supervisor Associate Professor Mary-Ann Davies) and an MSF supervisor (Annick 
Lenglet).  Dr Mehta provided oversight of the UCT PhD process and critical input on the overall 
design of the thesis.  Dr Mehta worked closely with the candidate and provided critical review on 
the introductory, literature review, risk factors and concluding chapters.  Dr Mehta is a co-author 
for the language and beliefs, outcomes, traditional healing and prevalence manuscripts.  Associate 
Professor Davies provided oversight of the UCT PhD process, critical input on the overall design 
of the thesis and on the introductory, literature review and concluding chapters as well as critical 
review of all the manuscripts with a particular focus on the prevalence and outcomes chapters.  Ms 
Lenglet played a critical role in all aspects of the thesis, from the protocol development for the 
individual MSF studies, through the implementation phase (with in the field support), and provided 
continual input on the analysis and write-up of each of the chapters. Ms Lenglet provided critical 
review on the introductory, literature review and concluding chapters and is a co-author on all 
publications.  
The candidate’s primary supervisor has confirmed to the University of Cape Town Doctoral 
Degrees Board that the included papers all overwhelmingly reflect the candidate’s own scientific 
work. 




List of Abbreviations 




American society of anaesthesiologists 
Body mass index  
Caretaker 
CI 95% confidence interval 
cm Centimetre 
DEFF Design effect  
ERB Ethical review board  
FGD Focus group discussions  
GAM Global acute malnutrition 
Hb Haemoglobin 
HIV Human immunodeficiency virus 
IDI In-depth interviews  
IQR Interquartile ranges 
Kg Kilogram 
MSF Médecins Sans Frontières 
MUAC Mid-upper arm circumference  




Moderate acute malnutrition 
Not applicable 
Neglected tropical disease 








Preferred reporting items for systematic reviews and meta-analyses 
SAM Severe acute malnutrition 
SD Standard deviation  






University of Cape Town 
Usmanu Danfodiyo University Teaching Hospital 
United States dollars 
WHZ Weight-for-height Z score 





Table of Contents 
 





List of Abbreviations xii 
List of Figures xx  
List of Tables xxii  
List of Appendices xxiv 
 
 
Chapter 1: Introduction 1 
1.1 Background  1 
1.2 Rationale  4 
1.3 Aims and objectives 5  
 1.3.1 Aim 5 
 1.3.2 Specific objectives 5  
1.4 Conceptual framework 5  
1.5 Overall structure of the thesis 6  
1.6 Data source 9  




Chapter 2: Scoping literature review 14 
2.1 Methods  14  
 2.1.1 Databases searched 15  
 2.1.2 Searching methods utilized 15  
 2.1.3 Eligibility criteria 15  
 2.1.4 Search terms 15  
 2.1.5 Data extraction 16  
 2.1.6 Analysis 16  
 2.1.7 Included articles 16  
2.2 History of noma 17  
xv 
 
2.3 Clinical progression 24  
2.4 Aetiology 25 
2.5 Treatment 29  
 2.5.1 Acute phase treatment (Stages 0 to 4) 29 
 2.5.2 Chronic phase treatment (Stage 5) 30 
2.6 Mortality 31 
2.7 Epidemiology 32 
2.8 Risk factors 39 
2.9 Gaps in the literature 46 
2.10 Contextualizing the thesis 47 
 2.10.1 Nigeria overview 47 
 2.10.2 Nigerian health system 50 
 2.10.3 Noma in Nigeria 51 
2.11 Limitations 52 




Chapter 3: Language and beliefs 54 
3.1 Abstract  55 
 3.1.1 Background 55 
 3.1.2 Methods 55 
 3.1.3 Results 56 
 3.1.4 Conclusion 56 
3.2 Introduction 56 
3.3 Methods  57 
 3.3.1 Setting 57 
 3.3.2 Study design 58 
 3.3.3 Recruitment and sampling 58 
 3.3.4 Data collection 59 
 3.3.5 Data validation and analysis 59 
 3.3.6 Ethics 60 
3.4 Results  60 
 3.4.1 Naming noma 66 
 3.4.2 Beliefs and explanations 66 
 3.4.3 Risks and consequences: access to health care 67 




3.5 Discussion 72 
 3.5.1 What's in a name? 72  
 3.5.2 Explanations for noma 73 




Chapter 4: Risk factors 78 
4.1 Abstract  79  
 4.1.1 Background 79 
 4.1.2 Methods 79 
 4.1.3 Results 79 
 4.1.4 Conclusion 80 
4.2 Introduction 80 
4.3 Methods  81 
 4.3.1 Setting 81 
 4.3.2 Study population 81 
 4.3.3 Sample size 82 
 4.3.4 Data collection 82 
 4.3.5 Data analysis 83 
 4.3.6 Ethics 84 
4.4 Results  84 
 4.4.1 General findings 84 
 4.4.2 Risk factor analysis 85 




Chapter 5: Outcomes at 18 months after surgery of patients  96 
  treated at NCH 
5.1 Abstract  98 
 5.1.1 Background 98 
 5.1.2 Methods 98 
 5.1.3 Results 98 
 5.1.4 Conclusion 99 





5.3 Methods  101 
 5.3.1 Study setting 101 
 5.3.2 Data collection 101 
  5.3.2.1 Routine data 102 
  5.3.2.2 Follow-up data 102  
 5.3.3 Data analysis 105 
  5.3.3.1 Data analysis routine data 105 
  5.3.3.2 Data analysis follow-up 106 
 5.3.4 Ethics 106 
5.4 Results  106 
 5.4.1 Demographic information of enrolled patients 106 
 5.4.2 NOITULP classification on admission 107 
 5.4.3 Surgical procedures 107 
 5.4.4 Anaesthesia information 112 
 5.4.5 Nutritional status 112 
 5.4.6 Trismus 113 
 5.4.7 Quality of life at follow-up 113 




Chapter 6: Noma and traditional healing 121 
6.1 Abstract  123 
 6.1.1 Background 123 
 6.1.2 Methods 123 
 6.1.3 Results 123 
 6.1.4 Conclusion 123 
6.2 Introduction 124 
6.3 Methods  126 
 6.3.1 Setting 126 
 6.3.2 Study design 126 
 6.3.3 Recruitment and sampling 126 
 6.3.4 Data collection 127 
 6.3.5 Data analysis 128 






6.4 Results  128 
 6.4.1 The role and experiences of traditional healers in Sokoto,  129 
  northwest Nigeria  
 6.4.2 Relationship dynamics between caretakers and traditional healers 130 
 6.4.3 Knowledge and perceptions of noma and health care practices for 132 
  the disease 




Chapter 7: Prevalence of noma stages 141 
7.1 Abstract  143 
 7.1.1 Background 143 
 7.1.2 Methods 143 
 7.1.3 Results 143 
 7.1.4 Conclusion 144 
7.2 Introduction 144 
7.3 Methods  146 
 7.3.1 Study design and setting 146 
 7.3.2 Sampling 146 
 7.3.3 Study participants 148  
 7.3.4 Data collection 149 
 7.3.5 Statistical analysis 150 
 7.3.6 Ethics 152  
7.4 Results  152 
 7.4.1 Prevalence 155 
 7.4.2 Factors associated with noma 155  




Chapter 8: Discussion and recommendations 175  
8.1 Synopsis and findings 175  
8.2 Noma:  an invisible and neglected disease 179 






8.4 Recommendations for practice 185 
 8.4.1 Health system strengthening 185 
  8.4.1.1 Access to care 185 
  8.4.1.2 Preventative activities 186 
  8.4.1.3 Surveillance 187 
 8.4.2 Training initiatives 188 
 8.4.2.1 Health care worker training 189  
  8.4.2.2 Community-based awareness raising and training 189 
 8.4.3 Single noma classification system 191  
8.5 Recommendations for further research 192 
 8.5.1 Distribution and burden of noma 192 
 8.5.2 Progression to later stage noma and death 193 
 8.5.3 Knowledge, attitudes and perceptions of health care workers 195 
 8.5.4 Economic evaluation 195 
 8.5.5 Quality of life scale in Hausa 196 
 8.6 Conclusion 196 
 




List of Figures 
 
Chapter 1  
Figure 1.1 Insert map of Africa indicating Nigeria (green).  Larger map of 3 
 Nigeria showing Sokoto and Kebbi States northwest Nigeria 
 (orange) and NCH (red circle) 
Figure 1.2 Conceptual framework 7 
 
 
Chapter 2  
Figure 2.1 Flow diagram of databases searched and articles included in the noma 18 
 scoping review 
Figure 2.2 Sketch of noma patient (4 years old), 1892 [63] 20  
Figure 2.3 Postmortem sketch of noma patient, 1872 [65] 21  
Figure 2.4 Noma patient, 3 years old, admitted 16th May, died 20th May 1885 [72] 22  
Figure 2.5 Noma patient, lived for only 6 days after admission to hospital,  23 
 1887 [72]   
Figure 2.6 Number and geographical distribution of case reports and case series  36  
 in1800's included in the literature review 
Figure 2.7 Number and geographical distribution of case reports and case series  37  
 in the 1900's included in the literature review 
Figure 2.8 Number and geographical distribution of case reports and case series 38  
 in the 2000's included in the literature review 




Chapter 3  
Figure 3.1 Analytical framework, lack of access to care 71  










Figure 5.1 Fractional loss of anatomical unit at admission for study cohort 109 
 (n=37) 
Figure 5.2 Trismus classification at admission for study cohort (mm = mouth 110 




Chapter 7  
Figure 7.1 Clusters where data was collected (pale grey dots) within Sokoto and  147  




Chapter 8  
Figure 8.1 Example pathways to care for noma patients in northwest Nigeria 178 
Figure 8.2 Invisible noma; depiction of the levels of invisibility of noma as 180 






List of Tables 
 
Chapter 1  
Table 1.1 Objectives met in each chapter of the thesis 10  
 
Chapter 2  
Table 2.1 Microorganisms found in the oral flora of noma patients by year 27 
Table 2.2 Mortality reported in included studies 33 
Table 2.3 Risk factors for noma identified in primary research 40 
 
Chapter 3  
Table 3.1 Names used by caretakers and staff to describe noma 61 
Table 3.2 Naming and explanations of noma with illustrative quotes 62 
Table 3.3 Risks and consequences of noma with illustrative quotes 64 
 
Chapter 4  
Table 4.1 Sociodemographic characteristics of cases and controls (p-values 86 
 from chi-squared, t-test or kwallis) 
Table 4.2 Univariable and multivariable risk factors for being a noma case  88 
 from conditional logistic regression 
 
Chapter 5  
Table 5.1 ASA Classification System 103 
Table 5.2 NOITULP Scale - Classification for noma [8] (nose, outer lining,  104 
 inner lining, trismus, upper lip, lower lip, particularities)  




Table 5.4 Surgical procedures performed on study cohort, 37 patients 111  
Table 5.5 Mouth opening categories on admission and follow-up by age group 114 
Table 5.6 Self-reported quality of life assessment at long-term follow-up 115 
 
 
Chapter 7  
Table 7.1 Demographic characteristics of households in the noma prevalence 153 
 survey population 
Table 7.2 Demographic characteristics of children in the noma prevalence survey 154 
 population 
Table 7.3 Noma stage and malnutrition prevalence (overall and by age groups) 156 
Table 7.4 Univariable analysis for Stage 1 and 2 noma 157 
Table 7.5 Univariable and multivariable analysis of associations with any 160 
 noma cases (Stage 0-5), 0-5 years  
Table 7.6 Univariable and multivariable analysis of associations with any 164 









List of Appendices 
Appendix 1 MSF documents 228 
Appendix 1.1 Letter of support from MSF 228  
Appendix 1.2 Data sharing agreement with MSF 229 
 
Appendix 2 Ethical Approvals 232 
Appendix 2.1 UCT ERB ethical approval 232 
Appendix 2.2 Risk factors and language and beliefs study ethical approvals 233 
 2.2.1 UDUTH ethical approval – risk factors and language 233 
  and beliefs study 
 2.2.2 MSF ethical approval – risk factors and language and 234 
  beliefs study 
 2.2.3 Kebbi ethical approval – risk factors and language and 235 
  beliefs study 
 2.2.4 Sokoto ethical approval – risk factors and language and 236 
  beliefs study 
Appendix 2.3 Traditional healer study ethical approvals 237 
 2.3.1 UDUTH ethical approval – traditional healer study 237 
 2.3.2 MSF ethical approval – traditional healer study 238 
 2.3.3 Sokoto ethical approval – traditional healer study 239 
Appendix 2.4 Outcomes ethical approvals 240 
 2.4.1 UDUTH ethical approval – outcome study 240 
 2.4.2 MSF ethical approval – outcome study 241 
 2.4.3 Kebbi ethical approval – outcome study 242 




Appendix 2.5 Prevalence study ethical approvals 245 
 2.5.1 UDUTH ethical approval – prevalence study 245 
 2.5.2 MSF ethical approval – prevalence study 246 
 2.5.3 Kebbi ethical approval – prevalence study 247 
 2.5.4 Sokoto ethical approval – prevalence study 248 
  
Appendix 3 Scoping literature review documents 249  
Appendix 3.1  PRISMA checklist for scoping literature review 249 
Appendix 3.2 Scoping literature review data extraction tool 252 
 
Appendix 4  WHO classified noma stages 254 
  
Appendix 5  Published manuscripts 255 
Appendix 5.1 Language and beliefs study manuscript 255  
Appendix 5.2 Risk factor manuscript 270 
Appendix 5.3 Outcomes manuscript 281 
Appendix 5.4 Traditional healer study manuscript 289 
Appendix 5.5 Prevalence manuscript 297 
 
Appendix 6  Questionnaires or question guides 312 
Appendix 6.1 Language and beliefs question guides 312  
 6.1.1 In-depth interview guide 312 
 6.1.2 Focus group discussion question guide 314 
Appendix 6.2 Risk factor questionnaire 316 





Appendix 6.4 Traditional healer study question guides 330 
 6.4.1 Interview guide caretakers 330 
 6.4.2 Interview guide traditional healers 334 
Appendix 6.5 Prevalence questionnaire 337 
 
Appendix 7  Informed consent and assent forms 342  
Appendix 7.1 Language and beliefs informed consent forms 342  
 7.1.1 Focus group discussion informed consent forms 342  
 7.1.2 In-depth interview informed consent form 348 
Appendix 7.2 Risk factors informed consent forms 353 
 7.2.1 Cases informed consent form 353 
 7.2.2 Controls informed consent form 360 
Appendix 7.3 Outcomes informed consent and assent forms 367 
 7.3.1 Information sheet and informed consent for retrospective 367 
  outcome measurement 
 7.3.2 Assent form for any Under 18's 373  
Appendix 7.4 Traditional healer study informed consent forms 383  
 7.4.1 Information sheet and informed consent - caretakers 383 
 7.4.2 Information sheet and informed consent - traditional healers 390 
Appendix 7.5 Prevalence informed consent and assent forms 397 
 7.5.1 Information sheet and informed consent 397 
 7.5.2 Information sheet and verbal assent for child study participants 404  
  from 8 to 15 years of age (following informed 






Chapter 1  Introduction 
1.1  Background 
Noma, also known as cancrum oris is a gangrenous infection of the oral cavity which causes 
rapid, widespread orofacial destruction [1].  If untreated, death usually occurs within weeks 
after the onset of first symptoms [1, 2].  Treatment with antibiotics, wound debridement, and 
nutritional support in the early reversible stages of the disease greatly reduces mortality and 
morbidity [2].  Noma occurs mainly in children aged between two and five years [1].  Those 
who survive often have severe facial disfigurements and multiple functional impairments 
including difficulties eating, seeing, and breathing, contributing towards stigmatization [2].  
For those who survive the acute stages of infection, the defect heals with contractures, resulting 
in various degrees of disfigurement that change with time as the child grows and teeth erupt.  
Extensive reconstructive surgery can provide substantial cosmetic improvement and assist with 
regaining functionality, although long-term functional benefits may be limited [3–6]. 
 
Noma is a biological indicator of extreme poverty, severe malnutrition, unsafe drinking water, 
poor sanitation, poor oral hygiene practices, high infant mortality, limited access to quality 
health care, low childhood vaccination rates [2] and comorbidities such as measles [7, 8] and 
human immunodeficiency virus (HIV) [9–18].  
 
In 1998, the World Health Organisation (WHO) estimated that 140,000 new cases of noma 
occur each year globally and that 770,000 patients were living with noma sequelae at that time 
[19].  Noma is most prevalent in low socioeconomic settings [2].  The majority of cases are 
currently reported in Africa [3, 7, 16, 18, 20–23] and Asia [21, 24–32].  However, over the past 
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15 years, there have been sporadic reports of cases originating and being treated in Turkey [33], 
Afghanistan [34], Italy [35], the United Kingdom [36] and the United States [11]. 
 
Many of the noma cases reported in the 1900’s and 2000’s were from Nigeria [7, 23, 25, 37–
43].  The Noma Children’s Hospital (NCH) in Sokoto, northwest Nigeria (Figure 1.1) is run 
by the Nigerian Ministry of Health and has been providing treatment for noma patients for 
many years.  Since 2014, Médecins Sans Frontières (MSF) has supported noma initiatives at 
the hospital. Conditions other than noma (cleft lip and palate, burns and a range of 
ophthalmological conditions) are treated at the NCH by Nigerian Ministry of Health teams.  
Programmes offered specifically for noma patients include: clinical treatment for acute cases, 
nutritional support, counselling for patients and family members, surgical interventions 
performed four times a year, outreach training for health workers and community members and 
active case finding.  Since 2014, 476 noma patients have been admitted and treated at the NCH.  
Four times a year, an MSF volunteer team comprising of approximately six health professionals 
including plastic and maxillofacial surgeons, anaesthetists and nurses, travel to Sokoto to 
participate in surgical interventions.  Approximately 20 patients are operated on over a period 
of two weeks.  During the intervening periods, patients are cared for by two Ministry of Health 
doctors, a team of nurses (Ministry of Health and MSF staff), mental health professionals (MSF 
staff) a nutrition team (Ministry of Health and MSF staff) and a physiotherapist (MSF staff).  
Spending time at the hospital allows patients and caretakers to meet and interact with one 
another, and the mental health team facilitate group discussions that provide a further layer of 
peer based support.  There is no cost to noma patients for in-hospital medical care, surgery, 
medications or food during the duration of stay. Transport costs for noma patients are 
reimbursed once they arrive at the hospital. An adult caretaker stays with paediatric patients.  
This would incur additional direct costs for the caretaker (time  
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Figure 1. 1 Insert map of Africa indicating Nigeria (green).  Larger map of Nigeria 






away from other children, home and/or job) which are not covered by the MSF and Ministry 
of Health partnership.  On top of these direct costs, there are indirect costs that can affect the 
whole family such as stigma, discrimination and mental health difficulties.  The MSF team 
offer mental health support for patients and caretakers at the hospital and attempt to decrease 
stigma and discrimination at a community level through the awareness raising initiatives run 
by the outreach team.  The combined Ministry of Health and MSF outreach team operate in 
Sokoto and Kebbi States and visit approximately 30 villages each month where they conduct 
active noma case finding, awareness raising (with community members, leaders and health care 
workers), defaulter tracing (those who have missed their most recent appointment at the 
hospital) and follow-up with previously operated noma patients.  Patients are referred to the 
NCH via contacts made by the outreach team, and by other health facilities in northwest 




As a neglected disease, little is known or understood about noma despite the fact that it has 
catastrophic outcomes including high mortality rates and is debilitating and disfiguring in a 
vulnerable paediatric population.  The knowledge gained through this thesis will support the: 
 
- Assessment of the need for advocacy around noma and to support such advocacy efforts 
if needed, 
- Effective and efficient resource allocation by policy-makers towards eradicating this 
neglected disease  and; 
- The planning of intervention strategies aimed at improving both prevention and 
management of noma. 
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As the thesis was carried out with the full support and collaboration of key role-players 
including MSF, the network of noma organisations and the Nigerian Ministry of Health, it is 
anticipated to have a meaningful impact on the prevention and management programmes of 
this devastating condition.   
 
1.3 Aims and objectives 
1.3.1 Aim 
By employing both qualitative and quantitative methods, we sought to examine 
biopsychosocial features of noma, its epidemiology and treatment in northwest Nigeria in order 
to inform advocacy and prevention efforts.  
 
1.3.2 Specific objectives 
1. To assess the distribution of noma among children in Sokoto and Kebbi States, 
northwest Nigeria. 
2. To identify factors associated with noma in this setting, including factors influencing 
health-seeking behaviour and risk factors for the development of noma. 
3. To gain an understanding of the biomedical and non-biomedical care provided to noma 
patients in this setting. 
 
1.4 Conceptual framework 
This thesis is based on a socioecological framework of factors associated with noma.  The risk 
of acquisition, clinical progression and health outcomes of noma are shaped by a web of inter-
related factors. This is perhaps more relevant in the case of diseases that disproportionately 
affect the world’s poorest children.  Health decisions made by individuals are influenced by 
circumstances, local beliefs, cultural norms as well as political and economic conditions [44].  
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Socioecological frameworks have been utilised in other public health studies [44–48] to 
illustrate the complexities and the webs within which these individuals live. Socioecological 
frameworks are illustrated with overlapping concentric circles to show how the individuals’ 
behaviours, decisions and health outcomes are nested in different layers of social organisation 
[44].  
 
The noma socioecological framework (Figure 1.2), developed for the thesis, was based on 
frameworks used in previous public health studies [45, 47, 48].  This framework illustrates how 
this thesis will explore the interplay between individual, family, community and societal 
factors.  Noma has been associated with factors within each layer of this framework as 
illustrated in the Figure 1.2.  This framework was utilised during the planning of the thesis and 
as a result, participants in each layer of the framework including the individual (case control, 
outcomes, qualitative studies), the family (case control, language and beliefs study), 
community (traditional healer study) and society (qualitative and prevalence studies) were 
included.  By utilising this socioecological framework, we have been able to better understand 
the complex interplay between individual, familial, community and societal factors that 
influence the causes and consequences of noma.   
 
1.5 Overall structure of the thesis 
The dissertation includes this introductory chapter that contextualises the dissertation; a review 
of the available literature on noma up to January 2019; five chapters based on manuscripts from 
studies that involve the collection and analysis of primary data (two qualitative and three 
quantitative – one descriptive and two analytical) and a concluding chapter which synthesises 
and highlights the major findings across the thesis, and outlines the recommendations  that  
stem from  the findings  of the  thesis.    Due  to  the  paucity in noma  
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literature, the studies included in this thesis are necessarily diverse and some are descriptive in 
nature.  
 
Chapter 2 presents a scoping review of the literature on noma and provides information on 
noma's pathology, clinical progression, the history and epidemiology of the disease, the known 
risk factors for the development of noma, aetiology, therapeutic management and outcomes 
including mortality. 
 
Chapter 3 describes an exploratory qualitative study aimed at improving our understanding of 
the local concepts (language and beliefs) of noma amongst health care workers at the NCH and 
caretakers of noma patients.  The development of the question guides for this chapter were 
based on the findings from the scoping literature review. 
 
Chapter 4 presents an analysis of risk factors for diagnosed noma in northwest Nigeria.  The 
need to assess risk factors for noma and the development of the questionnaire for this chapter 
were based on the findings from the scoping literature review. The language around disease 
naming used in the questionnaire was based on the findings from Chapter 3. 
 
Chapter 5 describes the demographic characteristics, surgeries performed, complications seen 
and the longer-term follow-up status of a cohort of patients from the NCH.  The need to assess 
noma patient outcomes and the development of the questionnaire for this chapter were based 
on the findings from the scoping literature review. The language around disease naming used 




Chapter 6 explores traditional healers’ perceptions of noma. This manuscript offered insight 
into the pluralistic nature of the Nigerian health system, with a specific focus on the role of 
traditional healers’ in the pathway to care for noma patients.  The topic for this chapter was 
derived from the findings of the scoping literature review which showed there was no research 
on the role of traditional healers in noma care as well as Chapter 3 and Chapter 4 in which 
patients mentioned visiting traditional healers or taking traditional treatments. The language 
around disease naming used in the questionnaire was based on the findings from Chapter 3. 
 
Chapter 7 enumerates the burden of disease in Sokoto and Kebbi States by conducting a point 
prevalence study among children. The findings of the scoping literature review indicated the 
need for further enumeration of the burden of disease, which was the foundational idea of this 
chapter. The language around disease naming used in the questionnaire was based on the 
findings from Chapter 3. The risk factors identified in Chapter 4 were included in this 
questionnaire. 
 
Objective 1 was fulfilled in Chapters 2 and 7.  Objective 2 was achieved in Chapters 2, 3, 4, 6 
and 7.  Objective 3 was addressed in Chapters 2, 5, and 6 (Table 1.1). 
 
1.6 Data source 
All data for the thesis was collected as part of continuing operational research that MSF is 
conducting to support its noma programmes.  Noma is a challenging disease to study due to 
the remote location of patients, the stigma and isolation of the patients, a lack of robust 
surveillance, difficulties accessing healthcare and healthcare workers lack of knowledge about 




Table 1. 1 Objectives met in each chapter of the thesis. 
 
Objective Ch Manuscript title and publication status Data source/ 
MSF study 
Objective 1:  
To assess the distribution 
of noma among children in 




Title: Scoping literature review 
Status: Not for publication 
NA 
Ch 7 Title: Prevalence of noma in northwest Nigeria: cross-
sectional study 
Status: Published in BMJ Global Health 
MSF study 4 
 
Objective 2:  
To identify factors 
associated with noma in 
this setting, including 
factors influencing health-
seeking behaviour and risk 






Title: Scoping literature review 




Title: Language and beliefs in relation to noma: a qualitative 
study, northwest Nigeria. 
Status: Published in PLoS Neglected Tropical Diseases 
MSF study 1 
Ch 4 Title: Risk factors for diagnosed noma in northwest Nigeria: 
A case-control study, 2017 
Status: Published in PLoS Neglected Tropical Diseases 
MSF study 1 
Ch 6 
 
Title: ‘I treat it but I don’t know what this disease is’: a 
qualitative study on noma (cancrum oris) and traditional 
healing in northwest Nigeria 
Status: Published in Transactions of  the Royal Society of 
Tropical Medicine and Hygiene  
MSF study 2 
Ch 7 Title: Prevalence of noma in northwest Nigeria: cross-
sectional study 
Status: Published in BMJ Global Health 
MSF study 4 
 
Objective 3:  
To gain an understanding 
of the biomedical and non-
biomedical care provided 






Title: Scoping literature review 
Status: Not for publication 
NA 
Ch 5 Title: Outcomes at 18 months of 37 noma (cancrum oris) 
cases surgically treated at the Noma Children’s Hospital, 
Sokoto, Nigeria. 
Status: Published in Transactions of the Royal Society of 
Tropical Medicine and Hygiene 
MSF study 3 
Ch 6 
 
Title: ‘I treat it but I don’t know what this disease is’: a 
qualitative study on noma (cancrum oris) and traditional 
healing in northwest Nigeria 
Status: Published in International Health 





continual access to noma patients through its support to the NCH.  MSF believe that research 
is essential to improve the effectiveness of humanitarian aid programmes, and that publishing 
research forms a vital part of advocacy on behalf of the populations that the organisation assists. 
As such, the organization is committed to conducting operational research,  endeavouring to 
add to the  scant  body of knowledge around noma.  
 
The aims of the operational research studies were to guide evidence-based policy and practices 
with local and international stakeholders.  The operational research studies were structured 
around the main gaps in knowledge and the MSF noma project needs, to enable evidence-based 
decision-making. 
 
The data included in this thesis were drawn from four operational research studies.  The titles 
of these studies are as follows: 
 
MSF study 1:  Risk factors for diagnosed noma and language and beliefs about the 
disease in northwest Nigeria, 2017. 
MSF study 2:  Long-term follow-up of noma patients after surgical, nutritional and 
mental health interventions at the Noma Children’s Hospital in 
northwest Nigeria, 2018 to 2020. 
MSF study 3:  Noma and traditional healing in northwest Nigeria. A qualitative study 
with caretakers of noma patients and traditional healers, 2018. 





MSF study 1 was the first study conducted, followed by MSF study 2 and MSF study 3 which 
were begun in parallel.  MSF study 4 was the final project.  The PhD candidate has permission 
and support from MSF to use the data from these studies towards a PhD (Appendix 1.1 and 
1.2).  MSF study 1 was a mixed methods study that incorporated an initial qualitative part 
assessing the language and beliefs around noma, and a subsequent case control study assessing 
the risk factors for noma.  This study is the basis for two of the PhD chapters, Chapter 3 
(Language and Beliefs) and Chapter 4 (Risk Factors).  MSF study 2 was a dual-phased study.  
The data collected during the first phase of this study was included in the thesis in Chapter 5.  
Only surgical interventions with patients who survived the acute stage of infection (i.e. not 
nutritional and mental health interventions) are described in this thesis.  The second phase is a 
prospective cohort study; data collection for this phase is still ongoing and has not been 
included in this thesis.  All of the data from MSF study 3 and 4 were included in thesis Chapter 
6 and Chapter 7 respectively (Table 1.1). The role of the PhD candidate during these studies is 
described in the preface of the thesis, and the contributions of the candidate to each specific 
chapter is noted on the first page of each chapter. 
 
1.7 Ethics 
All data gathered as part of the dissertation gained approval from the University of Cape Town 
(UCT) Human Research Ethics Committee, MSF Ethical Review Board (ERB), Usmanu 
Danfodiyo University Teaching Hospital (UDUTH) ERB in Nigeria and the Sokoto and Kebbi 
States Ministry of Health ERB (the states in which the data collection occurred). All approvals 
are in Appendix 2.  Written informed consent from research participants and, where applicable, 
primary caretakers was gained for data collection in all chapters.  Where applicable, assent was 
requested from child respondents aged between eight and 17 years.  A confidentiality and 
conflict of interest certificate was signed by all research staff.  All electronic recordings were 
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deleted off any recording devices and data collection tablets once uploaded to the secure MSF 
cloud server.  All paper copies are locked in a secure cupboard at the program site and will be 
destroyed after five years.  All data was collected using a unique participant identification 
number and did not include names or other identifying data.  Where necessary, a separate data 
collection form containing identifying data linked to the participant’s unique identifying 
number was kept.  This information was only accessible to the PhD candidate and a limited 
number of other research team members directly involved in data collection.  No names or 
identifying data of research participants were mentioned in reports, publications or abstracts. 
Individuals participating in the project were treated equitably and fairly.  No photographs were 








Chapter 2  Scoping literature review 
There is a paucity of literature on noma (cancrum oris) due to the neglected nature of this 
disease in general and in the scientific community [25].  The rapid progression and reported 
high mortality rate [1], the remote location of patients, under-reporting and misdiagnosis of 
cases [21] contribute to limited literature being available and a poor understanding of the 
disease.  There has however, been ongoing reporting of noma cases from around the world for 
many centuries and a few scientists have, for decades, been researching noma.  These include 
Dr Enwonwu [10, 43, 50–53], Dr Marck [10, 43, 50–53], Dr Baratti-Mayer [25, 54–56], Dr 
Chidzonga [18, 20], Dr Srour [32, 57, 58] and Dr Feller [9, 59, 60].  Using empirical evidence, 
the thesis aims to fill some of the gaps in knowledge around noma with the hope of adding 
valuable insight into the disease while contributing to the existing body of research.   
 
2.1 Methods 
We conducted a scoping review of the literature on noma to consolidate the information 
available and to understand the size and scope of available research on the disease.  The main 
topics of interest included: the history and epidemiology of the disease, noma’s clinical 
progression and aetiology, treatment regimens, mortality rates and the risk factors for the 
development of noma.  The scoping review methodology was chosen as it uses rigorous and 
transparent methods, allowing for the collation of a large and diverse body of literature while 
incorporating findings from multiple study designs [61, 62].  This scoping review was 
conducted in line with Preferred Reporting Items for Systemic review and Meta-Analyses 






2.1.1 Databases searched 
The following databases were searched for articles to include in this literature review: PubMed; 
PsycINFO via Ebsco Host; Science Direct; Social Science Citation Index via Web of Science; 
MEDLINE via PubMed; Cumulative Index to Nursing and Allied Health Literature via Ebsco 
Host; Cochrane Library; Population Information Online; LILACS; SciELO and Scopus. 
 
2.1.2 Searching methods utilized 
An initial search of each database was done online via the UCT Health Sciences Library 
platform by the PhD candidate.  All articles identified were listed and if full text articles were 
available, they were downloaded.  For articles where full text was not initially available, the 
individual journals were searched and, where available, articles were downloaded.  For any full 
text articles not found, the UCT Health Sciences Librarian was requested to source some of the 
outstanding articles.  The corresponding authors of outstanding articles were contacted where 
possible for copies of their manuscripts. 
 
2.1.3 Eligibility criteria 
The databases and journals were searched using the following eligibility criteria: 1) noma, 
cancrum oris related; 2) peer reviewed; 3) primary study; 4) addressed a main theme of interest; 
5) any publication date;  6) all study designs; and 7) all languages.  
 
2.1.4 Search Terms 
Databases were searched with the following terms: "cancrum oris" OR “noma” OR "cancrum 
oris cases" OR "cancrum oris defects" OR "cancrum oris like lesions" OR "cancrum oris noma" 




2.1.5 Data extraction 
Data from the eligible studies were extracted using a standardized data extraction tool 
(Appendix 3.2). Data extracted included: title; author; journal; year of publication; geographic 
location of first author; geographic location of study; number of cases/individuals in study; 
research question/aim; methodology; analysis; results; area of interest; conclusions; 
implications for future research and practice; gaps in knowledge and any other noteworthy 
comments.  
 
All non-English papers were translated into English using Google translate, anything unclear 
was checked with a language expert.  The PhD candidate performed the standardized data 
extraction and eligibility evaluations on each study and evaluated if the study addressed one of 
the research topics of interest.  
 
2.1.6 Analysis 
An analysis was conducted by grouping individual factors into themes within the topics of 
interest (the history and epidemiology of the disease, noma’s clinical progression and 
aetiology, treatment regimens, mortality rates and the risk factors for the development of 
noma).  These topics of interest were explored in-depth and findings on each of these topics 
are concisely reported.  
 
2.1.7 Included articles 
Our initial search identified 171 manuscripts for review, of which 125 were included in the 
literature review.  The oldest manuscript was from 1843 and the most recently published 
manuscript was from January 2019.  The other 46 manuscripts were excluded as they either 
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did not directly relate to noma, did not meet the inclusion criteria, or they were not considered 
to be primary research. The majority of the studies (n=85, 68%) were case reports (Figure 2.1). 
 
2.2  History of noma 
There are reports of noma by physicians such as Hippocrates (460-370 BC) and Galen (129- 
200 AD) [22].  However; others believe that these referred to general ulceration of the body 
and not noma as the disease is currently understood [63].  The first clinical description of the 
disease we now call noma, was written by Battus in 1620, who labelled it ‘water canker’ [63, 
64].  The word ‘noma’ is derived from a Greek word which, loosely translated, means ‘to 
devour’ [65] and was first used by Dutch surgeon Cornelis van de Voorde in 1680, for a rapidly-
spreading ulceration originating in wet soft tissues in children, ‘typical of the mouth’ [64]. 
 
The term ‘noma’ and ‘cancrum oris’ are currently used interchangeably [10, 12, 33, 39].  In the 
1800’s, there were ongoing discussions about the usage of the terms with some viewing them 
as two separate diseases [66].  In a publication from 1862, ‘noma’ referred to ulcerative 
stomatitis (lesion on the skin or an internal mucous surface of the mouth) and  ‘cancrum oris’ 
referred to gangrenous stomatitis (death of the tissue of the mouth) [66].  In contrast, in 1848, 
Tourdes defined the disease of ‘noma’ as it is currently understood today as “a gangrenous 
disease affecting the mouth and face of children living in bad hygiene conditions and suffering 
from debilitating diseases, especially eruptive fever, beginning with an ulcer on the oral mucosa 

































PubMed; PsycINFO via Ebsco Host; Science Direct; Social 
Science Citation Index (SSCI) via Web of Science; MEDLINE 
via PubMed; Cumulative Index to Nursing and Allied Health 
Literature via Ebscohost; Cochrane Library; Population 
Information Online; LILACS ; SciELO; Scopus. 
 
Databases were searched with the following terms: 
"cancrum oris" OR “noma” OR "cancrum oris cases" OR 
"cancrum oris defects" OR "cancrum oris like lesions" OR 
"cancrum oris noma" OR "cancrum oris, noma" 
11 databases searched   
171 studies identified 
125 studies included in final synthesis 
- Modelling estimates for incidence (n=1) 
- Prospective cohort (n=2)  
- Case report animals (n=2)  
- Case control (n=5) 
- Cross sectional (n=7) 
- Retrospective chart review (n=10) 
- Case series (n=13) 
- Case report humans (n=85) 
 
171 studies reviewed and assessed for 
eligibility with the following criteria: 
 
1) Noma, cancrum oris related 
2) Peer reviewed 
3) Primary study 
4) Addressed a main theme of 
 interest  
5) Any publication date 
6) All study designs 
 
Excluded the following papers (n=46): 
 
 1)   Focus not on noma or cancrum 
  oris  (n=24)  








Our literature review revealed many illustrations by physicians.  Below are a select few 
showing a range of impressions from these physicians.  Each sketch shows the severity of the 
facial destruction (Figures 2.2-2.5). 
 
There have been some inconsistencies in the literature, with infections not likely to be noma, 
being labelled as noma.  In one study the lesions were not isolated in the oral region but were 
also on the perineum [53], but a diagnosis of noma was still given.  Noma neonatorum was first 
described in 1977 [67], and is a necrotizing infection seen in neonates in which gangrenous 
lesions involve the mucocutaneous junctions of oral, nasal, and anal area, and, occasionally, 
the eyelids and the scrotum [10, 53, 67–69].  This infection resembles noma, and is sometimes 
incorrectly reported as noma, but this infection is not noma, and needs to be differentiated as 
such [53, 70].  The main differentiating factors being that noma neonatorum is caused by 
Pseudomonas aeruginosa while with noma numerous other pathogens are implicated; and 
noma neonatorum affects neonates while noma mostly affects children aged between two and 
five years [53, 67, 68, 71].  
 
In Laos, the name commonly used for noma is ‘Pagnad Pak Poue’ meaning ‘disease of mouth 
rotting’ [32].  In Zambia, tribes in a specific area have labelled the disease as ‘aka popo’, 
meaning the child has been fed a stillborn fetus, and the flesh is ‘coming out’ (describing the 
sloughing of the cheek) [3].  In Hausa, the most widely spoken language in northwest Nigeria, 
the term ‘ciwon iska’ and ‘bakin kare’ are reportedly used for noma [64].  Both of these words 
are generalized terms (disease of the wind and mouth of the dog) which have reportedly caused 
confusion in patient recruitment drives for surgical interventions, as patients  with  ailments  













Figure 2. 4 Noma patient, 3 years old, admitted 16th May, died 20th May 1885 [72]. 
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Other reported Hausa names include ‘gaude’ and ‘sadde’, translated as ‘the disease of cattle 
rearers’ [8]. This name is indicative of the beliefs in the Hausa community that the disease is 
transmitted from animals to children [8]. 
 
2.3  Clinical progression 
Noma is a rapidly progressing infection of the oral cavity, associated with a reported 90% 
mortality rate within weeks after the onset of noma, if left untreated [1]. Noma most commonly 
affects children between two and five years of age [2]; however, reports of acute noma cases 
in adults, mostly in conjunction with other infections have been reported [15, 27, 51, 73].  
While the clinical manifestation and sequelae of noma in each case is unique, the infection 
invariably starts as an inflammation of the gums, which then leads to ulceration and the rapid 
destruction (within weeks [1]) of the cheek and in some cases the jaw, lip, nose and/or the eye 
[3, 4]. Deaths are primarily due to starvation, aspiration pneumonia, respiratory insufficiency 
or sepsis [25, 74].  Treatment with antibiotics, wound debridement and nutritional support in 
the early reversible stages of the disease can reduce the duration and severity of the acute phase 
of noma and the extent of tissue damage, thus reducing mortality and morbidity of noma 
(discussed in detail below) [2].  The infection can become inactive (with or to a lesser extent 
without antibiotic treatment), after which, patients often need complex surgical reconstruction 
to restore form and function [4].  Patients who survive often have severe facial disfigurements 
[2] and multiple physical impairments such as difficulty eating, seeing and breathing [1].  
Noma can cause stigmatization due to these impairments [2]. 
 
For the purposes of case detection in the field, the WHO has classified noma into stages, the 
first stages (Stage 0 to 4) are the active or acute stages of noma lasting only a couple of weeks; 
Stage 0: simple gingivitis; Stage 1: acute necrotizing gingivitis; Stage 2: oedema; Stage 3: 
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gangrene.  Stage 4: scarring is accompanied by contractures, which develop as the child grows 
and Stage 5: sequelae is the final stage and is also known as the inactive or chronic stage of 
noma and refers to the condition of patients who survive the acute stages of infection with 
varying degrees of physical and/or functional deformities [1] (Appendix 4).  There were no 
reports of noma reoccurring once reaching Stage 5 [59].  None of the literature included in this 
review reported that noma was contagious [59].  There was also no evidence on the triggers 
which would cause a progression to the later gangrenous stages of the disease.   
 
2.4  Aetiology 
The pathogenesis of noma is poorly understood and the microbiology is debated.  Strikingly, 
this quote from a paper written in 1893 still partly reflects the current debated nature of the 
pathogenesis of noma “There must surely be a specific organism and a combination of 
predisposing causes, not poverty alone, but poverty plus a sickly habit of body” [63].  
 
A range of organisms have been identified in the oral flora of noma patients [8, 50, 52, 56], 
such as Fusobacterium necrophorum [8, 50, 52].  The causal association with noma, however 
has been debated as it has not consistently featured in oral microbial studies [10, 56, 75].  Other 
studies have noted that noma incorporates the characteristics of an opportunistic infection, 
implicating a change in the equilibrium of commensal bacteria due to a derailment of host 
defences [20, 22, 75, 76].  There is a strong likelihood this may be true as most cases have 






Table 2.1 below offers a summary of the etiologic studies included in this review and the 
organisms identified, the details of each study and limitations of the study methods.   One of 
these limitations is delayed acquisition of a culture [50] which may result in identification of 
super infectious agents rather than the causative agent(s). The acute phase of noma is relatively 
short and delayed treatment-seeking may pose challenges in acquiring samples in the early 
acute phase.  Non-probability sampling methodologies, that do not choose the study 
participants at random, are a further limitation [77, 78] which mean the findings have 
restrictions in terms of generalizability as the findings are only relevant to the group enrolled 
in the study and not the population as a whole [79].  Some of the studies included in the review 
and detailed in Table 2.1 have no comparison group [20, 50]. This makes it impossible to 
identify causal links between the organisms and noma infection as there is no control group to 
compare the results to [78].  Other studies included that utilize case control study designs [10, 
54, 56] do not provide evidence of causal links but do provide information on which to base 
future research hypotheses to be tested.  The case control study design has the potential for 
introducing biases, including measurement bias (due to the retrospective nature of collecting 
data about predictor variables) and selection bias (can occur during the identification of case-
patients and control-patients if their inclusion depends on the exposure of interest) [77], 
affecting associations seen. These limitations will impact on the generalizability of the findings 




Table 2. 1 Microorganisms found in the oral flora of noma patients by year. 
 
Study Study details Organism Limitations 
Falkler, 1999 [50] Study type:  Cross-sectional study 
Location:  Nigeria 
n:   Eight cases 
Additional details: Cancrum oris lesions (present for six 
weeks to two years) were cultured for anaerobic 
microorganisms.  
Fusobacter iumnecrophorum and Prevotella 
intermedia were isolated from seven and six of the 
eight lesions, respectively. 
Long duration of infection before 
testing (up to two years), small 
sample size, no healthy matched 
comparison group. 
Phillips, 2005 [10] Study type:  Case control study 
Location:  Nigeria   
n:   68 acute noma cases, 63 village and 45 
  urban controls 
Additional details: Cases were found over four years 
through house visits. Controls were matched by age and 
were children attending out-patient clinics and primary 
health care centres for routine checks, and had no recent 
history of any disease, fever and diarrhoea. Oral bacteria 
were studied by polymerase chain reaction on six cases. 
Excluded those treated with antibiotics or traditional 
medicine in last 48hrs. Excluded measles, HIV and 
malaria comorbid patients. 
Bacteria observed at the highest frequencies in 
noma lesions were Prevotella intermedia (83%), 
Tannerella  for sythensis (83%), Porphyromonas 
gingivalis (50%), Campylobacter rectus (50%) and 
Treponema denticola (50%). 
Control selection (children attending 
health care facility) could have 
biased results as these children were 
already accessing care. It is 
unknown how long each patient had 
noma for. The sample size for 




Study type:  Retrospective chart review 
Location:  Zimbabwe 
n:  48 acute noma cases, five cases had 
microbiologic investigations 
Additional details: All cases presented one to two weeks 
after onset of symptoms 
 
Staphylococcus aureus, Klebsiella species, group 
D Streptococcus, and group B hemolytic 
Streptococcus.  
Small sample size, retrospective 






Study type:  Prospective matched, case-control 
study 
Location:  Niger 
n:  82 acute noma cases, 327 matched 
controls 
Additional details: Study took place over six years. 
Exact stage of noma cases not defined. Controls 
matched on age and home village. Extracted total 
genomic deoxyribonucleic acid. Cases who received 
antibiotics or whose specimens deteriorated were 
excluded (n=20), 117 microbial samples were processed 
from noma cases and 235 from controls. Multivariable 
model showed organisms associated with noma.  
A reduced proportion of Spirochaeta, 
Fusobacterium, Capnocytophaga, and Neisseria in 
the oral microbiota, but an increased proportion of 
Prevotella associated with noma. Controls had 
higher Fusobacterium genus levels raising doubts 
about previous findings. 
Controls were significantly older 
than cases. 28% of observations in 
the analysis were excluded because 
of missing data for microbiological 
variables due to problems collecting 
data due to poor health.  
Huyghe, 2013 [54] 
 
Study type: Case control study 
Location:  Niger 
n:  84 acute noma cases, 37 acute 
necrotizing gingivitis cases and 343 
controls 
Additional details: Cases had no antibiotics, no dental 
cleaning and did not receive fortified food during the 3 
previous months. Subjects with lesions older than 4 
weeks were excluded.  
Compared to the healthy controls, a lower bacterial 
diversity was found in noma samples. Less 
Porphyromonadaceae, Tannerella spp., 
Capnocytophaga spp., Fusobacteria and 
Cetobacterium spp. were found in noma samples. 
Raises doubts about Fusobacterium necrophorum. 
Authors state need for time series 
data and the utilization of high-
throughput sequencing capacity to 




2.5  Treatment 
There are recommended treatments, which are reported to be effective in the differing stages 
of noma.  
 
2.5.1 Acute phase treatment (Stages 0 to 4) 
Historically (1800’s and early 1900’s), noma cases presenting at biomedical institutions were 
managed with nutritional support with high protein foods (fruit, eggs, milk, meat [63, 80, 81]) 
alcohol (wine, brandy and whisky [63, 66, 80, 82, 83]) and wound cleaning using bicarbonate 
of soda [80, 84], leeches [84] and nitric acid [66, 85, 86].  It is difficult to know whether these 
methods were beneficial as all evidence was derived from case series and case reports. 
 
More recently (later 1900’s and 2000’s), timely administration of broad-spectrum antibiotics 
have shown to be effective in reducing the severity and sequelae of noma by arresting the acute 
phase of the infection in some patients [9, 20, 21, 31, 32].  A range of antibiotics were reported 
in the included studies such as amoxicillin [9, 87–89], metronidazole [11, 33, 39, 50, 87], 
lincomycin [35] and cefotaxime [33, 90].  No studies comparing the relative efficacy of these 
antibiotics were identified. 
 
Wound cleaning and debridement was shown to be important including daily irrigation with 
saline [8, 9, 39, 87–89, 91] and antiseptic dressings [37, 92].  Wound debridement involves the 
removal of necrotic tissue to promote healing and reduce the risk of secondary infection [20, 
22, 25, 32, 37, 92].  Nutritional support, either orally or via a nasogastric tube, is another 
cornerstone of noma treatment as it builds the patients’ immune systems, which enables their 
body to fight off infection [20, 21, 25, 93].  This nutritional support has not been reported to 
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be effective in isolation, but only when accompanied by wound debridement and antibiotic 
treatment [2]. 
 
Therefore, the current WHO guidelines for the management of the active stages of noma in 
clinical settings includes [1]: oral hygiene (mouth wash Chlorhexidine 0,2%, 10 ml), antibiotic 
treatment (Amoxicillin), nutritional support (high protein), wound cleaning (compresses 
soaked in hydrogen peroxide) and dressing (honey for local dressing and for antibacterial action 
and regeneration) [1]. 
 
2.5.2 Chronic phase treatment (Stage 5) 
Once noma becomes inactive, patients can survive into adulthood but often require extensive 
reconstructive surgery and physiotherapy to correct the resulting structural and functional 
defects [94].  Physical sequelae include displacement of the teeth and intense scarring and bony 
fusion between the maxilla and mandible [2, 4, 92, 94–96].  Sequelae around daily functioning 
may include difficulty eating, seeing, talking and breathing [57, 94, 96].  Trismus (a restriction 
in mouth opening) is one of the most disabling sequelae [6] and can lead to complications such 
as aspiration, malnutrition, poor oral hygiene, speech deficits, a compromised airway and pain 
[97]. 
 
The clinical manifestation of each noma case is unique, and as such, the surgical procedures 
used to treat each noma case differ [3, 5, 38, 55, 98–101].  Reported surgical techniques include 
pedicled supraclavicular flaps for the treatment of large unilateral facial defects [100]; 
myocutaneous submental artery flaps, bony and/or soft tissue trismus releases [92], forehead 
flaps for nasal reconstructions [92] and lower lid ectropion release [92].  In one study, extra-
articular ankylosis due to noma was treated using soft tissue reconstruction with large free flaps 
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[55].  Mouth opening was performed by bone-bridge excision, sometimes associated with 
contralateral coronoidectomy [55].  In a further study, the reconstruction of an upper lip defect 
was conducted using Gillies fan flaps [102].  A 2006 book on noma surgical techniques 
includes information on the reconstruction of the lips and corner of the mouth using Abbe, 
Estlander and fan flaps; and the reconstruction of the cheek using temporo-parietal fascia and 
deltopectoral flaps; and the reconstruction of central defects using radial forearm and local 
turnover flaps [4].  
 
Physiotherapy is an essential part of noma treatment, especially to prevent or minimise trismus 
[98] and can lead to improvements in eating, chewing and speaking [103].  
 
Noma can often lead to stigmatization and resultant social isolation of the patients and their 
family members from the communities [2].  The management of noma patients invariably 
requires social and psychological support.  There are no publications exploring or examining 
the effectiveness of these mental health interventions. 
 
Outcomes of noma treatment are difficult to ascertain due to inconsistent patient follow-up [6].  
This is mostly due to the remote locations of the home villages of patients and difficulties in 
accessing health care facilities [24, 25, 32].  The extent of long-term sequelae and their impact 
on quality of life depends on the severity of the disease at initial presentation, efficacy of 
antibiotic treatment, wound debridement and the facial structures affected [6, 9, 20, 21].  No 
reports of traditional or non-biomedical treatments were found during this review.  
 
2.6  Mortality 
There is limited evidence around the pathogenesis of noma leading to death.  Deaths have 
primarily been reported due to starvation, aspiration pneumonia, respiratory insufficiency or 
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sepsis [25, 74].  Factors that favour survival (apart from antibiotic treatment and wound 
debridement) are unknown.  The mortality rate of noma depends on multiple factors and is 
poorly enumerated.  The WHO (based on expert opinion and retrospective chart analyses) 
states that noma has a mortality rate of 90% within weeks after the onset of noma if left 
untreated [1].  The speed with which death occurs is also debated, some state death occurs in 
as little as two weeks from the onset of first symptoms [1] but it is unclear about which 
symptoms these are.  The clearest reported estimate is that death can occur in a matter of days 
after the onset of oedema [25].  What is certain is that when noma is identified and treated 
timeously, mortality greatly decreases [58]. 
 
Table 2.2 explores the mortality rates reported in various studies included in this review. These 
estimates highlight the differences in mortality rates in groups who received no antibiotic 
treatment (49-94%) in comparison to those who had received drug therapies such as antibiotics 
(0-38%) (Table 2.2).  It should be noted that these estimates are derived from case series and 
retrospective chart reviews, no standardized reporting of noma stage was used and the studies 
do not all have the same follow-up periods, thus the evidence should be evaluated with these 
study design restrictions in mind as they could over- or under-estimate the mortality rates of 
noma patients.   
 
2.7  Epidemiology 
In recent years, noma has been reported in many countries around the world but primarily in 
low and middle income countries in Africa and Asia [3, 7, 16, 18, 20–32].  In 2007, the WHO 
carried out a survey in African member states, which found that 39 of the 46 countries surveyed 




Table 2. 2 Mortality reported in included studies. 
 
Study Location Study design Cases Mortality (%) Treatment 
Tourdes,  
1848 [105] 
Europe Case series  239  73% No drug therapy 
Barthez,  
1855 [105] 




Europe Case series  8  63% Iron with citric-acid, nutritional support 
Springer,  
1904 [105] 




India Case series  79  49% Pentavalent antimony (treatment of 
leishmaniasis), nutritional support, 
vitamins, blood transfusions, local 
antiseptic treatment 
Jelliffe,  
1952  [81] 
Nigeria Case series  53   30%  Penicillin 
Mehrotra,  
1966 [30] 
India Case series 
 
 20   15% Antibiotics, multivitamins, high protein 






Nigeria Case series 
 
 13  0% Antibiotics 
Bourgeois, 
1981-93  [25] 
Senegal Case series  73  10% Drug therapy, kind not specified 
Oginni,  
1982-96 [25] 






 117   20% Nutrition, wound care 
Chidzonga,  
1996  [106] 
 
Zimbabwe Case series  8  38% Antibiotics, wound debridement, 










 212  HIV co-infected 
patients 38%; non- 
HIV patients 6% 













Those with the highest number of reported cases were Burkina Faso, Ethiopia, Mali, Niger, 
Nigeria and Senegal which led to these countries being labelled the ‘noma-belt’ [104].  This 
term is commonly used when reporting the epidemiology of noma.  However; the information 
gathered that led to this term was not standardized and not based on robust prevalence or 
incidence estimates [104].  In the last 15 years, cases have also been reported to occur and be 
treated in southern Africa [3, 16, 18, 21], Turkey [33], Afghanistan [34], South Korea [108], 
India [24, 31, 109, 110], Laos [32], Italy [35] the United Kingdom [36] and the United States 
[11, 74], indicating a much wider distribution than the usually reported ‘noma-belt’ [104]. 
 
The oldest estimate we found of the burden of disease, based on hospital admissions, indicated 
that, noma was diagnosed once out of every 5,000 cases of children admitted to hospital with 
an illness, between 1860 to 1871 in Edinburgh [65].  In 1997, Barnes et al. estimated that, 
based on records from three referral centres, the prevalence of noma was 1 case per 1,250 
children aged two to six years per year in Nigeria [53].  In 1998, the World Health Organisation 
(WHO) estimated that 140,000 new cases of noma occur each year globally and that 770,000 
patients were living with noma sequelae at that time [19], the origin of this estimate is unclear 
[111].  In 1999, it was estimated that there was an annual incidence of 4.2 acute noma cases 
per million Senegalese children aged 1–4 years [112]. This estimate was calculated using a 
WHO recommended formulae, based on a 5-20% presentation rate of both acute and chronic 
noma, and an 80-90% mortality rate in the acute stages of the disease [112]: 
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Through a retrospective chart review (n=6,390) in 2003, Denloye et al. estimated seven cases 
per 1,000 children aged between one and 16 years had noma between 1986 and 2000 in Nigeria  
[42].  In that same year, a northwest Nigerian study by Fieger et al. modelling noma incidence 
based on the number of clefts, concluded that the incidence of noma is estimated to be 6.4 per 
1,000 children from 1996 to 2001 [7].  These estimates may not accurately reflect the present 
incidence of acute noma or the prevalence of patients with noma sequelae as they are based on 
expert opinion or data collected many years ago.  It is also unclear which stages of noma are 
included in these estimates [49].  
 
Figures 2.6, 2.7 and 2.8 explore the changing geographical distribution of noma case reports 
and case series from the 1800’s to 2019.  There is a shift in case reporting from primarily in 
Europe and India in the 1800’s, to parts of Africa and North America in the 1900’s to South 
America and Asia in the 2000’s.  Noma cases were reported in war-time soldiers in the 1880’s 
[80, 85];  in Belsen and Auschwitz concentration camps during World War II [7, 8, 32, 39, 
113–115] and the general population in war-time Netherlands where the population suffered 
through famine in the winter of 1944/1945 [7].  Since these war-time reports in Europe, the 
occurrence of noma dramatically decreased and is only sporadically reported in the region 
today [36]. 
 
The maps in Figures 2.6 to 2.8 do not necessarily indicate increasing prevalence of noma, as 
the quality of evidence is low (based on cases reports and case series [116]).  Without robust 
prevalence and estimates across countries at various times, it is not possible to accurately 





















2.8  Risk factors 
There is limited primary evidence on the risk factors for the development of noma. The table 
below explores the risk factors noted in the primary studies included in this review (Table 2.3). 
Reported risk factors for the development of noma in these primary studies include being aged 
between two and five years [3, 20, 22, 23, 40–42, 117], not being breastfed [43], comorbidities 
either at the time of noma diagnosis or in the three months leading up to diagnosis [3, 8, 17, 
22, 23, 40–43, 56, 107, 117], lack of access to quality health care [117] including childhood 
vaccinations [34], low vitamin A and vitamin C levels [10], poor oral hygiene practices leading 
to gingivitis (Stage 0 noma) [34], low socioeconomic status of the family [107], a high number 
of previous pregnancies in the mother [56] and the absence of chickens at home [56]. 
 
Other studies have hypothesized further risk factors for noma development including 
household variables such as proximity of livestock to living areas and poor sanitation [34], 
which is thought to lead to possible contamination of water and food sources and consequently 
increasing the risk of infections [118, 119].  However; caution is needed when interpreting these 
findings as they are based on the proportions of cases vs controls having these risk factors 





Table 2.3 Risk factors for noma identified in primary research. 




Study type:  Cross-sectional 
Location:  Nigeria 
n:  58 cases of 
acute necrotizing gingivitis 
(Stage 1 noma as categorized 
under the WHO system [1]), 5 
noma cases (diagnosed as 
advanced acute necrotizing 
gingivitis with sequestrum 
formation) 
 Respondents aged 
between 2-7 years (n=49, 
85% acute necrotizing 
gingivitis cases, n=3, 
60% noma cases)  
 Rainy season (n= 42, 
67%) 
 History of recent febrile 
illness (n=55, 87%)  
Data collected retrospectively. 
18 children examined by authors, the 
remaining charts were reviewed- could 
provide inconsistent data. Limited 
standardization of data collection. No robust 




Study type: Retrospective chart 
review, reviewing charts of 
cancrum oris patients from the 
previous 35 years 
Location: South Africa 
n:  26 respondents 
 Respondents mean age 4 
years 4 months (range 1-
15 years) 
 Malnutrition (n=7/ 11 
(whose records had 
comorbidity 
information), 64%) 
 Gastroenteritis (n=4/11, 
36%)  
 Measles (n=3/11, 27%)  
Data collected retrospectively, no 




Study type: Retrospective chart 
review over 15 years 
n:  81 respondents 
 
 Respondents aged 
between 1 and 4 years 
(n=67, 83%),  
 Diarrhoea (n=13, 28.9%) 
 HIV (n=26/45 (children 
admitted between 1989-
93), 60.5%), 
 Malnutrition (n=15/ 45 
(no. children assessed for 
malnutrition), 33.3%) 
 Rainy season (n=60, 
74.1%),  
Data collected retrospectively, no 




Study type:  Prospective 
cohort 
Location:  Senegal 
n:  25 later stage 
noma cases, 1058 acute 
necrotizing gingivitis cases 
 
 Noma respondents 
mostly aged >15 years 
(n=13, 52%), acute 
necrotizing gingivitis 
respondents mostly aged 
between 1-4 years 
(n=465, 44%)  
 No access to quality care 
(n=20/25 (noma only), 
80%) 
 
The definitions of a noma case were not clear, 
results were not always separated into noma 
stages. Descriptive, uncontrolled case series, 
risk factors not clearly laid out or examined, 
and no clarity on which risk factors were 
present for each stage of noma. Most of the 
children aged between 0-4 years were acute 
but the remaining respondents were chronic 
noma patients, this could introduce recall bias 
and skew associations seen due to the long 
length of time between the acute phase and 






Study type: Case control  
study 
Location:  Nigeria 
n:  86 noma cases 
 Respondents mean age 
5.9 years (Standard 
Deviation)  (SD)  2.6 
years 
 Malnutrition (Weight-
for-height Z score 
(WHZ)        ≤ -2.0 SD) 
(n=9, 10.2% controls, n= 
17, 19.4% cases) 
Risk factor analysis confined to prevalence of 
factor in cases vs controls. Some risk factors 
are not clearly examined with statistical 




Study type:  Retrospective 
chart review of noma patients 
from 1982 to 1996 
Location:  Nigeria 
n:  146 noma 
patients, 133 acute, 13 chronic 
(which was 1.7% of all patients 
admitted to the hospital during 
this time). 
 Respondents mean age 
4.7 years (SD 2.6 years)  
 Malnutrition (n=146, 
100 %) 
 Poor oral hygiene 
(n=122, 83.6%) 
 
Missing/incomplete clinical data; no 
standardization in diagnosis. Risk factors 
identified by descriptive analysis. Percentages 




Study type:  Retrospective 
chart review 1986 to 2000 
Location:  Nigeria 
n:  45 noma cases  
 Respondents mean age 
4.2 years (SD 2.7 years) 
 Malnutrition (n= 45, 
100%) 
 Malaria (n= 14, 31%)  
 Measles (n=14, 31%)  
Missing/incomplete clinical data including 





Study type:  Case control 
Location:  Nigeria 
n:  91 noma cases 
 Respondents mean age 
2.6 years (SD 1.0) 
 Malnutrition (median 
height for age z-score 
noma group -3.74, 
control group 1 -1.41, 
control group 2 0.85) 
Children with comorbidities excluded. 
Phillips,  
2005 [10] 
Study type:  Case control 
Location:  Nigeria 
n:  68 noma acute 
cases  
 Biological markers 
suggestive of 
malnutrition (lower 
plasma levels of vitamin 
A (p<0.001), vitamin C 
(p<0.05) and zinc 
(p<0.001)) 
 Marked reductions 
(p<0.001) in albumin 
and blood haemoglobin. 
Healthy controls matched by age and village 
not included. Respondents’ ages not clear 





Study type:  Retrospective 
chart review of charts between 
2002 and 2006 
Location:  Zimbabwe 
n:  48 acute noma 
cases, all HIV positive (by 
design) 
 Respondents aged <16 
years (n=11, 64.7%) 
 Gender (female n= 31, 
64.6%) 
No control group, limited information and 






Study type:  Retrospective 
chart review from 1988 to 2007 
Location:  Burkina Faso 
n:  212 patients 
(n=14, 6.6% had HIV)  
 Respondents mean age 
15.3 years for HIV 
group, 4.7 years for non-
HIV infected group 
 Concurrently HIV-
infected patients had 
higher mortality (38% vs 
6%) 




Study type:  Case control  
Location:  Niger 
n:  82 cases and 
327 controls 
 Respondents aged 0-12 
years 
 Severe stunting (Height-
for-age Z score ≤3 SD) 
(Odds Ratio) (OR) 4.87, 
95% Confidence Interval 
(CI) 2.35–10.09) 
 Wasting (WHZ ≤3 SD) 
(OR 2.45, CI 1.25–4.83),   
 High number of previous 
pregnancies in the 
mother (OR 1.16, CI 
1.04–1.31) 
 Presence of respiratory 
disease, diarrhoea or 
fever in the 3 months 
prior to data collection 
(OR 2.70, CI 1.35–5.40) 
 Absence of chickens at 
home (OR 1.90, CI 0.93–
3.88) 
Age matching of cases not strictly followed, 




Study type:  Chart review 
2003 to 2012 
Location:  Burkina Faso 
n:  55 acute noma 
cases 




(n=20, 36.4%)  
 Malaria (n=14, 25.4%)  
 HIV (n=11, 20.0%) 
 Low standard of living 
(n=21, 38.2%) 
 Anaemia (n=14, 25.4%) 




Study type:  Retrospective 
chart review from 1999 to 2011 
Location:  Nigeria 
n:  159 acute noma 
cases 
 Respondents aged 
between 1–5 years (n= 
139, 87.4%)  
 Concurrent disease at 
presentation or in the 3 
months preceding their 
presentation at the 
hospital (n=148, 93.1%)  
 Measles (n=75, 47.2%)  
Data collected retrospectively, lack of 








WHZ- weight-for-height Z score 
OR = Odds Ratio 
SD = Standard Deviation 
CI = Confidence Interval 
WHO = World Health Organisation 




Reported comorbidities in the primary studies (case control, cohort, retrospective chart 
reviews) include malnutrition [22, 23, 41–43, 56], respiratory disease [56, 107], diarrhoea [22, 
56], HIV [17, 20, 107], malaria [42, 107] and vaccine preventable diseases, specifically measles 
[22, 41, 42].  Most of the case reports and case series (n=68, 72%) listed at least one 
comorbidity. The most widely reported comorbidities in the case reports and case series 
included in this review were malnutrition [11, 28, 29, 32, 34, 81, 85, 88, 89, 120–122], HIV 
[13, 15, 18, 73, 121, 123], anaemia [20, 33, 89, 103] and measles [30, 65, 86, 101] (Figure 2.9).  
As this information is based solely on case reports and case series, primarily reported from 
health care centres, no causal link or strength of association can be measured.  Infections are 
usually the product of a compromised host and a single offending agent or multiple offending 
agents.  Due to challenges with conducting scientifically robust risk factor analysis for noma, 
it is difficult to separate comorbidities from predisposing conditions and true causative factors.  
 
One theory for the higher incidence of noma in the two to five year age group, is that this is the 
teething age when deciduous teeth are formed, this tooth formation slows down the circulatory 
flow to the gums due to compression, leaving the oral cavity more susceptible to infections 
[117].  A Zambian study postulated that during the weaning period, children eat more solid 
food, which was less nutritious and less sterile than breast milk, and this placed them at 
potential risk for noma development [3].  Another study showed that if weaning foods are 
prepared under unhygienic conditions, they are frequently contaminated with pathogens and 
are a major factor in the cause of diarrhoeal diseases [124], a further reported risk factor for 













Studies that attempted to identify risk factors for noma were hampered by the retrospective 
nature of case ascertainment limiting the kinds and standardization of risk factor data collected  
[3, 17, 20, 22, 23, 41, 42, 107].   The absence of a suitable control group precluded the ability 
to find associations between noma and potential risk factors [3, 20, 22, 78, 117].  In other 
studies there was no statistically robust examination of risk factors using proven statistical 
methods such as multivariable regression (which would adjust for confounders), limiting the 
validity and reliability of results [8, 23, 40, 117].  More robust studies, in the form of either 
prospective cohorts, cross-sectional studies or case control studies are needed to understand the 
risk factors for the disease.  
 
2.9  Gaps in the literature 
There is a dearth of literature on noma. The date of the first study included in this review was 
1843, and since this time, an average of one publication has been written on the disease per 
year (calculated based on the studies included in this review).  Despite significant progress in 
scientific methods since the first study, the literature remains predominantly populated with 
case reports and case series of noma.  Ideally, more scientifically robust studies are needed to 
better characterize the aetiology, risk factors and effective treatment and prevention measures 
of this neglected disease.  The reasons behind this neglect include the lack of knowledge about 
the disease by healthcare workers [21, 125], the hypothesized low prevalence of the disease 
[1], which may, in part, be due to assumed inconsistent surveillance and reporting on the 
disease [41], the relative inaccessibility of the affected communities and the rapid progression 
of the disease.  This inaccessibility is characterized by difficulties faced by these communities 
in accessing formal health care.  As evidenced by this review, the changing patterns of noma 
mostly follow the changing global patterns of wealth and development.  As countries have 
developed, access to health care and living conditions have improved and noma prevalence has 
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declined (besides the few continuing sporadic case reports).  Currently, noma cases continue 
to be reported in the most underserved, remote and disenfranchised areas of Africa and Asia in 
particular [3, 7, 16, 18, 20–32].  In the absence of sound evidence-based public health measures, 
noma is likely to persist for the foreseeable future.  
 
Based on this literature review, some of the main gaps in knowledge are enumerating the 
burden of disease (both incidence and prevalence); describing the true mortality rate and 
pathogenic cause(s) of noma and the role of different comorbidities (specifically measles and 
HIV) and social structures in the development of noma.  Factors that influence prognosis and 
the long-term outcomes after care (surgical and non-surgical) [37] including the most effective 
antibiotic treatment protocols [6] need to be assessed.  The knowledge of health care workers 
(biomedical and traditional) about noma in high risk areas, the number of medical school and 
tropical medicine curriculums that include noma; and the role the varying healthcare actors 
could play in prevention [126] also need to be explored.  An additional area for future studies 




2.10  Contextualizing the thesis 
2.10.1  Nigeria overview 
Nigeria, situated in West Africa (Figure 1.1) is home to more than 202 million people and is 
Africa’s most populous country [127]. Nigeria is comprised of an overarching federal 
government, and then subdivided into 36 autonomous states with 774 local government areas 
[127–129].  There are 250 ethnic groups in Nigeria with three dominant tribes – the Ibo, Hausa-
Fulani and Yorubu [130].  Over 500 languages are spoken across the country, Hausa is the 
48 
 
most commonly spoken language (spoken by 63 million people, predominantly in the north), 
English and Pidgin English are the most commonly spoken communal languages (spoken by 
60 million people) [131].  The two main religions in Nigeria are Christianity and Islam which 
are roughly equally practiced by the country’s population along a north-south divide, 
Christianity in the south and Islam in the north [130].  1999 marked the year of return to 
democracy for Nigeria, and since then six democratic elections have taken place [128].  Prior 
to this Nigeria had a range of political systems in place. 1804 saw the creation of the caliphate 
in Sokoto, Nigeria which still exists today with the area being overseen by the Sultan [132].  
The colonial takeover of Nigeria by Britain occurred in the 1800s [132].  The 1900s marked 
the rise in nationalism leading to independence in 1960 followed shortly thereafter in 1966 by 
the first of many coups [132].  Several secession attempts of various parts of the country were 
met with brutal suppression [132], the most notorious of these being the 1967 - 1970 Biafran 
war which led to the death of an estimated three million people, the majority of these were 
civilians who died due to starvation [133].  This conflict had many underlying causes but was 
largely linked to the economic value of the crude oil found in the Niger Delta, the region ear-
marked for secession [133].  
 
Nigeria is Africa’s largest crude oil supplier [130] and has the largest natural gas reserves on 
the continent [128].  Fluctuating oil prices have seen the GDP growth drop from an average of 
7% between 2000 and 2014 to the first recession in Nigeria in 25 years in 2016, when the 
economy contracted by 1.6% [128].  There is great inequality in Nigeria (Gini coefficient 43.0 
(0 represents perfect equality, while an index of 100 implies perfect inequality)) [134]. 
Economic growth is too slow to lift the bottom half of the population out of poverty and growth 
projections remain dire indicating living conditions will worsen [128]. The core reason for the 
high levels of poverty in Nigeria are the high unemployment rates (23%) [128] paired with 
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widespread corruption and political instability [132].  Large sections of the population are 
unable to access basic services [128].  These issues are magnified in the north due to regional 
insecurity (discussed below) and non-inclusive development policies [128], 74% of the 
population in the north live below the poverty line vs 54% in the south  [135]. 
 
Women are at increased risk of suffering from the effects of poverty as they are frequently 
excluded from many aspects of life including the economy, social society, politics and 
intellectual endeavours [130].  Violence against women is rife, 23% of women have reported 
being victims of physical or sexual violence [130].  Nigeria has reported more than 23 million 
girls married as children [130].  Higher rates of illiteracy are reported amongst females 
nationwide but this gender divide is magnified in the north where only 20% of women are 
literate and have attended school [130].  In many traditional Hausa speaking communities in 
the north (including the areas where data collection for this thesis occurred) many females are 
confined to their compounds after marriage where they are reliant on their husbands to provide 
all necessary goods (clothes, food, firewood etc.), non-family males are not permitted entry to 
these compounds [136, 137]. 
 
Several security challenges currently plague Nigeria.  The most notorious is the Boko Haram 
insurgency in the northeast of the country which has resulted in 30,000 deaths and the 
displacement of over two million people [138].  The group is most well-known for their 2011 
bombing of the United Nations headquarters in Abuja and the 2014 kidnapping of 276 school 
girls from Chibok which caused global outrange and bought the group much desired attention 
which has spurred it on to further kidnappings and mass casualty bombings [138, 139].  A less 
well publicised but even more deadly conflict is occurring in the northwest where rising levels 
of farmer-herder conflict have led to the death of thousands of people and the displacement of 
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hundreds of thousands [130, 140].  There has also been a rise of banditry and kidnappings for 
ransom in Nigeria [140–142], further increasing the levels of insecurity in the country. 
 
2.10.2  Nigerian health system 
The structure of the health system in Nigeria is complex.  The three tiers of the Nigerian 
political system are responsible for the three tiers of the health system: the local government 
areas provide primary health care;  the state governments provide secondary health care and 
the federal government provide tertiary healthcare [129].  Access to quality health care is a 
challenge in Nigeria, a lack of resources and differing allocations between these tiers have led 
to poor health outcomes in general in the country [129]. 
 
Health care is mostly reliant on patient service fees [129].  As of 2005, the WHO estimate that 
one night in a tertiary level hospital would cost United States Dollars (USD) 22, an outpatient 
visit to a secondary hospital would cost USD 5 and a 20 minute health centre visit would cost 
USD 7 [143].   These costs are catastrophic for households that earn a median household 
income of  USD 2 per day [143].   
 
Nigeria has one of the highest number of health care workers in Africa; however, at 1.95 health 
care workers per 1,000 population members [144], the number is still too low to effectively 
deliver essential health services with distribution of the health care workers largely confined to 
urban settings.  Access to oral health services is also limited.  There are an estimated 1.2 dentists 
per 100,000 population members [145].   In one Nigerian study, 94% of respondents (n=154, 
mean age 33.44 years (SD 2.34 years) living in rural areas) had never visited the dentist [146].  
The violence and displacement mentioned above leads to further challenges in accessing health 
care for citizens as travelling is dangerous, and it also means a decrease in services reaching 
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these communities.  This lack of access leads to significant poor health status and outcomes in 
this population [129, 147]. 
 
There is variation of the services offered and the coverage of the health system in the different 
states of Nigeria with northern states, where data collection for this thesis took place, being 
less well served than the southern states [129, 147].  Per capita government spending on health 
is greater in the south than in the north, and private companies employing people and 
contributing to their staffs health care is more common in the south than in the north [129]. 
This leads to more catastrophic health expenditure in the north than the south  [129].  
 
2.10.3  Noma in Nigeria 
Nigeria stands out as a country with a high number of cases reported in the 1900’s and 2000’s 
[6–8, 23, 37–39, 41–43, 50, 64, 71, 81, 89, 99, 100, 102, 148]. This could be due to the presence 
of a dedicated noma hospital in Sokoto which is closely linked to an international network of 
researchers rather than as a result of the true distribution of this condition.  The NCH staff [5, 
6, 41] and members of international non-governmental organizations including the Dutch 
Noma Foundation who have supported programmes at the hospital [7, 21, 37, 38, 64, 99, 149] 
have frequently published on noma. The presence of a dedicated facility to support noma care 
has also likely improved detection and referral of noma cases in the region. There is also a 
culture of academic publishing in the country, Nigeria publishes the second most publications 
in Africa, second only to South Africa [150].  This could elevate the number of publications 
on noma, skewing assumptions on distribution. Only robust prevalence estimates derived from 
systematic surveillance efforts in settings where noma has been reported are likely to improve 




In terms of the comorbidities listed in this review, in 2011, 71% of children in Nigeria aged 
under five years were classified as anaemic (Haemoglobin (Hb) <110 g/L) [151].  The WHO 
reported that in Nigeria in 2017, there were 11,190 measles cases reported [152].  Immunization 
coverage in Nigeria for measles is estimated at 42%; much lower than the 70% average for 
Africa [152]. The fertility rate in Nigeria between 2010 and 2013 was 5.5 births per women 
(rural 6.2, urban 4.7), the median age at first birth is 20.2 years [153]. 
 
Given the national interest in noma, the unique health facility dedicated to treating noma and 
high prevalence of known risk factors for noma, this setting was identified as a unique setting 
for answering some of the outstanding questions around noma. The gaps in knowledge 
identified in this review have informed the goals and objectives of this thesis. By consolidating 
and expanding our knowledge on the prevalence, risk factors, beliefs, perceptions and 
traditional healing practices around noma, we hypothesise that we will be able to improve our 
ability to recommend interventions and approaches aimed at reducing the impact of this 
debilitating disease on children in northwest Nigeria.  
 
2.11  Limitations 
Given the inclusion time period of the review (from the 1800’s to present) it is likely that some 
manuscripts (especially in the earlier years) were not available on current indexing systems and 
hence not included in this review. The candidate used Google Translate to translate non-
English papers, which could have led to some misinterpretation as it is not an official academic 
translating service. The inclusion of published manuscripts only and not grey literature could 




2.12  Conclusion 
Noma is a disease that affects young children in the most disenfranchised communities.  It is a 
devastating, disfiguring and often fatal condition that requires urgent and intensive clinical and 
surgical care, often difficult to access in these settings.  Noma has been reported in the literature 
for many hundreds of years.  Given the assumed rarity of the disease and limited accessibility 
of the communities at greatest risk, there are limited primary epidemiological studies on the 
disease, with the majority of the literature being case reports. Little is understood about the 
offending organism(s) and preventable risk factors. The clinical presentation of each noma case 
is unique and depending on the stage of presentation, and extent of physical damage could 
require a variety of surgical, clinical and social interventions to manage.  What is clear from 
the literature is the wide geographical spread of noma, the need for better controlled studies to 
identify the offending pathogens, understand and prioritise the risk factors in order to develop 
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3.1  Abstract 
3.1.1 Background 
Noma is an orofacial gangrene that rapidly disintegrates the tissues of the face.  Little is known 
about noma, as most patients live in underserved and inaccessible regions.  We aimed to assess 
the descriptive language used and beliefs around noma, at the NCH in Sokoto, Nigeria.  
Findings will be used to inform prevention programmes. 
 
3.1.2 Methods 
Five focus group discussions (FGD) were held with caretakers of patients with noma who were 
admitted to the hospital at the time of interview, and 12 in-depth interviews (IDI) were held 
with staff at the hospital.  Topic guides used for interviews were adapted to encourage the 
natural flow of conversation.  Emergent codes, patterns and themes were deciphered from the 
data derived from IDIs and FGDs.  
 
3.1.3 Results 
Our study uncovered two main themes: names; descriptions and explanations for the disease, 
and risks and consequences of noma.  Naming of the disease differed between caretakers and 
heath care workers.  The general names used for noma illustrate the beliefs and social system 
used to explain the disease.  Beliefs were varied; participant responses demonstrate a wide 
range of understanding of the disease and its causes.  Difficulty in accessing care for patients 
with noma was evident and the findings suggest a variety of actions taking place before 
reaching a health centre or health worker.  Patient caretakers mentioned that barriers to care 
included a lack of knowledge regarding this disease, as well as a lack of trust in seeking medical 
care. Participants in our study spoke of the mental health strain the disease placed on them, 




Caretaker and practitioner perspectives may enhance our understanding of the disease in this 
setting and can be used to improve treatment and prevention programmes, and to understand 
barriers to accessing health care.  Differences in disease naming illustrate the difference in 
beliefs about the disease.  This has an impact on health-seeking behaviours, which for noma 
patients has important ramifications on outcomes, due to the rapid progression of the disease. 
 
3.2  Introduction 
Noma, also known as cancrum oris, is a neglected disease of extreme poverty.  It presents as a 
rapidly progressing gangrenous infection of the oral cavity, and is associated with a high 
mortality rate [96].  Noma mostly affects children under the age of five years [94]; if untreated, 
it has been estimated that up to 90% of patients with noma die within weeks after the onset of 
noma [1, 154], and those who survive have severe facial disfigurements [94]. Due to the 
widespread destruction of the facial structures including the cheek, nose, lips and eyes, patients 
with noma also have multiple physical impairments such as difficulty eating, seeing and 
breathing, and many suffer from stigmatization in their communities [2].  Noma is thought to 
be most prevalent in low socioeconomic regions in Africa and Asia [2].  The WHO estimate 
that 140,000 new cases of noma occur annually [1], however this figure is debated due to a 
lack of robust evidence on the epidemiology of the disease. 
 
Since 2014, MSF has collaborated with the Nigerian Ministry of Health to treat noma patients 
identified across the northwest of Nigeria, at the NCH in Sokoto.  This program provides 
nutritional, psychosocial, and surgical interventions for patients with noma.  Identification of 
patients with noma relies on active case detection within villages through extensive outreach 
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activities and widespread communication campaigns to raise awareness of the existence of the 
NCH.  
 
There is still much to learn about noma, as most patients live in difficult to reach areas, and the 
disease often goes undiagnosed and is under-reported.  Given that many cases occur in 
underserved areas, few studies have aimed to explore and describe societal and community 
perceptions of this medical condition.  One study in the medical literature examined the 
language used to describe noma in Hausa (the predominant language in northwest Nigeria).  
The term most commonly used was “ciwon iska”, which translates to ‘the disease of the wind’ 
[64]. Language used to describe diseases carry culturally determined associative meanings 
[155] and have been reported to affect people’s conceptions of disease and the health care 
options they choose [156].  
 
Understanding and using appropriate language is one of the cornerstones of ensuring an 
effective communication strategy with patients, as well as their families and communities. We 
conducted this qualitative study to gain an understanding of the locally used descriptive 
language and concepts of noma.  Specifically, we aimed to understand the perspectives of 
family members of patients with noma and treating practitioners.  We anticipated that our 
findings would inform future interventions and prevention programmes. 
 
3.3  Methods 
3.3.1 Setting  
The NCH in Sokoto, northwest Nigeria, has provided treatment for patients with noma for 




3.3.2 Study Design 
A descriptive qualitative research design was used in which data was gathered from caretakers 
of patients with noma and staff at the hospital using FGDs and IDIs guided by topic-led 
questions.  Both IDIs and FGDs were carried out using themes relevant to the study aims, 
adhering to the open-ended, qualitative interview procedure.  The choice of methods was used 
to gain a rich understanding of the topic specifically the patient and practitioner perspectives 
of the disease [157].  
 
3.3.3 Recruitment and Sampling 
Five FGDs with adult caretakers were conducted between June and July 2017 (predominantly 
the mothers, grandmothers or fathers of the patient with noma) who were looking after the 
patients at the hospital as were 12 IDIs with healthcare staff.  Convenience sampling was paired 
with multivariate sampling (the selection of a wide range of participants from both urban and 
rural areas and a mix of male and females) to ensure a wide variety of participants for the five 
FGDs.  The research assistant (AA) selected men and women for the groups separately, due to 
the social norms of this region, respecting any cultural sensitivities.  There were three female 
groups and two male groups as the majority of caretakers were female. FGDs were composed 
of not more than eight participants at a time.  Vignettes were used to encourage participant 
reflections [158] on relevant life memories, and current experiences related to noma were 
explored.  Purposeful multivariate sampling (participants selected who would offer the widest 
variety of information) [159] was used to recruit healthcare staff members for in-depth 
interviews in order to ensure rich descriptive data from a diverse group. Twelve staff members 
were actively selected at the NCH, by which time data saturation occurred [160].  Three male 
program management staff, one male and four female medical team members and three male 





3.3.4 Data Collection 
Interviews were audio-recorded in quiet, private, locations that were familiar to participants. 
All FGDs were conducted by AA in Hausa; the Principal Investigator (EF) conducted the IDIs 
in English as all respondents were fluent in English.  AA translated transcriptions of recorded 
interviews verbatim from Hausa to English.  Confidentiality was enabled for all participants by 
replacing the names of the respondents and all data referring to them with numerical codes 
indicating the type of sample (IDI for in-depth interview; FGD for focus group).  During the 
FGD, participants agreed to keep confidential what was discussed during the group session.  
Both FGD and IDI respondents were reassured that data that could potentially identify a person 
or location was anonymized using pseudonyms that could not be traced back to them.  
Electronic data were password-protected.  
 
3.3.5 Data Validation and Analysis 
Data validation was conducted through continual checking throughout the IDIs and FGDs; by 
repeating an understanding of what participants were saying throughout the interview, to ensure 
a correct and clear interpretation.  
 
Data analysis started from the moment data were gathered.  Data were initially managed 
through reading and re-reading all transcriptions of recorded conversations allowing for 
familiarisation and initial coding of data.  EF and BS manually analysed the data by 
highlighting words, phrases or paragraphs, which then emerged into codes that were constantly 
compared. Participant responses from IDIs were compared with FGD findings.  Common 
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patterns and themes were identified.  Points of agreement and divergent themes were 
established through this process. 
 
3.3.6 Ethics 
Ethical approval was obtained from the MSF, UDUTH and the Sokoto and Kebbi States 
Ministry of Health ERBs.  Informed consent for interviews and audio-recordings were sought 
using an information sheet translated into Hausa stating the purpose of the study and the 
voluntary nature of participation. All interviewees were over the age of 18 and each participant 
provided written informed consent (for participants who were illiterate, the consent form was 
read aloud to them and a thumbprint was then requested).  All participants were assured that 
there was limited risk of harm from participation in this study, and that they were free to 
withdraw at any point. 
 
3.4  Results 
We present two themes that emerged during analysis: naming and explanations for noma 
(Table 3.1 and 3.2) and risks and consequences of noma (Table 3.3). We illustrate our 





Table 3.1 Names used by caretakers and staff to describe noma. 
 
 Caretakers Staff 
Danhurawa X  
Tuareg X  
Akin X  
Ciwon iska X X 
Ciwon daji X X 
Ciwon/maci dan wawa X  X 
Zaizayar baki  X 
Noma  X 
















“Danhurawa” that is the name we called it. Danhurawa that is the name we called our own. 
Everyone that comes to see it will say yes it is the one. They will say that she is suffering from it.   
FGD 1, female 
They called “iska” and another name is “maci dan wawa” which eats the gums that is the names I 
know iska and maci dan wawa. maci dan wawa eats the teeth and eats the mouth and make a hole 
just like this one 
FGD2, male 
They called the disease “disease of Tuareg” and another name is like Akin FGD 2, Male 
They were saying it was ciwon daji (cancer) FGD 3, Female 
Health care staff 
The word noma itself in the local language it means farming.  So often they mixed it up with 
farming.  
IDI 3, Male, 
Paramedical 
The only name they given to the disease either they say ciwon daji locally which is example like 
is disease from the bush.   
IDI 7, Male, 
Paramedical 
Ciwon daji!  
 
IDI 9, Female, 
Medical 
They always call it noma 
 
IDI 11, Female, 
Medical 
Beliefs and explanations 
Caretakers 
This disease is caused by insect, even the measles they did is caused by an insect, insect from the 
bush. This insect of these Jinn is also an insect.  The measles they called is also an insect from 
the bush. 
FGD 1, Female 
(I) am sure it is one of the traps of iska (Jinn).  FGD 2, Male 
Measles is the cause of the disease. FGD 3, Female 
Some will say it is (caused by) a bird. We told you that if someone get the disease they will say 
that the bird has catch him, it will make your mouth to swell up until they poke it and it will burst 
out and destroy the mouth by falling off. It is all happening. 
FGD 3, Female 
It is God that brings the disease; God gave you the disease FGD 3, Female 
It was henna that is the cause. It was henna that my mother applied on me (henna beautifully 
designed) then she put me on her back then a witch saw me but then nobody knew that she was a 
witch. She then said this henna that you put on her? Is so beautiful! That is all she said! Then 
people said that my mother should quickly cover my legs.  The next day an abscess came out that 
is the first thing that people saw. After a week then I changed and transformed to what I am 
today.  








Health care staff 
The patients believe that it is because of evil cast or evil eye. 
 
 
IDI 1, Male, 
Non- medical 
program staff 
I think I have heard someone saying it's like witchcraft.  
 
IDI 3, Male, 
Paramedical 
They (patients and caretakers) have a strong belief that whatever happened is from God.  
 
IDI 3, Male, 
Paramedical 
It is just evil spirit that is responsible for it. They don’t believe that it is medical problem. 
 
IDI 6, Female, 
Paramedical 
They always believe it is iska that is the belief; iska they believe is just like a wind or let us say 
Jinns. This Jinn are something that are in between us but we cannot see them, Jinn can appear in 
trees and in wind in something, or that is they believe that the Jinns are the ones that came in and 
cause such kind of problem.  
IDI 7, Male, 
Paramedical 





Table 3.3 Risks and consequences of noma with illustrative quotes. 
 
Access to Health Care 
Caretakers 
After some few days we heard the news of this hospital. They said that they can treat this 
type of case. Then they prayed and wish us well and success.  Then we were told to 
hurry and go there so that we can confirm that they can really treat the disease. When we 
arrived, there was a test being carried out and we told that it is possible.  Then they show 
us. All praise be to Almighty Allah he is much better now. We are optimistic that it will 
be successful.  
FGD 4, Male 
But if it is the village, they will be given a treatment that is different from the disease. 
You will be struggling to get the medicines while the sickness will be spreading.  You 
will be running up and down looking for treatment while disease will be expanding.  
FGC 4, Male 
Health care staff 
I can say that noma is not widely known, and this is the only hospital which is 
exclusively dedicated for the noma children disease.  The one of its kind and then more 
than 300 patients have benefited from the plastic surgeries, re-constructive surgeries.  
IDI 1, Male 
Non- medical 
program staff 
We go to all the LGAs in Sokoto, Kebbi and Niger State. We do active case findings that 
mean trying to find new patients. Also, we do health promotion along the way.   
 
IDI 1, Male, 
Non- medical 
program staff 
Impact of the Disease 
Caretakers 
People run away from whatever you use, just because someone’s mouth has cut they will 
say they will not eat with him. 
FGD 2, Male 
When you get this disease some people will be discriminating you, some will be running 
away from you.    But you will not be very happy in life. 
FGD 3, Female 
After some time it will form water then they will poke it (using the traditional hot iron) 
after that then the mouth will burst out and fall off.   
FGD 3, Female 
We were collecting traditional medicines.  We were given it to him. We were using 
Traditional medicines. Woods, powder and so many different types was given to him.   
FGD 4, Male 
The issue is that it destroys and eats the gums, destroys someone’s mouth, that people is 
destroyed also; there is no destruction that is more than this.  
FGD 2, Male 
After some days before a week she changes and transform to this. FGD 3, Female 
What scared us more and makes us to quickly rushed here was that it was itching him 
and he was scratching it the suddenly I saw his fingers going inside the mouth area 
where the disease has affected it cut and falls off. 
 
FGD 4, Male 
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Health care staff 
The success story I would like to share is from a patient that had noma for a long time 
and she was operated in Lagos without success, she was operated in Ibadan without 
success. Until somebody saw her (a doctor who has worked at NCH before). The doctor 
saw her covering her face and she wrote a letter for her to come down to Sokoto. So she 
got surgery about two, three surgeries, she is fine and she is even an employee of this 
hospital. So is a good story. 
IDI 4, Female, 
Medical 
He is always afraid of people because he stays in the bush. So I have to tell him that 
these people you are seeing they are just like your friends and your colleagues we are 
here to help you we will not do anything to harm you. Before he was discharge he has 
plenty friends in the ward he will go to this bed he will gist (talk with) he will go to that 
bed jumping from one ward to the other.  
IDI 9, Female 
Medical 







3.4.1 Naming noma 
The most commonly used name among the health care workers was noma.  One important 
finding was that:  
 “The word noma itself in the local language means farming.  The word noma, the same 
spelling, the same pronouncement, so often they (patients) refer to it in the context of 
farming” (IDI 3).   
 
Several names for the disease were given by the FGD participants:  
 “In our place we called it ciwon daji” (FGD 4).  
 
Naming of the disease differed between caretakers and heath care workers. Table 3.1 explores 
these differences, and suggests only a few overlapping terms; ciwon iska, ciwon daji and 
ciwon/maci dan wawa. 
 
3.4.2 Beliefs and explanations 
Names form a part of the understanding of the disease in this setting; the broad names used for 
noma such as ciwon daji are described in association with the beliefs and social system used to 
explain the disease.  Caretakers shared several terms for the disease as well as beliefs about 
why and how the disease is caused. The three causative categories that were identified were 
spirits, living creatures (insects and animals), and connections with previous illness. 
 
Spirits including Jinn and God were frequently reported: 
 “(I) am sure it is one of the traps of Jinn” (FGD2), 
 “They always believe this thing happens (because) God allow it to be” (IDI7).  
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Jinn was described as the world of other creatures that we cannot see.  The world of Jinn is a 
spiritual realm all around us filled with normal people leading normal lives.  There are good 
Jinn and bad Jinn, and Jinn can enter human bodies and cause harm:  
 “Jinn are something that are between us but we cannot see them.  Jinn can appear in 
trees and in wind in something, Jinns are the ones that came in and cause such kind of 
problem (referring to noma)” (IDI 7). 
 
Some respondents linked the disease to evil spirits or people: 
 “One of the patients believed that it is because of evil cast or evil eye” (IDI 1), 
 “It is just evil spirit that is responsible for it” (IDI6).  
 
Various animals and insects were also mentioned as the potential cause behind noma:  
 “This disease is caused by insect; even the measles they did is caused by an insect.  
Insect from the bush” (FGD 1).  
 
Previous infections were also noted as a potential cause: 
 “Measles is the cause of the disease” (FGD 3).  
 
Whilst beliefs are varied, the participant responses demonstrated a broad range of 
understandings about the disease and as such, it is thought to exist for multiple reasons. 
 
3.4.3 Risks and consequences: access to health care 
Caretakers in our study stated they had taken patients to other health centres before being 
advised to go to the NCH: 
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 “We took him (to) Binji Town, Binji Hospital, they diagnose him and checked him, then 
they said go to Noma Hospital, that is the only place you can get treatment for this and 
that is why we came here” (FGD 2). 
 
Other first points of care were traditional healers, community health centres and private 
doctors.  Treatment options were varied, some attempted to treat the initial oedema phase of 
noma:  
 “After some time it will form water (swelling) then they (traditional healer) will poke it 
(using the traditional hot iron/knife) after that then the mouth will burst out and fall 
off” (FGD 3).  
 
Others struggled to find suitable treatment:  
 “You will be struggling to get the medicines while the sickness will be spreading.  You 
will be running up and down looking for treatment while disease will be expanding” 
(FGD 4).   
 
This suggests a combination of actions taking place before reaching a health centre or official 
health worker. Some participants mentioned barriers to care including a lack of knowledge 
about the disease and a lack of trust in the health system as well as distance from care:  
  “People are coming from very far distance; they said that some people are even 
coming as far as Kaduna they are coming here” (FGD 1). 
 
Limited access to prescribed medication was also reported: 
 “You will be struggling to get the medicines while the sickness will be spreading” (FGD 
4).   
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 “As we want to come to the hospital, everyone is saying not to go as we will just be 
wasting our time.  Then some people said how can we see this situation of life and death 
and just give up we have to try and save a life by seeking for treatment?” (FGD 1).  
 “Back home they will only be trying this and that because they don’t know what it is 
and they don’t know anything about it” (FGD 4). 
 
3.4.4 Impact of the disease 
The impact of noma is not just limited to physical presentation; participants in our study spoke 
of the strain on their mental health that the disease placed on them as caretakers, with 
stigmatization highlighted as a key difficulty: 
 “It cannot allow you to enjoy your life when you are in the company of people. You will 
not be happy when you are mingling with people. They will not include you in their 
important discussions. They will not like to sit with you. They will not eat food with you. 
The only thing is that you will be hiding yourself” (FGD 4).  
 
Caretakers spoke of the physical impact of the disease and its rapid progression along with 
concomitant infections: 
 “From the time (the patient had) measles to the time that she started this disease 
(noma), it was just two weeks” (FGD 1).  
 
The stages of noma were reported as moving rapidly from a swelling of the mouth, to the 
disintegration of the cheek:  
 “Her own started with the swelling, then the swelling will go down and again it will 
swell, after some time then the mouth was destroyed on the lower lip.  Then the flesh 
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was coming out and falling off that is all.  One day the mouth cut off, it was infected 
and destroyed, in just a day” (FGD 1).  
 
Health workers spoke of destructive patient interactions and stories were mentioned which 
indicated the impact stigmatization and social isolation have on the mental and physical health 
of patients and caretakers (also highlighted in [161–164]):  
 “He (patient) is always afraid of people because he stays in the bush.  So, I have to tell 
him that these people (other patients) you are seeing they are just like your friends and 
your colleagues we are here to help you we will not do anything to harm you. Before 
he was discharged he has plenty friends in the ward he will go to this bed he will gist 
(talk with) he will go to that bed jumping from one ward to the other” (IDI 9).  
 
The isolation that caretakers and healthcare professionals reported may influence the ability 
patients have to access health care and for outreach messaging to reach them.  The lack of 
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3.5  Discussion 
3.5.1 What’s in a name? 
Our primary emergent theme, naming of noma, shows this to have multiple attributes in 
northwest Nigeria.  Diseases often have multiple names, and frequently the most common name 
is only one of multiple reported for a single disease.  Naming of diseases can originate from 
visible symptoms; work on lymphatic filariasis in Nigeria has reported that local names for the 
disease include “elephant legs” and “swollen legs”, which appropriately describe the visible 
manifestation of the disease [165].  Other naming options come from expected causes or, quite 
commonly in biomedicine, diseases are named after the individuals involved in historical 
descriptions, such as Alzheimer’s or Parkinson’s [166]. 
 
Noma is a Latinised form of a common Greek word, and is a metaphor for the continuing 
process of a wildfire [64].  This metaphor links conceptually with the rapid progression of the 
disease, as does the Hausa word ciwon iska, which loosely translates to ‘the disease of the 
wind’ [64], this could also refer to the understanding of disease transmission (spirits or animals 
travelling by the wind).  The naming of noma as ciwon daji which loosely translates to ‘cancer’ 
in English is also of interest, as this is similar to a biomedical name for the disease which is 
frequently used, cancrum oris, meaning mouth cancer [64].  Some of the other names for noma 
used by staff in our study were different to those used by patients.  Health care workers in our 
study most commonly reported using the word noma when discussing the disease; this is 
expected, as it is the name used most commonly in the biomedical community. Noma, however 
is not the only name used in this community to describe this disease; other terms include 
necrotizing ulcerative stomatitis and cancrum oris [64].  Our results suggest that the name most 
commonly used by patients to describe noma was ciwon daji. The use of names such as ciwon 
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iska by caretakers shows a naming system more linked to a spiritual conceptualisation of the 
disease, and limited biomedical understanding of the disease process. 
 
A further novel finding from this work is that the word noma in Hausa means farming.  This 
has the potential to cause confusion during awareness campaigns and should be taken into 
consideration during the planning phase. The commonly used names for identifying noma 
should be incorporated into all messaging used in noma prevention and treatment programmes.  
This will create clearer communication between project staff, the community, patients and their 
caretakers and allow for an incorporation of more comprehensive language around this disease 
to ensure messaging is clear and effective. 
 
3.5.2 Explanations for noma 
The way diseases are described and understood can differ between people and groups due to a 
wide range of perceptions and shared social understanding of the illness, differences in 
language used [156], understanding of the clinical diagnosis itself [167], and the value 
judgements placed on these concepts [168].  Producing an explanatory model of disease [169] 
can provide a significant contribution to effective treatment programmes and therefore positive 
program outcomes.  An explanatory model for noma was formed as the names used for noma 
were seen to be associated with a social understanding about the disease, which can be shown 
to impact upon what care is sought or followed by patients. 
 
There is limited literature on the explanatory models around noma in this setting.  However, a 
study on models for health-seeking behaviour for leprosy patients in Adamawa State, central 
Nigeria has shown that the majority of respondents explained the illness in terms of traditional 
beliefs and as ’God’s wish’[170], as did patients in a further Nigerian study on orofacial clefts 
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[171].  The leprosy and cleft participants in these studies reported seeking help from alternate 
health sources, for example traditional healers [170, 171], as did a study assessing health-
seeking behaviours for hypertension in Nigeria [172].  Patients were all able to identify what 
disease they had by name in both the leprosy [170] and hypertension [172] studies, which 
indicates that these diseases are better understood in the Nigeria context than noma.  
 
From our findings, the notion that noma is linked to the spirit world, is reiterated in a study 
from northern Nigeria.  In that work, it was reported that not much was known about noma in 
those communities, and as such, broad names such as ‘ciwon iska’ (disease of the wind) were 
used [64].  During our interviews, the caretakers explained iska as being sent by ‘Jinn’, the 
spirit world.  This name links noma to the spirit world and offers insight into the potential 
explanation for noma in this community.  If caretakers believe noma has a spiritual cause, this 
could explain why many caretakers seek care from traditional healers.  Traditional healers 
typically offer treatment strategies which probe deeply into the psychological, spiritual, and 
social contexts of illness [173], as well as physical treatment including piercing the cheek with 
a sharp object and/or offering herb mixtures to place on the wound or ingest.  
 
Our findings suggest there is no primary explanation within this community for the disease; 
biomedical beliefs are less dominant, thus suggesting a pluralistic understanding of the disease.  
The neglected nature of this disease could contribute to and exacerbate this.  As so little is 
known about the disease globally, there is limited knowledge to share on prevention. This has 
an impact on the care that is sought with consequences such as poor linkage to treatment, under-
reporting and poor outcomes for patients. Our findings suggest that a caretaker’s knowledge 
and explanations for the disease may affect health-seeking treatment decisions (Figure 3.2).  
The beliefs people hold about disease have been shown in other studies to impact health- 
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Figure 3.2 Explanatory model for noma.   
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seeking behaviours [155, 156, 174–176].   Figure 3.2 illustrates how beliefs can result in certain 
actions.  We do however, note that decisions are very unlikely to be as simplistic as illustrated 
in the diagram, and that several different actions could take place due to a certain set of beliefs.  
 
3.5.3 Risk and consequences of noma 
Access to health care in this part of Nigeria is difficult, health care is expensive and poor 
infrastructure makes transportation to health facilities challenging [177].  A lack of access to 
healthcare has been widely reported as a risk factor for noma development [7, 32, 75, 94], and 
our results add weight to these assertions in that caretakers mention the difficulties they 
experienced accessing care for this disease.  The rapid progression of noma, lack of access to 
care, and the delays caused by caretakers having to progress through several facilities (clinics 
or traditional healers), means that resulting morbidity and mortality can be severe. 
 
The impact of noma is multifactorial; both caretakers and health workers in our study spoke of 
the mental health strain the disease placed on both patients and caretakers.  The social isolation 
caused from stigmatization of diseases is well documented [161–164].  Mental strain caused 
by social isolation has a wide ranging impact and can negatively affect both the mental and 
physical health of patients and their families [161–163].  Caretakers described the physical 
impact of the disease and its rapid progression along with associated links with concomitant 
diseases.  The stages of noma were reported as moving from a swelling of the mouth, to the 
disintegration of the cheek skin, which follows clinical descriptions in the literature [1]. 
 
Names, beliefs, access to health care and the impact of noma are all interlinked, and form a 
web of issues that compound the ruthlessness of the disease.  The strength of this study is that 
it explored the topic from two perspectives; that of the caretakers of patients, and the healthcare 
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staff at the NCH.  There were several limitations to the study, the caretakers being interviewed 
were already at the hospital, and had likely had education on the disease from hospital staff 
prior to our interviews, and the beliefs they reported could have been different from caretakers 
in the population who did not reach the hospital.  This bias could be mitigated by conducting a 
similar project with community members who do not have a family member affected by the 
disease.  Further research needs to focus on the link with traditional healing, understanding the 
true burden of the disease and the pathogenic cause. This would enable efficient prevention 
programmes to be formulated. 
 
This chapter has offered an overview of the naming, explanatory models for and risks and 
consequences of noma in northwest Nigeria.  Caretaker and practitioner perspectives enhance 
a better understanding to support case finding, referral and knowledge on barriers to care.  The 
impact of the differences noted between the names used between health workers and patients 
is apparent.  Different naming of diseases illustrates the difference in beliefs and has an impact 
on health-seeking behaviour, which for noma patients, has severe ramifications due to the rapid 
progression of the disease.  Other areas where noma is endemic would benefit from similar 
assessments that include patient caretaker and practitioner perspectives to ensure a 
comprehensive understanding of the contextual issues and explanatory models of the disease. 
The commonly used names for identifying noma should be incorporated into all messaging 
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4.1  Abstract 
4.1.1 Background 
Noma (cancrum oris), a neglected disease, rapidly disintegrates the hard and soft tissue of the 
face and leads to severe disfiguration and high mortality.  The disease is poorly understood. 
We aimed to estimate risk factors for diagnosed noma to better guide existing prevention and 
treatment strategies using a case-control study design. 
 
4.1.2 Methods 
Cases were patients admitted between May 2015 and June 2016, who were under 15 years of 
age at reported onset of the disease.  Community controls were individuals matched to cases 
by village, age and sex (three per case).  Caretakers answered the questionnaires.  Risk factors 
for diagnosed noma were estimated by calculating univariable and multivariable ORs and 
adjusted odds ratios (aOR) and respective CI’s using conditional logistic regression.   
 
4.1.3 Results 
We included 74 cases and 222 controls (both median age five (interquartile range 3, 15) years).  
Five cases (6.5%) and 36 (16.2%) controls had a vaccination card (p=0.03). Vaccination 
coverage for polio and measles was below 7% in both groups.  The two main reported water 
sources were a bore hole in the village (cases n=27, 35.1%; controls n=63, 28.4%; p=0.08), 
and a well in the compound (cases n=24, 31.2%; controls n=102, 45.9%; p=0.08).  The 
multivariable analysis identified potential risk and protective factors for diagnosed noma which 
need further exploration.  These include the potential risk factor of the child being fed pap (type 
of porridge staple made from maize, sorghum, or millet), every day (aOR 9.8; CI 1.5, 62.7); 
and potential protective factors including the mother being the primary caretaker (aOR 0.08; 





This study suggests that social conditions and infant feeding practices are potentially associated 
with being a diagnosed noma case in northwest Nigeria; the findings warrant further 
investigation into these factors. 
 
4.2  Introduction 
Noma or cancrum oris, is a poorly understood, rapidly progressing gangrenous infection of the 
oral cavity, associated with a high mortality rate [1].  It mostly affects children under the age 
of five years [1].  It is estimated that if left untreated, up to 90% of noma cases die within weeks 
after the onset of noma [1, 154], and those who survive have severe facial disfigurements [94].  
These can result in multiple physical impairments such as difficulty speaking, swallowing, 
eating, seeing and breathing which can lead to stigmatization in their communities [2].  The 
majority of cases are currently reported in Africa [3, 7, 16, 18, 20–23] and Asia [21, 24–32].  
However, over the past 15 years, there have been sporadic reports of cases originating and 
being treated in Turkey [33], Afghanistan [34], Italy [35], the United Kingdom [36] and the 
United States [11].  A northwest Nigerian-based study concluded that the incidence of noma is 
estimated to be 6.4 per 1,000 children from 1996 to 2001 [7], and the WHO estimates that 
140,000 children contract noma each year globally [19].  
 
Little is understood about noma as most cases live in underserved, difficult to reach locations, 
many cases go undiagnosed and the mortality rate is so high.  Previous observational studies 
have suggested that risk factors for the development of noma include malnutrition, low 
birthweight, absence of breastfeeding, poor oral hygiene, comorbidities, proximity of livestock 
to area of residence, large family size, access to unsafe drinking water  and living in a village 
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with a high prevalence of acute necrotizing gingivitis [1, 2, 34, 43, 56].  Recently, an increased 
incidence of noma has been reported in higher resource settings in patients with 
immunosuppressive diseases such as HIV [17, 20, 107]. 
 
Since 2014, MSF has collaborated with the Nigerian Ministry of Health to treat noma patients 
identified across the northwest of Nigeria, in Sokoto. The program provides nutritional, 
psychosocial (for the patient and their families) and medical care to prepare noma patients for 
the required surgical interventions at the NCH.  These are conducted by Nigerian Ministry of 
Health and MSF surgical teams on a routine basis; since August 2015, the program has treated 
227 noma patients.  We conducted a case-control study to identify risk factors for diagnosed 
noma in terms of demographic characteristics, medical history, socioeconomic-behavioural 
aspects and access to health care in order to better guide existing prevention and treatment 
strategies for this neglected disease. 
 
4.3  Methods 
4.3.1 Setting 
The study was conducted in Sokoto and Kebbi States, which are located in northwest Nigeria.  
 
4.3.2 Study population 
Cases were defined as patients with diagnosed noma admitted to the NCH between May 2015 
and June 2016 who were under 15 years of age at self-reported onset of the disease.  Controls 






4.3.3 Sample size 
Our aim was to include all cases enrolled at the NCH in the year before data collection, and we 
calculated that with a sample size of 67 cases and 200 controls (three controls per case), we 
would be able to estimate an OR of 2.5 for suspected risk factors with a power of 80% and 60% 
of controls being exposed to that risk factor.  Controls were selected from houses neighbouring 
those in which the cases and their families live. 
 
4.3.4 Data collection 
Parents or caretakers of cases and controls were asked questions, topics covered included 
sociodemographic characteristics (age, gender, education, employment, total household 
members), their current living conditions (water source, proximity to livestock, material of 
houses) and their vaccination history (read on vaccination card if available).  Additionally, 
parents and/or caretakers were asked to respond to questions pertaining to the duration of 
breastfeeding after the cases and controls were born and other nutrition-related practices during 
the neonatal period and current practices.  The health status, access to health care and health 
care seeking behaviour for the case or control in the previous 12 months were also assessed.  
Finally, all cases and controls aged less than five years at the time of interview had a mid-upper 
arm circumference (MUAC) measurement taken at the time of the interview.  
 
The questionnaire was formatted in KoBoCollect (KoboToolBox ©) and uploaded to tablets 
for mobile data collection purposes.  Completed questionnaires were uploaded daily to a secure 
MSF server through an internet connection.  The study co-ordinator verified all completed 





4.3.5 Data analysis 
We calculated the frequencies and respective proportions for all categorical variables and used 
chi-square tests for comparison of these variables between cases and controls.  For continuous 
variables, we calculated means with SD or medians and interquartile ranges (IQR) (depending 
if approximately normally distributed) for cases and controls separately, and used t-tests to 
compare normally distributed variables, and Kruskal Wallis tests for non-normally distributed 
variables. 
 
Food variables for current feeding practices were categorised as animal products (meat, milk, 
egg), grains (fura, mashed rice, millet, corn, bread) and vegetables (sweet potato, beans, bean 
cake, moringa leaf, ground nut cake, cassava).  Respondents could answer with ‘Yes’, ‘No’ 
and ‘Don’t know’.  We grouped all responses for ‘No’ and ‘Don’t know’ into a single category.  
To investigate the impact of this grouping, we conducted a sensitivity analysis for each of these 
variables.   As the results showed that the direction of association remained the same, we 
retained this grouping as the reference category.   
 
We estimated risk factors for being a diagnosed noma patient by comparing odds of exposure 
in cases and controls using univariable and multivariable conditional logistic regression to 
calculate OR and their respective CIs and p-values.  The multivariable conditional logistic 
regression model was constructed using all risk factors that had a p-value of <0.2 in the 
univariable analysis and sufficient outcomes in each category.  Variables were eliminated from 
the multivariable model using a manual backwards stepwise approach [178], and multivariable 
models were compared using the likelihood ratio test, any variable with a p-value under 0.2 
was kept in the model.  All data analyses were conducted with Stata 14 (StataCorp, College 




Ethical approval was obtained from the MSF, UDUTH and the Sokoto and Kebbi States 
Ministry of Health ERBs.  All interviewees were over the age of 18 years and written informed 
consent was provided by each participant (for participants who were illiterate, the consent form 
was read aloud to them and a thumbprint was then requested).  Caretakers were defined as the 
primary caretaker of the child in question.  All participants were assured that there was limited 
risk of harm from participation in this study, and that they were free to withdraw at any point.  
 
4.4  Results 
4.4.1 General findings 
Out of the 112 noma patients who had sought care in the program between May 2015 and June 
2016, we identified 87 who lived in Kebbi and Sokoto States and were eligible for inclusion in 
the study.  Of these, ten could not be located, and we managed to interview 77 cases (88.5%).  
We were unable to reach the village of three identified cases for logistical reasons.  Thus, the 
final analysis included 74 noma cases and 222 controls.  Six of the cases had died in the time 
between discharge and the interview; the interviews were still conducted with their caretakers.  
At the time of first admission to the hospital, 17 of these cases had acute noma, 57 had inactive 
noma, two had trismus and one had no diagnosis noted at time of admission to the hospital.  
Twenty-one cases were hospitalized at the time of interview and the remaining 56 were 
interviewed in their home villages. 
 
As expected, there were no significant differences in matching variables (sex and age of child) 
between cases and controls.  The control group differed from the case group in that caretakers 
were younger, their family sizes were smaller (and houses in the compound fewer) and most 
of their houses were made of mud, wood or bamboo (which might be a proxy for higher 
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socioeconomic status) (Table 4.1).  Also, the respondents for the control group were more 
frequently the mother of the child.  The self-reported median age of onset of noma amongst 
cases was 2.0 (IQR 2.0, 3.0) years.  
 
Cases between six months and five years old had lower mean MUAC measurements (mean 
134; SD 20) than controls (mean 142; SD 11; p=0.002).  Six percent of cases (n=5) had a 
vaccination card available at the time of interview, compared with 16% (n=36; p=0.03) of 
controls.  The vaccination coverage (based on the vaccination card) for polio (cases n=3, 3.9%; 
controls n=13, 5.9%; p=0.7) and measles (cases n=2, 2.6%; controls n=15, 6.8%; p=0.1) was 
very low for both cases and controls.  Parents and caretakers reported that most cases (n= 63, 
81.8%) and controls (n= 158, 71.2%; p=0.22) had been breastfed for between one to two years 
after birth.  With respect to the main source of drinking water, parents reported that the two 
main water sources were a borehole in the village (cases n=27, 35.1%; controls n=63, 28.4%; 
p=0.08) and a well in the family compound (cases n=24, 31.2%; controls n=102, 46.0%; 
p=0.08).  In terms of animal ownership, the proportion of case and control families reporting 
owning donkeys, dogs, sheep, goats and chickens were similar. Case families, however, were 
less likely to have cows in their compound compared with controls (cases n=36, 46.8%; 
controls n=128, 57.7%; p=0.09). 
 
4.4.2 Risk factor analysis 
The univariable analysis suggested that the likelihood of being a diagnosed noma case 
increased when the household was large (>10 people), the child had a higher birth weight (self-





Table 4.1 Sociodemographic characteristics of cases and controls (p-values from chi-
squared, t-test or kwallis). 
 





Child age (years) at time of interview,  
Median (IQR) 
5.0 (3.0, 15.0) 5.0 (3.0, 15.0) 0.94 
Child sex (female) 113 (50.9%) 37 (48.1%) 0.67 
Caretaker age (years) 18-34 147 (68.7%) 37 (48.7%) 0.002 
35-90 67 (31.3%) 39 (51.3%) 
Missing 8 1 
Child first born (yes) 33 (14.9%) 13 (16.9%) 0.4 
Family size (number of children 
sleeping in 1 hut), Mean (SD) 
11.5 (8.8) 15.8 (13.8) 0.0016 
Number of wives, Mean (SD) 2.0 (7.6) 1.6 (0.7) 0.64 
Main caretaker Mother 132 (59.5%) 25 (32.5%) <0.001 
Other 36 (16.2%) 28 (36.4%) 
Relationship 
not specified 
54 (24.3%) 24 (31.2%) 
Caretaker employed No 76 (45.2%) 33 (51.6%) 0.39 
Yes 92 (54.8%) 31 (48.4%) 
Missing/NA 54 13 







102 (46.0%) 36 (56.3%) 
Number of houses in compound, 
Mean (SD) 
3.5 (2.8) 4.5 (3.5) 0.008 
Main materials of house wall Wood, mud, 
bamboo 
175 (78.8%) 41 (53.3%) <0.001 
Stone, brick, 
cement 
45 (20.3%) 12 (15.6%) 
Other 2 (0.9%) 24 (31.2%) 
IQR-:interquartile range, SD: standard deviation, NA: not applicable 
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age of 12 months, the child ate pap (type of porridge staple made from maize, sorghum, or 
millet), and grains each day.  Protective factors against acquiring noma included: the mother 
being the primary caretaker, the caretaker being married, having a well in the compound, 
colostrum being given to the child, child first given water over the age of seven months, all 
children in the household being alive and the child having taken medication (traditional or 
biomedicine) in the year preceding the interview (Table 4.2).   
 
Due to collinearity, the following variables were not included in the multivariable analysis: the 
food group variable “Grains” (fura, mashed rice, millet, corn, bread), material the walls of the 
house was made out of, wealth score, measles, polio, one or more vaccination being reported 
on a vaccination card. In the multivariable analysis, eating pap every day remained strongly 
associated with diagnosed noma (OR 9.8; CI 1.5, 62.7; p=0.02) as did a later age of first solid 
food (>12 months) (OR 5.07; CI 0.9, 26.08; p=0.07). Variables that were protective against 
being a case included the mother being the primary caretaker (OR 0.08; CI 0.01, 0.5; p=0.007), 
the caretaker being married (OR 0.006; CI 0.0006, 0.5; p=<0.001) and colostrum being given 
to the baby (OR 0.4; CI 0.09, 2.09; p=0.07) (Table 4.2).  
 
4.5  Discussion 
This study has highlighted potential risk and protective factors associated with being a 
diagnosed noma case in northwest Nigeria, including caretaker demographics and infant 
feeding practices.  This identification aims to shed light on potential useful areas for further 
investigation.  Similar risk factors have been suggested including the absence of breastfeeding 
[56], dietary habits [3], unsafe drinking water, limited access to high quality health care, high 











n (%) n (%) OR CI P-Value aOR CI P-Value 
Primary caretaker is mother Yes 132 (60%) 25 (32%) 0.2 0.1, 0.5 <0.001 0.08 0.01, 0.5 0.007 
Caretaker married Yes 158 (71%) 14 (18%) 0.03 0.01,0.09 <0.001 0.006 0.0006, 0.5 <0.001 
Child first born Yes 33 (15%) 13 (17%) 1.2 0.6, 2.5 0.6  
Caretaker educated Yes 102 (46%) 36 (47%) 1 0.6, 1.8 1 
Caretaker employed Yes 92 (41%) 31 (40%) 0.9 0.5, 1.7 0.9 
Total household members 1-9 113 (51%) 29 (38%) Reference 
10 or above 109 (49%) 48 (62%) 1.8 1.006, 3.09 0.05 2.06 0.8, 5.3 0.1 
Compound life 
Water source Other 120 (54%) 53 (69%) Reference  
Well 102 (46%) 24 (31%) 0.5 0.2, 0.9 0.04 
Water treated Yes 73 (33%) 24 (31%) 0.9 0.5, 1.6 0.8 
Electricity Yes 77 (35%) 25 (32%) 0.5 0.2, 1.4 0.2 0.2 0.04, 1.5 0.1 
Number of livestock species 
in compound 
 
1-3 100 (45%) 40 (52%) Reference  
4 or more 122 (55%) 37 (48%) 0.8 0.4, 1.4 0.4 
Nutrition 
Colostrum No 19 (9%) 19 (25%) Reference Reference 
Yes 149 (67%) 44 (57%) 0.3 0.2, 0.7 0.002 0.4 0.09, 2.09 0.07 
Don’t know 54 (24%) 14 (18%) 0.05 0.005, 0.4 0.001 <0.001, 0.5 
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Breast fed duration 7-12 months, other 64 (29%) 14 (18%) Reference  
>1 year and <2 
years 
158 (71%) 63 (82%) 16.9 2.1, 134.5 0.008 
Age (months) child first 
given water 
0.6 126 (57%) 53 (69%) Reference 
7 or above months 26 (12%) 6 (8%) 0.4 0.2, 1.2 0.03 
Don't know 70 (32%) 18 (23%) 0.2 0.07, 0.8 
Age (months) first given 
solid food 
0-11 112 (51%) 44 (57%) Reference Reference 
12 months or after 38 (17%) 16 (21%) 1.2 0.6, 2.3 0.03 5.07 0.9, 26.08 0.07 
Don't know 72 (33%) 17 (22%) 0.2 0.05, 0.7 0.2 0.01, 2.9 
Pap every day Yes 124 (56%) 55 (71%) 3.5 1.5, 8.2 0.004 9.8 1.5, 62.7 0.02 
Food eaten at least once a 
day (ref = no/don't know) 
 
- Animal products Yes 28 (13%) 10 (13%) 0.9 0.4, 2.1 0.9  
- Grains Yes 165 (74%) 62 (81%) 5.9 1.2, 29.7 0.03 
- Vegetables Yes 57 (26%) 21 (27%) 1 0.5, 1.9 1 
- Drinks Yes 94 (42%) 36 (47%) 1.2 0.7, 2.2 0.6 
- Child, family eat same 
meals 
Yes 165 (74%) 61 (79%) 3.4 0.8, 13.6 0.09 
Health 
Births in total (mother of 
child) 
0-5 99 (46%) 30 (39%) Reference  
6 or more 69 (31%) 34 (44%) 1.4 0.8, 2.6 0.5 
Don't know 54 (24%) 13 (17%) <0.001 0, - 0.5 
Births alive Some died 64 (29%) 43 (56%) Reference 
All still alive 103 (46%) 20 (26%) 0.4 0.2, 0.6 0.003 
Don't know 55 (25%) 14 (18%) <0.001 0, - 
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Birth weight Low/normal 27 (12%) 9 (12%) Reference  
High 78 (35%) 39 (51%) 1.6 0.7, 3.7 0.03 
Don't know 117 (53%) 29 (38%) 0.7 0.3, 1.7 
Medication in previous year Yes 127 (57%) 32 (42%) 0.4 0.2, 0.7 0.006 0.3 0.07, 1.6 0.2 





measles vaccination was a protective factor for noma [57], but we were unable to corroborate 
this as the estimated vaccination coverage in both cases and controls was too low for a relevant 
comparison to be conducted.  Our multivariable analysis did not identify an association 
between noma and household size or water source as reported elsewhere [75, 179], however, 
the univariable analysis suggested a possible association between these exposures and 
diagnosed noma and therefore warrants further investigation.  We were also unable to confirm 
other reported risk factors for noma including high numbers of previous pregnancies in the 
mother [56] pre-existing illness, malnutrition [41], poor oral hygiene practices [34] and 
proximity of livestock to the area of residence [34]. 
 
One novel observation of the study was some weak evidence for the possible protective nature 
of colostrum.  There are inherent health benefits associated with colostrum as it is rich in 
antibodies that confer passive immunity and growth factors which have been shown in recent 
studies to assist in the treatment of autoimmune disorders and gastrointestinal conditions [180].  
Recent case reports have highlighted the global problem of noma and in some cases a 
relationship to concomitant infections including HIV positive patients in London [36] and the 
United States [11], and a Korean child with Crohn’s disease [108]. These reports offer insight 
into the disease and strongly suggest that immunosuppression plays a role in the causal pathway 
of noma development which supports the finding of the protective nature of colostrum.  
However, it should be noted that these are clinical case reports and not analytical 
epidemiological studies.  It is also possible that mothers who give their children colostrum are 
also more likely to follow other health messaging.  Both aspects would have a favourable 
impact on the overall health status of an infant and therefore render the child to be at a lower 
risk of noma development.  Our findings on this point were not definitive but this could be a 




The finding in the univariable analysis that having taken medication in the year prior to the 
study was a protective factor could indicate that having access to health care plays a role in 
noma development.  This could be due to health care proximity or possibly due to improved 
socioeconomic status which would allow the families to pay for transport to get to health care 
and/or health care provision.  Those who develop noma would conceivably have fewer 
possibilities to seek care for other diseases or the beginning stages of noma, and as such are at 
higher risk of developing the disease.  
 
The finding that eating pap every day is a risk factor for diagnosed noma development, could 
be due to the fact that pap is the food usually used for weaning in Nigeria, it has a low nutrient 
density and has been reported to be at risk of unhygienic handling [181].  Two microbiological 
analyses of foods commonly used in weaning (including pap) in Nigeria, showed bacterial 
contamination at higher levels than international guidelines recommend [182, 183].  All of 
these factors mean that during the weaning period, the use of pap can predispose infants to 
infections and subsequently high mortality rates [181]. Possible solutions to reduce this 
exposure, would be to strengthen education about hygienic food preparation [182], the benefits 
of alternate practices such as fermentation which enhances nutritive value of the food [181] or 
encouraging variety in the diet.  Improving feeding during the weaning time is crucial to 
decrease child malnutrition, mortality rates and to enhance development  [183].  
 
The findings showed that in both the case and control groups there was a high proportion of 
child morbidity and that families where the majority of infants born to the same mother 
survived, were less likely to have a noma case.  This finding suggests that sociodemographic 
characteristics of families and households play a role in the disease dynamics of diagnosed 




This could indicate that children in these households are also more exposed to unsafe water, 
poorer standards of living and reduced access to care, as all of these exposures are known to 
be associated with higher infant mortality [184–189]. 
 
Vaccination coverage in the study population is well below the standards recommended by the 
Nigerian Ministry of Health [190] and WHO [191].  There is evidence that the occurrence of  
vaccine preventable diseases and malnutrition precede the onset of noma [2, 11, 20, 32, 192].  
The low coverage of vaccination not only increases the risk of morbidity and mortality from 
vaccine preventable diseases, but is a contributing factor in immunosuppression which is 
thought to play a key role in the sequence of events for noma development.  
 
Our study is unique because available evidence around noma manifestation and risk factors for 
the development of the disease is based on a handful of primary studies [56, 75, 179], case 
reports [32, 34, 36, 108] and reviews [2, 20, 94].  These studies were methodologically different 
from ours which could offer reasons for the differing findings.  A case control study conducted 
in Niger came closest to the current study design, although this study was conducted over six 
years and the controls were not matched on sex [56].  Our results also differ from those of a 
further Niger-based study [179], which included four villages in the study population and 
focused on the link between noma and acute necrotizing gingivitis.  In comparison, our study 
was conducted over a relatively short time period and was retrospective in nature.  Furthermore, 
our cases and controls were matched on sex in addition to village of residence and age, which 
might have eliminated some bias that could have been present in the previously mentioned 
studies.  Finally, our study included diagnosed noma cases who were resident across 80 villages 




previous studies, which might have contributed to the differences in risk factors identified 
[179].   
 
We attempted to interview all patients cared for at the hospital in the year before data collection, 
however this was not possible due to several constraints.  Even though we managed to exceed 
our minimum sample size, we identified strong associations between only a minority of the 
explored risk factors and diagnosed noma.  It is likely that the risks associated with individual 
exposures for noma are weaker than we assumed in the original sample size calculation.  
 
A further limitation is that our risk factor analysis only represents those cases who sought care 
at the NCH in Sokoto.  Due to the reported 90% mortality rate within weeks after the onset of 
noma [1] if untreated and rapid progression of noma, this likely means that the results of the 
current study are only applicable to the subset of noma cases who experienced the least severe 
complications from the disease.  
 
The measurement of malnutrition using only the MUAC was a limitation as this tool is useful 
to diagnose severe acute malnutrition but noma is reported to be associated with chronic 
malnutrition or stunting.  Finally, we included all cases who were under the age of 15 at the 
time of self-reported disease onset.  Therefore some cases (and thus controls) were under 15 
years at the age of onset but were currently ≥18 years (13 cases) thus we interviewed them 
personally and not their caretaker.  This might have introduced some bias into the study as 
certain questions around infant feeding practices etc. would only have been possible to be 
answered by their caretakers, leading to missing information on these questions.  We tried to 





In conclusion, our case control study suggests that infant and current feeding behaviours as 
well as caretaker demographics may affect the risk of developing noma.  Malnutrition and low 
vaccination coverage, high morbidity of infectious diseases along with limited access to health 
care are all likely contributing factors.  We recommend that prospective studies are 
implemented to better understand the sequence of events contributing to the development of 
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5.1  Abstract 
5.1.1 Background 
Noma is a rapidly progressing infection of the oral cavity often resulting in severe facial 




A retrospective descriptive analysis of routinely collected data was undertaken (demographics, 
diagnosis and surgical procedures undergone) and follow-up assessments (anthropometry, 
mouth opening and quality of life measurements) were conducted.  Patients living in Sokoto or 
Kebbi States who had noma surgery more than six months prior to data collection were 
included.   
 
5.1.3 Results 
Of the 37 patients included, 21 (56.8%) were male and 22 (62.9%) were aged six years or older.  
The median time between last surgery and follow-up was 18 months (IQR 13, 25 months).  At 
admission, the most severely affected anatomical area was the outer cheek (n=9; 36% of 
patient’s had lost between 26% and 50%).  Twelve patients (32.4%) had one surgery and 15 
patients (40.5%) had two to three surgeries. The most frequently used surgical procedures were 
the deltopectoral flap (n=16 patients; 43.2%) and trismus release (n=12, 32.4%).  For the eight 
trismus release patients where mouth opening was documented at admission, all had a mouth 
opening of between 0-20 millimetres (mm) at follow-up visit. All of the patients reported that 







Our findings show that at follow-up, surgically treated noma patients report improvements in 
their quality of life despite limited increases in mouth opening.  Although reconstructive 
surgery in noma patients can improve aesthetics and function, it did not restore patients to their 
pre-noma level of function.  
 
5.2  Introduction 
Noma (cancrum oris) is a poorly understood, rapidly progressing infection of the oral cavity 
with a reported 90% mortality rate within weeks after the onset of first symptoms if untreated 
[154]. Noma begins as a mouth ulcer and, within days, progresses to oedema of the cheek 
followed by necrosis and the rapid destruction of the hard and soft tissues of the face [94].  
Treatment with antibiotics, wound debridement and nutritional support in the early reversible 
stages of the disease greatly reduce mortality and morbidity [2].  Noma is thought to be 
multifactorial in nature [2]. The aetiology of noma is currently debated, organisms such as 
Fusobacterium necrophorum and Prevotella intermedia [52, 192] have been identified in noma 
cases but are not consistently present [2]. 
 
If the patient survives the acute stages, the disease can become inactive (with or without 
antibiotic treatment), after which patients often need complex surgical reconstruction in order 
to restore orofacial function and improve aesthetics [94].  Reconstruction often entails 
rebuilding the lips and cheeks and in some cases the eyelids and nose [4, 25].  However, each 





Long-term physical sequelae of noma include displacement of the teeth and severe scarring 
and bony fusion between the maxilla and mandible [2, 4, 92, 94–96].  Sequelae around daily 
functioning may include difficulty eating, seeing, talking and breathing [57, 94, 96].  The social 
isolation or mental health sequelae of noma patients have not been documented in the literature 
but should not be underestimated. 
 
Trismus (restriction of the mouth opening) is one of the most disabling sequelae [6] of noma 
and can lead to complications such as aspiration, malnutrition, poor oral hygiene, speech 
deficits, airway compromise and pain [97].  Trismus associated with noma can be caused by 
scarring around the temporo-mandibular joint capsule (extra-articular ankylosis) or by 
destruction and scarring of the temporo-mandibular joint itself (intra-articular ankylosis) [6, 
38, 55, 193, 194]. 
 
Reported surgical techniques to address the spectrum of noma defects include pedicled 
supraclavicular flaps for the treatment of large unilateral facial defects [100], Abbe, Estlander, 
and fan flaps for the reconstruction of the lips and corner of the mouth [4, 102], forehead, 
deltopectoral, radial forearm and free flaps for the reconstruction of the cheek [4, 55] and Abbe, 
radial forearm, free, medial forehead and local turnover flaps for the reconstruction of central 
defects (upper lip and nose) [4, 55, 92].  Mouth opening is improved by performing bone-
bridge excision, sometimes associated with contralateral coronoidectomy [55]. 
 
Outcomes of noma treatment are difficult to ascertain due to inconsistent patient follow-up. 
This is mostly due to the remote locations of the home villages of patients.  One of the only 




Nigeria (n=36) and showed that after a mean follow-up time of 43 months, results were poor 
with only 39% of patients showing improvement in mouth opening [6]. 
 
The NCH in northwest Nigeria, run by the Nigerian Ministry of Health and supported by MSF 
since 2014, offers care to noma patients including reconstructive surgical interventions. We 
present a description of the follow-up of a case series of patients treated surgically at the NCH 
to inform ongoing clinical treatment and areas for future study.  Our study adds to the existing 
noma case series and is unique as we have followed-up patients over a longer period (median 
of 18 months) in comparison to other studies which had follow-up periods of between two and 
six weeks [5, 92, 99]. 
 
5.3  Methods 
5.3.1 Study setting 
We conducted a case series study with patients who had been surgically treated for noma at the 
NCH more than six months before data collection and who lived in Sokoto or Kebbi States.  
Data collection took place from April to June 2018. 
 
5.3.2 Data collection 
Data collection was done in two stages.  The first stage was based on data collected at admission 
and for the duration of their stay at the NCH (routine data).  The second stage of data collection 








5.3.2.1  Routine data 
The routinely collected data were stored in a bespoke database at the NCH.  Information 
gathered on each of the patients included demographics, diagnosis upon admission (chronic is 
defined as the absence of ongoing acute infection) and nutritional status.  
 
Surgical data collected included the number and type of surgical procedures and surgical 
complications (infection, dehiscence, flap necrosis, flap failure). American Society of 
Anaesthesiologists (ASA) scores were assigned to patients prior to surgery (indicating the 
fitness of patients before surgery) (Table 5.1).  Anaesthesia complications during and after 
surgery were recorded (difficult airway, hypothermia, equipment failure). The nose, outer 
lining, inner lining, trismus, upper lip, lower lip, particularities (NOITULP) classification 
system was used by a surgeon with experience in the treatment of noma to grade patients upon 
admission.  This classification system delineates the extent of orofacial damage and related 
functional compromise, according to fractional loss of anatomical units (nose, outer and inner 
cheek lining, upper and lower lip) and trismus categories ranging from normal mouth opening 
(>40 mm) to no mouth opening [38] (Table 5.2).  
 
5.3.2.2  Follow-up data  
Data collected included weight (kilograms; kg), height (centimetres; cm), age (years), MUAC, 
for children aged six months to five years and maximum mouth opening.  Height was measured 
using a height board for those under and including five years of age and a tape measure for 
those older than five years.  One manual floor scale was used for weighing all participants, this 
was calibrated daily. Training for anthropometry measurements was conducted before data 




Table 5.1 ASA classification system. 
 
ASA Score Score definition 
ASA I A normal healthy patient 
ASA II A patient with mild systemic disease 
ASA III A patient with severe systemic disease 
ASA IV A patient with severe systemic disease that is a constant threat 
to life 
ASA V A moribund patient who is not expected to survive without the 
operation 
ASA VI  A declared brain-dead patient whose organs are being removed 
for donor purposes 






Table 5.2 NOITULP scale – classification for noma (nose, outer lining, inner lining, 
trismus, upper lip, lower lip, particularities) [4]. 
 
 Fractional loss of anatomical unit 
 0 1 2 3 4 
Nose No loss 1-25% lost 26-50% lost 51-75% lost 76-100% lost 
Outer lining No loss 1-25% lost 26-50% lost 51-75% lost 76-100% lost 
Inner lining No loss 1-25% lost 26-50% lost 51-75% lost 76-100% lost 
Upper lip No loss 1-25% lost 26-50% lost 51-75% lost 76-100% lost 
Lower lip No loss 1-25% lost 26-50% lost 51-75% lost 76-100% lost 
Trismus* T0:  
normal mouth 
opening  
> 40 mm 
T1:  
mouth opening  
20-40 mm 
T2:  
mouth opening  
0-20mm 
T3:  




Brief description of particularity:  
NA- not applicable;  
*Trismus is not an anatomical unit but a functional problem – the inability to open the mouth properly. It has been 
included in the system because of its clinical relevance (e.g. for intubation); 
**Particularities represent pathologic findings pertinent to reconstruction, i.e.: Loss of lower eyelid tissue (Eyelid 
retraction by a scarred cheek is not to be noted); Affection of the orbit; loss of an eye is seen quite commonly; Palatal 







patient (if >18 years) or their caretaker.  Mouth opening was measured by trained research 
assistants using a ruler.  The maximum mouth opening measurements were measured as the 
millimetres of mouth wide open minus the millimetres of mouth closed (incisor-to-incisor 
where possible or alveolar ridge to alveolar ridge).  
 
As there was no validated quality of life scale in Hausa, we asked questions related to the 
patients’ ability to eat and drink, their self-reported changes in appearance and how they 
currently experienced social inclusion in their community.  These questions were based on 
tools used in prior reconstructive surgery studies [195–199].  Questions were extracted from 
these tools.  The questions were translated in Hausa and back translated into English to ensure 
accuracy of translations. These questions have not to our knowledge been used in other noma 
studies.  Quality of life questions were asked to adult respondents directly and to child 
respondents if the child felt comfortable discussing the issues with the interviewer.  If children 
were aged under seven years or felt uncomfortable talking with the interviewers, the children’s 
caretakers were asked the questions. 
 
5.3.3 Data analysis 
5.3.3.1  Data analysis routine data 
A descriptive analysis was conducted.  Median and IQR were reported for non-normally 
distributed continuous values; means and SDs were reported for values with normal 
distributions.  For children aged six months to five years, MUAC measurements were used to 
classify the nutritional status of children upon admission as having severe acute malnutrition 
(SAM; MUAC <115 mm), moderate acute malnutrition (MAM; MUAC ≥116 mm ≤125 mm)  
or global acute malnutrition (GAM; MUAC <126 mm) [200].  For children aged six to 15 




to categorise children according to BMI for age.  Children were classified as underweight (BMI 
<5th percentile), normal (6th–84th percentile), overweight (85th and 95th percentile) and obese 
(above the 95th percentile) [201].  For individuals aged 16 years and older, weight and height 
were used to classify individuals’ BMI ranges as underweight: under 18.5 kg/m2, normal: 18.5 
to 25kg/m2, overweight: 25 to 30kg/m2, obese: over 30kg/m2 [202]. 
 
5.3.3.2  Data analysis follow-up 
Nutritional status at follow-up was assessed by the same means as at admission: SAM, MAM, 
GAM and BMI were calculated.  Mouth opening measurements were used to grade patients 
according to the NOITULP scale trismus categories at follow-up by the research team in 
conjunction with a consultant level surgeon.  Quality of life answers were stratified by age 
group (below and above 15 years). 
 
All analyses were conducted in Stata 15 (StataCorp LP, College Station, TX, USA). 
 
5.3.4 Ethics 
The MSF, UDUTH and Sokoto and Kebbi State Ministry of Health ERBs approved the study 
protocol.  Informed consent was sought at follow-up.  Consent to review medical records was 
explicitly sought.  All participants were treated in accordance with the ethical principles of the 
Helsinki Declaration. 
 
5.4  Results 
5.4.1 Demographic information of enrolled patients 
We included 37 (82.2%) of the 45 eligible patients.  The remaining eight could not be located 




patients were alive at follow-up.  Of these 37 patients, 21 (56.8%) were male, 34 (91.9%) were 
from Sokoto and 12 (34.3%) were aged above 15 years at admission as were 17 at follow-up 
(patients were aged between four and 50 years at follow-up).  Most patients (n=35; 94.5%) 
were diagnosed as having chronic noma upon admission.  The main reported reasons for 
seeking care were cosmetic (n=25; 67.6%) and the related stigmatisation (n=24; 64.9%) with 
only 14 (37.8%) reporting functional disability as a reason for seeking care (Table 5.3).  The 
median number of months between last surgery and follow-up was 18 (IQR 13, 25 months).  
 
5.4.2 NOITULP classification at admission 
At admission, the most severely affected anatomical area was the outer cheek (n=9; 36.0% of 
patient’s had lost between 26% and 50%)  (Figure 5.1 and Figure 5.2). 
 
5.4.3 Surgical procedures  
Of the 37 patients included in our study, 12 (32.4%) had one surgery, 15 (40.5%) had two to 
three surgeries, and the remaining 10 (27.0%) had four or more surgeries.  In total, 92 surgeries 
were conducted during which 125 procedures were performed.  The mean duration of each 
surgery was 90 minutes (SD 49 minutes). The most frequently used surgical procedure was a 
deltopectoral flap (n=16 patients; 43.2%) followed by trismus release (n=12 patients; 32.4%) 
(Table 5.4).  No blood transfusions were required for any patients during their surgeries. 
 
Eight surgical complications were noted in seven patients (18.9%), one patient had a superficial 
infection and an abscess.  Complete dehiscence was reported in two patients (5.4%).  One 
(2.7%) of each of the following complications were reported: flap failure, flap necrosis, flap 
detachment, neck pain needing physiotherapy and infection on corner of mouth. There were no 




Table 5.3 Respondent characteristics at admission. 
 
Demographic characteristic n= 37 (%) 
 Sex  
 
Female 16 (43.2%) 
Male 21 (56.8%) 
 State 
 
Kebbi 3 (8.1%) 
Sokoto 34 (91.9%) 
 Patient age upon admission (years) 
 
 
0-5 13 (37.1%) 
6-15 10 (28.6%) 
>15 12 (34.3%) 
 Patient education 
 
 
None 1 (2.8%) 
Arabic Studies 34 (94.4%) 
Primary school  1 (2.8%) 
 Noma diagnosis on admission 
 
Acute noma 2 (5.4%) 
Chronic noma 35 (94.6%) 
 Had treatment for noma prior to coming to NCH 
 
No 22 (59.5%) 
Yes 15 (40.5) 
 Kinds of previous noma treatment 
 
Antibiotics 11 (73.3%) 
Traditional 4 (26.7%) 




Malaria 10 (27.0%) 
HIV 0 (0.0%) 
TB 0 (0.0%) 
Measles 14 (37.8%) 
 Any vaccination before hospital admission 
 
No 17 (46.0%) 
Yes 20 (54.1%) 
 Health care seeking reason Cosmetic 25 (67.6%) 
Stigmatization 24 (64.9%) 
Functional disability 14 (37.8%) 










* Missing information: nose (n=13); outer and inner cheek lining (n=12); upper lip (n=15); 






Figure 5.2 Trismus classification at admission for study cohort (mm = mouth opening 



















































Table 5.4 Surgical procedures performed on study cohort, 37 patients*. 
 
Surgical procedure n=37 (%) 
Deltopectoral flap  16 (43.2%) 
Release of trismus  12 (32.4%) 
Commissuroplasty and lip reconstruction 11 (29.7%) 
Estlander flap  10 (27.0%) 
Forehead flap  6 (16.2%) 
Nasal reconstruction  5 (13.5%) 
Fan flap 5 (13.5%) 
Cheek rotation flap 2 (5.4%) 
Other procedures  14 (37.8%) 






5.4.4 Anaesthesia information 
All patients who had data available on the type of anaesthesia received (n=35) had undergone 
general anaesthesia.  ASA scores were assigned for the 87 surgeries for these 35 patients: 69 
(79.3%) surgeries had an ASA score of I, 17 surgeries (19.5%) had a score II and one surgery 
(1.15%) had a score of III.  Four (10.8%) patients had anaesthesia complications noted during 
five surgeries. Three surgeries had unanticipated difficult airways (difficulty with facemask 
ventilation, difficulty with endotracheal intubation); there was one case of hypothermia and 
one case of anaesthesia equipment failure. 
 
5.4.5 Nutritional status 
Of the 37 patients included in the study, five (13.5%) had an improved nutritional status at 
follow-up and in four (10.8%) patients the nutritional status had deteriorated.  The other 
patients had an unchanged nutritional status.  Of the three patients under five years of age at 
admission, two (66.7%) patients aged between six months and five years were classified as 
having SAM and one (33.3%) patient was classified as having GAM using MUAC 
measurements.  At follow-up, all three (100%) patients fell within the normal range indicating 
that these three children had an improved nutritional status at follow-up.  In the six to 15 year 
age group (n=17), 12 (70.6%) children were categorised as normal weight at admission, four 
(23.5%) of these children were underweight at follow-up, and the others (47.1%) were normal. 
Two patients (11.8%) were underweight at admission, one (5.9%) of these was classified as 
normal at follow-up and the other was still underweight (5.9%).  One (5.9%) patient was 
overweight at admission and normal at follow-up.  For those aged 16 years and above (n=17), 
mean BMI was 19.0 (SD 3.3) upon admission and 18.7 (SD 3.5) at follow-up.  The difference 






There were 17 trismus release procedures conducted on 12 patients (8 = 1 procedure, 3 = 2 
procedures, 1= 3 procedures).  At follow-up, the median maximum mouth opening for those 
aged 15 years and under (n=7) was 15.3 mm (IQR 7mm, 18mm) and 10 mm (IQR 2mm, 20mm) 
for those aged 16 years and older (n=5).  Although we had mouth opening measurements at 
follow-up that could be translated into the NOITULP mouth opening score for all patients, at 
admission we only had the allocated NOITULP score and not the actual mouth opening 
measurements for eight patients.  As such, a comparison of the pre- and post-operative mouth 
opening NOITULP classification for these eight patients is seen in Table 5.5.   No patient had 
a normal mouth opening status at the follow-up visit (all classified as T2, 0-20 mm).  
 
5.4.7 Quality of life at follow-up 
All respondents reported that the surgery had improved their quality of life in one facet or 
another.  Respondents in the under 15 year age group reported that the surgery had led to 
decreased social isolation (n=17; 85.0%) and improvements in functional aspects such as eating 
(n=16; 80.0%) and talking (n=16; 80.0%).   Respondents in the 15 year and older age group 
reported improvements in social acceptance (n=17; 100.0%) and enhanced self-esteem 





Table 5.5 Mouth opening categories on admission and follow-up. 
 
Patient Age at 
follow-up 
Admission Follow-up 
Patient 1 7 T2:  mouth opening 0-20 mm T2: mouth opening 0-20 mm 
Patient 2 7 T3: no mouth opening T2: mouth opening 0-20 mm 
Patient 3 8 
 
T1: mouth opening 20-40 mm 
 
T2: mouth opening 0-20 mm 
Patient 4 8 
 
T0: normal mouth opening:  
 >40 mm 
T2: mouth opening 0-20 mm 
Patient 5 10 T3: no mouth opening T2: mouth opening 0-20 mm 
Patient 6 18 T3: no mouth opening T2: mouth opening 0-20 mm 
Patient 7 20 T3: no mouth opening T2: mouth opening 0-20 mm 
Patient 8 22 
 
T2: mouth opening 0-20 mm 
 






Table 5.6 Self-reported quality of life assessment at long-term follow-up. 
 
 
Quality of life indicator 
≤15 year olds* 
n=20 (%) 
>15 year olds* 
n=17 (%) 
The surgery has improved your quality of life 18 (90.0%) 16 (94.2%) 
At this point in time, I can go to school 10 (50.0%) 13 (76.5%) 
At this point in time, I have friends    17 (85.0%) 17 (100.0%) 
I am now included in the community 15 (75.0%) 17 (100.0%) 
I can now get married 5 (25.0%) 2 (11.8%) 
I can eat more easily than before the surgery 16 (80.0%) 16 (94.1%) 
I can drink more easily than before the surgery 15 (75.0%) 16 (94.2%) 
People can now understand what I am saying more easily 





I feel more happy with the way I look than before the 
surgery 
15 (75.0%) 17 (100.0%) 






At the follow-up visits, patients and caretakers were asked if and how the surgery had changed 
their lives.  Some feedback from patient caretakers was negative, and they did not want any 
further care: 
“The surgery was not successful and I do not want to come back to the hospital.” 
(Patient age 8 year old). 
 
Other caretakers reported difficulties with restricted mouth opening and related functional 
issues: 
“The opening of the mouth is very small making it difficult to eat or drink.” (Patient 
age 29 year old). 
 
There was some mixed feedback showing improvements in quality of life but continued 
difficulty with mouth opening: 
“The mouth opening is a bit difficult because the side stitches are tight.  However she 
can eat and talk well.” (Patient age 28 year old). 
 
And some other patients reported positive functional changes and social acceptance:  
“He was shy and angry before the surgery and he is now able to eat and go to school. 
He used to not be audible but now he talks loud and clear.” (Patient age 10 year old). 
 
“He is very happy to have the treatment and he can meet different people since the 





5.5  Discussion 
Our findings suggest after surgical care, all patients reported improvements in at least one 
aspect of their quality of life, with many reporting functional improvement in eating, drinking 
and speech, despite minimal evidence that trismus had improved.  This corroborates findings 
from an Ethiopian study, which showed that post-operative follow-up revealed significant 
improvement in the lives of noma patients [111].  Most of the patients had more than one 
surgery, and the most commonly used procedure in our cohort was the deltopectoral flap which 
is utilized in the reconstruction of the cheek, the most commonly affected anatomical area.  
Children aged over 15 years reported more social and aesthetic improvements in their lives 
than the younger children (going to school, being accepted into the community, having more 
friends). This could be indicative of the stage of life these respondents are at, in comparison to 
the likely more home bound younger children who might experience less social isolation due 
to their appearance. 
 
Our case series confirms the complexity and unique manifestation of noma, and the need for 
numerous surgical procedures to obtain an acceptable functional and cosmetic result.  As most 
patients had more than one surgery, this needs to be taken into account for program planning 
and patients should be informed of the need to potentially return to the hospital multiple times 
for these surgeries in order to manage treatment expectations.  The most commonly performed 
procedures were the deltopectoral flap, release of trismus, commissuroplasty and lip 
reconstruction, Estlander flap, forehead flap and nasal reconstruction.  The procedures 
performed rely on regional flaps and local tissue and are in line with other reported surgical 
techniques used to treat noma [4, 24, 55, 92, 100, 102, 203]. Other providers have described 




microsurgery, these techniques are not currently utilised at the NCH.  The surgical program 
instead enlists older but reliable reconstructive techniques that are less risky in this context.  
 
Noma cases are at high risk of developing trismus resulting in difficulties in speech, chewing, 
and maintaining healthy oral hygiene practices [6]. This case series has highlighted that despite 
surgical intervention, none of the patients in this cohort regained a normal mouth opening.  
Respondents reported ongoing concerns with their restricted mouth opening and the impact 
this restriction had on their lives.  Similar studies with noma patients noted that the results of 
trismus release in noma patients was extremely poor [6, 193].  A northwest Nigerian study 
reported that 43 months after surgery the mean mouth opening of 36 patients was 10 mm [6].  
A similar study with 95 patients from Niger and Burkina Faso reported that after three years, 
mean mouth opening was 21 mm [55]. Our results were similar to these studies and showed 
that all patients had a mouth opening of between 0 and 20 mm at follow-up (median mouth 
opening of our cohort (aged ≤15 years 15 mm; aged >16 years 10 mm).  
 
This outcome is not unique to noma. The overall success rates of curing trismus in 
inflammatory processes other than noma (oral submucous fibrosis, chronic non-bacterial 
osteomyelitis) in the paediatric population can be low [204, 205].  In the majority of noma 
patients (as well as patients with other inflammatory causes of trismus), the trismus is extra-
articular [55].  Noma can disrupt the peri-articular bony tissues of the subcondylar area, which 
is the location of the growth plate of the mandible.  Other research into mandibular trauma has 
also reported that this disruption of the growth plate has resulted in increased fibrosis and 
trismus [97, 205–207], and we can hypothesise this is also a contributory factor in noma.  
Similarly, this area of the mandible can be disrupted by surgery to correct trismus (such as gap 




release until the mid-teen years to avoid, or at least decrease, the need for revision trismus 
surgery. Delaying trismus release surgery until skeletal maturity is likely to be effective for 
noma patients to reduce the post-surgical reduction in mouth opening.  This delay should only 
occur if a child with noma can drink and eat enough calories to continue to feed, grow and gain 
weight.  In these cases longer-term follow-up will be necessary as they will almost certainly 
need to undergo a revision procedure in future.  While there are no specific rules or 
recommendations for trismus release and ankylosis repair in the literature, in studies and meta-
analyses demonstrating high success rates for inflammatory causes, the patients are typically 
in the teenage years [204].  The success rates for paediatric trismus surgery are far higher in 
congenital and traumatic causes, where the surrounding capsule and other structures are 
unaffected [204].  A very important further step which has been shown to maintain adequate 
mouth opening and resulting quality of life after trismus release surgery is longer-term post-
operative physiotherapy which can enable patients to have an improved mouth opening [55, 
204].  We do not have physiotherapy treatment or uptake information for patients included in 
the study, however; the NCH program currently includes rigorous physiotherapy following 
trismus release while at the hospital, patients are also provided with an exercise list to complete 
when at home after discharge and they are assessed by the physiotherapist at the follow-up 
appointments at the hospital. 
 
Our study has illuminated three potential changes for program planning and potential 
interventions. Firstly, as the anaesthesia complications were notable, it is important that 
surgical teams should include anaesthesia professionals who are specialised in difficult airway 
management.  Secondly, as some patients remained malnourished, it is important to conduct 
nutritional follow-up with all patients.  Lastly, vaccine preventable diseases and a lack of 




of the patients included in this study shows that these populations should be the target for public 
health interventions, which could reduce the number of noma cases along with a host of other 
diseases. 
 
Eighteen patients who were eligible to be included in the study were lost to follow-up, this 
could have introduced selection bias into the study and altered our findings.  Most patients in 
this study reported improvements in quality of life; however, these questions were only asked 
at follow-up and not prior to surgery.  Social desirability bias could have influenced the quality 
of life answers, particularly given that trismus was not markedly improved in most cases.  As 
there is no validated tool for assessing quality of life following surgery for noma, comparisons 
with other study results will be difficult.  In order to improve our assessment of quality of life 
changes, it would be beneficial to use a standardised, validated assessment tool at admission 
and follow-up [208]. Furthermore, the retrospective review of routinely collected data limited 
the type and quality of data available for analysis. We have now implemented a prospective 
study to assess the outcomes of patients that will address many of the weaknesses of this current 
case series as the same data will be systematically collected at standardized time points 
(admission, pre-surgery, post-operatively; six and 12 months after the date of last surgery).   
 
Following their last surgical intervention, noma patients do experience some improvements in 
their quality of life, but debilitating long-term sequelae persist.  Reconstructive surgery does 
appear to restore form and function in some patients.  However, noma is a preventable 
condition that, if detected early can be effectively treated with antibiotics before the devastating 
consequences described in this cohort of patients occur.  Therefore, public health interventions 
should prioritise strategies that address known risk factors through community-based health 
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6.1  Abstract 
6.1.1 Background 
Noma, a neglected disease mostly affecting children, with a 90% mortality rate within weeks 
after the onset of noma if untreated, is an orofacial gangrene that disintegrates the tissues of 
the face in <1 week. Noma can become inactive with early-stage antibiotic treatment. 
Traditional healers, known as mai maganin gargajiya in Hausa (the most commonly spoken 
language in northwest Nigeria), play an important role in the health system and provide care to 
noma patients in Nigeria. We interviewed caretakers of noma patients and traditional healers 
and explored perceptions of noma, relationship dynamics, health care practices and 
intervention opportunities. 
 
6.1.2 Methods  
We conducted IDIs with 12 caretakers who were looking after noma patients admitted to the 
NCH and 15 traditional healers in their home villages in Sokoto State, northwest Nigeria. 
Interviews were audio-recorded, transcribed and translated. Manual coding and thematic 
analysis were utilised. 
 
6.1.3 Results  
Traditional healers offered specialised forms of care for specific conditions and referral 
guidance. They viewed the stages of noma as distinct conditions with individualised remedies.  
Caretakers trusted traditional healers. 
 
6.1.4 Conclusion 
Traditional healers could play a crucial role in the early detection of noma and the health-




traditional healers through training and referral partnerships.  This collaboration could save 
lives and reduce the severity of noma complications. 
 
6.2  Introduction 
Noma (cancrum oris) is a rapidly progressing gangrenous infection of the oral cavity, which 
mostly affects children aged two to five years.  If left untreated, noma is associated with a 
reported 90% mortality rate within weeks after the onset of first symptoms [1, 154].  Those 
who survive have severe facial disfigurements and multiple physical impairments including 
difficulties in eating, seeing and breathing [2]. Noma manifests in stages which are categorised 
by the WHO: simple gingivitis; acute necrotizing gingivitis (accompanied by fetid breath), 
oedema, gangrene (hard and soft tissue destruction), scarring and sequelae [1].  The total 
destruction of the cheek can take place in less than one week [1].  During the early stages of 
noma, infections can become inactive if patients are treated with antibiotics, wound cleaning 
and nutritional support; thus decreasing morbidity and mortality [2].  In many cases, however, 
patients live in remote locations and access to health care takes considerable time.  
 
Primary research on noma is limited, hence knowledge sharing about the disease is impeded. 
The most commonly reported risk factors are malnutrition, poverty, immunosuppression, co-
infections, poor vaccination coverage, lack of access to quality health care, not receiving 
colostrum at birth and caretakers (also known as caregivers) being someone other than the 
mother [2, 56, 209].  The majority of cases are currently reported in Africa [3, 7, 16, 18, 20–
23] and Asia [21, 24–32].  However, over the past 15 years, there have been sporadic reports 
of cases originating and being treated in Turkey [33], Afghanistan [34], Italy [35], the United 





The Nigerian Ministry of Health supported by MSF implements prevention and treatment 
programmes for noma at the NCH in Sokoto, northwest Nigeria.  The program includes a strong 
outreach component focussing on finding cases and awareness raising about noma with 
community members and health workers. 
 
The health system in Nigeria is comprised of three levels: primary (local government), 
secondary (state government) and tertiary (federal government) [210].  These levels of the 
health system operate in tandem alongside traditional medicine.  Mai maganin gargajiya (the 
Hausa name for traditional healers) play an important role in health care globally [211] and in 
Nigeria, with an estimated 80% of the population exclusively using this form of care [212].  A 
Nigerian study reported that close to 10% of rural dwellers and 4% of urban dwellers in Nigeria 
were traditional healers, proportions much higher than those trained in biomedicine [213].  
Patronage of traditional healing waned due to restrictions and the introduction of biomedicine, 
but recently, there has been an increase in seeking this form of care due to the ability of 
traditional healers to provide physical, psychological and spiritual care [214]. Traditional 
healers are said to either reside in the villages within which they serve, or to move around from 
village to village providing care as they go [215].  Traditional healers practices include utilizing 
remedies such as plants and trees [213, 216–219], piercing and cuts [220] and prayer [221].  
 
As prevention and early detection are the most important strategies in reducing the impact of 
noma, it is crucial to consider the role of traditional healers in the pathway to care for noma 
patients.  We interviewed caretakers of noma patients and traditional healers to explore their 
perceptions of noma, the relationship dynamics between the two; traditional healers’ health 




partnerships with traditional healers.  The information generated through this research will be 
used to guide noma outreach strategies. 
 
6.3  Methods 
6.3.1 Setting  
Interviews with caretakers of noma patients were conducted at the NCH and interviews with 
traditional healers were conducted in their home villages in Sokoto State, northwest Nigeria. 
Among 110 noma patients who were admitted at NCH from January to December 2018, 53 
(48.2%) had early-stage noma, 50 (45.5%) were female and 58 (52.7%) came from Sokoto 
State.  The median age of self-reported onset was three years (IQR 1, 7 years) and 40 (36.4%) 
patients had sought care from traditional healers before coming to the hospital. 
 
6.3.2 Study design 
A qualitative study was conducted between April and June 2018.  Semi-structured interview 
guides with open-ended questions were used, and the course of the interviews were left open 
so that any new themes that emerged could be fully explored.  
 
6.3.3 Recruitment and sampling  
IDIs were conducted with 12 caretakers (looking after child patients admitted to the NCH at 
the time of data collection) who were recruited using convenience sampling.  The interviews 
were carried out by HMB, a first language Hausa speaker who was thoroughly trained before 
data collection commenced and who has experience working with noma patients, accompanied 
by the Principal Investigator, EF.  The researchers interviewed caretakers who were present at 
the hospital during the data collection period.  The head matron of the hospital invited 




periods of times (up to six months), they were known to the head matron.  We met with the 
matron and requested that she invite caretakers from both rural and urban locations to increase 
the variety of potential participants.  Fifteen traditional healers (people in the community who 
have taken on the role of providing non-biomedical health care and have not received 
biomedical training) were recruited through purposive sampling. The outreach team at the NCH 
compiled a list of traditional healers working in Sokoto State where the MSF program was 
based (between a 30 minute and three hour drive from the hospital).  Traditional healers were 
then contacted from this list by telephone.  If they could not be reached by phone, the research 
team visited their villages and invited them to participate.  
 
All participants were informed of the aims of the study prior to the interviews taking place. 
The researchers conducted interviews until data saturation occurred, saturation being the point 
at which no new information emerged from the interviews [160]. 
 
6.3.4 Data collection 
Interview guides were developed for both interview groups (caretakers and traditional healers) 
in English, translated into Hausa by HMB and then back-translated by an independent Hausa 
speaker to ensure accurate translation.  Any inconsistencies were rectified and the final version 
was used for pilot interviews, after which additional adjustments were made and the guides 
were then finalised. Interviews were conducted in Hausa and audio-recorded in quiet, private, 
locations.  During the interviews, photographs of the five different stages of noma were shown 
to traditional healers to help interviewees discuss their knowledge and health care practices for 
the various stages of the disease.  Interviews lasted approximately 30-45 minutes.  No one else 





6.3.5 Data analysis 
Audio-recorded interviews were transcribed into Hausa and then translated verbatim into 
English by HMB and checked by EF.  Data saturation was discussed between investigators and 
once this occurred, data collection ended.  Transcripts were manually coded by EF.  EV and 
EF read the translated transcripts several times, and then codes that emerged were highlighted.  
The codes were then discussed within the research team, firstly between HMB and EF and then 
with three other members of the research team (EV, JGC and BS) [222]. Thematic analysis was 
undertaken to identify patterns in the data with attributed codes  [222].  
 
6.3.6 Ethics  
The MSF, UDUTH, and the Sokoto State Ministry of Health ERBs approved the study 
protocol.  Procedures followed were in accordance with the ethical standards of the Helsinki 
Declaration.  Written informed consent for interviews and audio-recordings were obtained in 
Hausa.  For participants who were illiterate, the consent form was read aloud to them and a 
thumbprint was then requested in place of a signature.  
 
6.4  Results 
We interviewed 12 caretakers of noma patients and 15 traditional healers.  Caretakers were 
predominantly the mothers of patients (10/12); one was the grandmother of a patient, and the 
other the father.  The median age of caretakers was 38 years and ranged from 22 to 55 years. 
Traditional healers were mostly male (13/15).  The median age of male traditional healers was 
55, ranging from 35 to 80 years, and they reported practicing traditional medicine for a median 
number of 30 years, ranging from two to 50 years.  Female traditional healers were younger 





Three main themes emerged during data analysis: 1) the role and experiences of traditional 
healers, particularly in the management of noma cases; 2) relationship dynamics between 
caretakers and traditional healers; and 3) knowledge and perceptions of noma and treatment 
health care practices for the different stages of the disease.  
 
6.4.1 The role and experiences of traditional healers in Sokoto, northwest Nigeria 
Traditional healers reported that they played specific roles in the community, were well known 
and believed that their healing skills were understood and appreciated in the areas where they 
lived and worked: 
 “Everybody in this village small or big… knows that it is my work” (Traditional Healer 
(TH) 8). 
 
Even though the traditional healers resided in the communities within which they worked, some 
were well known in a wider geographical region, and reported that patients visited them from 
hundreds of kilometres away, some even travelling across borders:  
 “Based on my ability, people are coming [from] everywhere [even] all the way [from] 
Tawa [in Niger].  They are all coming to search for help from me” (TH 15). 
 
Traditional healers reported learning their craft in different ways, including inheriting the 
knowledge from family members and others through dreams and spirits: 
 “I inherited [traditional healing knowledge] from my grandfather” (TH 3). 
 “This craft, I got it from a spirit.  In my dreams I am told what [treatments] to get and 





Many traditional healers stated that they had specializations and only treated specific diseases.  
One traditional healer reported treating an array of diseases, whereas others noted one or two.  
None of the traditional healers specifically mentioned noma, although some of them mentioned 
treating elements of it (such as ciwon daji [cancer] and iska [spirit]). 
 “We have remedies for gudawa (dysentery), shawara (typhoid) and for basur 
(haemorrhoids)” (TH 1). 
  “I sell remedies for ciwon baya (back pain) and zufanjiki (general swelling of the 
body)” (TH 4). 
 
These diseases were reportedly treated by the traditional healers with a variety of methods. 
Most of the remedies offered were obtained from sources surrounding their villages, such as 
trees and plants.  Remedies included giving patients dried herbs, grinded plants “to soak” and 
then to drink, ointments to rub onto the skin and piercing of the skin to create “bleeding marks”.  
In conjunction with other aspects of their healing traditional healers used spiritual beliefs 
including reciting the Qur’an to their patients. 
 
6.4.2 Relationship dynamics between caretakers and traditional healers  
Caretakers of noma patients reported seeking care from a range of health services in the 
community including hospitals, pharmacists (informal care providers who sell medication) and 
traditional healers. 
 “I prefer going to the hospital because they care most about a person’s health” 
(Caretaker (C)7). 






Caretakers had differing perceptions of traditional healing: some said they made use of 
traditional healers’ health care services because they were effective or accessible and some 
because they were affordable: 
 “If we go, we get better” (C9). 
 “Some people prefer visiting traditional healers if they are ill as they will quickly get 
treatment [in comparison] to [the time it would take at the] hospital” (C 10). 
 “I went there [to a traditional healer]. I find it much better, very much better, as there 
is less cost” (C6). 
 
Other interviewees said that they had heard positive things about the services offered but had 
not personally visited a traditional healer before.  One caretaker said: 
 “My neighbours used to go and they are happy about it and told me to try it but I did 
not try it” (C1). 
 
Caretakers who had visited traditional healers for general health issues, noted a positive 
relationship with them, and described the type of care offered as efficient: 
 “When we went he immediately said what it was, he then gathered the remedies and 
gave them to me.  He said “do as I say, do it like that”.  By His grace when we did it 
like that, [the treatment] worked” (C9). 
 
The same positive relationship was noted by traditional healers: 






Trust in the relationship between caretaker and traditional healer was mentioned by both 
parties:  
 “I am trusted by people.  Honestly, a lot of babies that are weaned that could not stop 
crying or choked while taking the breast are brought to me and are [treated] 
successfully” (TH 1). 
 “Ah, honestly we trust them because the healer is like our father” (C5). 
 
This trust was paired with accountability as partial payments were made upon care provision 
and the remaining payments made after the care provided was seen to be successful: 
 “[We] make a payment agreement that [the caretaker] will not [pay all] now.  If I treat 
and he gets healed after [you can pay me]. If you did not heal, I do not want your 
money” (TH 8). 
 
6.4.3 Knowledge and perceptions of noma and health care practices for the disease 
Many caretakers and traditional healers referred to noma as “ciwon daji” or “daude”, which 
when translated from Hausa to English, refers to a general cancer which can occur anywhere 
in the body.  
 “We conclude that it was ciwon daji (cancer)” (C2). 
 
Some caretakers believed that noma was the “disease of iska (spirit)” and that it was “brought 
by God”.  Views differed about the causes of noma, with some caretakers believing that measles 
“started” noma in their child.  There were also traditional healers, who believed that noma was 




 “This work is that of mumps.  Mumps make the teeth have inflammation.  This the same 
as remedy for mumps.  If it affects a person it will destroy their mouth and the mouth 
will smell” (TH12). 
 
Some traditional healers reported never having seen or treated the disease, even when shown 
photos of it during interviews: 
 “I never saw it honestly… I have not done a matter like this” (TH2). 
 “I do not know anything about this disease” (TH3). 
 
Caretakers reported seeking care at a variety of biomedical institutions including pharmacies, 
community health centres, clinics and hospitals, as well as from traditional healers, before 
coming to the NCH.  The pathway to care was at times complex and time-consuming: 
 “So it was the starting point of the disease, we saw that her face was getting chubby 
and then we went to collect traditional treatment.  We were mixing it and giving it to 
her to drink.  We saw the cheek getting bigger so we took her to the hospital where they 
dressed the wound and closed the affected area.  After two days he opened it and the 
area was spoiled and so we took her to [the big town]” (C 4). 
 “Before we came here we went to one hospital where he was given three injections.  
They referred us to the general hospital, and they referred us to a medical centre where 
we spent eleven days.  Someone who works at the other hospital came and saw the 
disease and asked the medical centre to refer us to Sokoto” (C 5). 
 
Some caretakers mentioned delays in accessing care; the main reasons were not having money 





A variety of symptoms for the different stages of noma were described by caretakers and 
traditional healers.  Many of the caretakers who were interviewed reported the first signs and 
symptoms of noma as a “fever”; “skin rash like a single grain of millet” and swelling: 
 “At first her eyes swelled.  The following morning everywhere had swollen up; you 
cannot even see the eye” (C 8). 
 
When traditional healers were asked about their knowledge of the different stages of noma, the 
majority saw them as separate diseases and treated them as such.  Traditional healers most 
often reported treating the earlier stages of noma (gingivitis and oedema), and referring 
children with the later stages of the disease to other forms of care.  One traditional healer noted 
that “[he] does not know noma disease”, but for the swelling stage of the disease he said “there 
is remedy for it”, and for the necrosis stage he stated he “does not know” the remedy showing 
noma was not seen as a single disease, but as multiple conditions. 
 
Gingivitis was usually treated with an ointment that was rubbed directly onto the gums:  
  “If the teeth are bleeding, I give a remedy.  If a person puts it inside the mouth and 
[swills] it around the mouth, the [bleeding] will stop” (TH 8). 
 
Some traditional healers diagnosed the stage of noma associated with swelling of the cheek as 
“ciwon daji” (cancer) or “ciwon iska” (spirit), and offered care to the patients accordingly. 
Caretakers also reported being given this diagnosis and relevant remedies.  
 “[We are] taught it is ciwon daji (cancer).  They find a branch of a tree and soak it to 
drink and to rub.  That is what we were taught to do if the cheeks become big” (C2). 
 “I will mix [the bark from three trees locally known as] tsada, tamarind and kaiwa and 




madarar tunwahiya [ground herbs], mix them all together and pour them onto the 
swollen area” (TH9). 
 
Some traditional healers noted uncertainty about the stages of the disease and whether the 
stages were related.   They had treated the swollen cheek stage which had a known remedy: 
 “I treat it but I do not know what the disease is unless I understand it is swelling.   If it 
is swelling I can understand it and give treatment remedy” (TH3). 
 
Traditional treatment options for a swollen cheek included piercing the cheek with a hot blade 
(initially placed in a fire) to decrease the swelling: 
 “If the remedy is drunk, it will go down or it will swell up to do piercing or it will burst” 
(TH8). 
Caretakers also reported visiting traditional healers for assistance with piercing the swollen 
cheek: 
 “I visited…this piercer, the piercing was done, the following morning the [swelling] 
did not stop we came here [NCH]” (C10). 
 
Traditional healers did not commonly report seeing patients in the necrosis stage of the disease, 
and as such, this stage was not widely known, although some were able to recognise it.  One 
traditional healer described this stage as “burnt meat”.  
 
Caretakers reported being offered various remedies from traditional healers when visiting them 
with the child later diagnosed at the NCH as having noma.  The remedies offered included 
“ground herbs or tree branches…for drinking, rubbing and bathing”; and “to be mixed with 




Caretakers reported mixed efficacy of these remedies:  
 “Last year when he was sick I took him [to the traditional healer] so this year when it 
came back I thought it is the same with the last one and I took him there, then I collected 
that remedy and it did not work so I took him to hospital” (C6). 
 “I collected [the remedy] but I did not see any improvement” (C7). 
 
Traditional healers reported utilising referral to hospitals and doctors for unknown ailments, or 
conditions they felt would be best treated elsewhere.  
  “For the [diseases I] cannot [treat], I will send them to a doctor who can treat them” 
(TH5). 
 “[I]f I see that [the disease] is much and beyond me and I cannot do the work I will 
refer him to the hospital.  If it is too much [for me] I can only send a person to hospital” 
(TH9).  
 
Referring to all stages of noma treatment, one traditional healer stated that, “For that disease, 
it is a doctor that gives help”.  Other traditional healers reported not knowing where to refer 
noma patients. 
 
One caretaker reported being referred to the NCH by a traditional healer who stated, “This 
disease is beyond my power but some kids are taken to Sokoto [NCH]”. 
 
And some traditional healers reported that now that they knew about the NCH, they would 
begin to refer any noma cases: 
 “As from today that we started the relationship, your issue [noma] is not a playing one 




When asked whether they would be interested in attending a training on noma, which would 
involve learning about the different stages of the disease, some traditional healers noted they 
were too old to travel, but most said they would be willing to attend and were enthusiastic about 
learning more about noma. 
 
6.5  Discussion 
Traditional healers play a role in the health system of northwest Nigeria; our findings showed 
that they are trustworthy, accessible, affordable care providers who offer specialised forms of 
care for specific conditions, and offer guidance on referral options.  Traditional healers viewed 
the stages of noma as different conditions with individualised remedies rather than as one 
disease, which is similar to the biomedical approach in that each stage of noma has a specific 
treatment protocol [1].  There are however, crucial differences in the understanding of the 
aetiology and pathogenesis of the disease.  Without the knowledge that the stages of noma are 
linked and are one condition, the impetus of referring noma cases in the early reversible stages 
of the disease may be lost.  Traditional healers reported referring people to other providers 
when they were unable to treat a specific condition, and the majority stated that they would be 
willing to refer noma patients to the NCH and attend training on the disease.  These are 
important indicators of the potential positive impact referral networks involving traditional 
healers could have.   
 
There is no other literature looking at how traditional healers diagnose and treat noma, making 
comparisons with other findings challenging, with only one study suggesting that qualitative 
research methodologies are useful in understanding craniofacial conditions such as noma [223].  




interest, as this is similar to a biomedical name for the disease which is frequently used, 
cancrum oris, meaning mouth cancer [64]. 
 
A third of caretakers at the NCH visited traditional healers before coming to the hospital.  Our 
study corroborates other research findings that show that traditional healers are the first point 
of care for many people, especially those living in rural areas with little access to biomedical 
health facilities [224], and that the first line of treatment for 60% of children living in Nigeria 
who have a high fever from malaria would be traditional medicine [225]. The pluralistic nature 
of the Nigerian health system, where biomedical and traditional care are offered together in a 
dynamic system is not unique to this setting and has been seen in other contexts including 
Ghana [226], Nepal [218] and South Africa [227]. 
 
Our study showed that caretakers trusted traditional healing methods, and that care was sought 
from traditional healers due to the belief in its quality, as seen in a study from Cameroon [220].  
Treatments offered by the traditional healers in our study such as ointments and 
piercings/bleeding marks were similar to those offered by healers in other studies [215, 228], 
as were the diversity of diseases treated [213, 217, 227–233].  
 
Due to the rapid evolution of noma [2], it is imperative that patients are detected early and 
receive the appropriate treatment (antibiotics, wound cleaning and nutritional support) during 
the reversible stages of the disease.  Some traditional healers reported recognising and treating 
the earlier stages of noma, and this, along with the fact that caretakers reported seeking care at 
traditional healers first, reinforces the importance of ensuring that traditional healers are able 
to detect cases of noma early and refer them to appropriate health care facilities.  Not many 




to the severe isolation patients with noma sequelae face or a lack of knowledge by patients, 
caretakers and traditional healers about the potential surgical treatments available, which could 
lead to care not being sought.  This could also suggest that caretakers seek care elsewhere for 
the later stages of disease, or that, due to the rapid progression of the disease, the patients die 
before seeking care. 
 
Partnering with traditional healers in order to set up robust referral networks for diseases has 
been implemented in a variety of settings [221, 234, 235].  A South African study noted that 
referrals by traditional healers were affected by the attitudes, subjective norms and perceived 
behavioural controls as influences on behaviour, which would need to be studied at a more in-
depth level in our setting [236].  
 
The willingness of traditional healers to be a part of referral networks and take part in a training, 
caretakers’ positive views of traditional healing and their geographical proximity to patients 
provides a unique opportunity to build such partnerships.  This could increase the frequency 
with which noma patients are detected at a community level and the speed with which they are 
referred, thus leading to efficient access to treatment in the crucial early, reversible stages of 
disease.  Traditional healers could also identify patients with noma sequelae who require 
surgical care and refer them to the appropriate facilities.  Training efforts should include a 
strong emphasis on the linkages between the noma stages, and the important need for rapid 
referral in the early stages.  Future studies on the effectiveness and efficiency of referrals are 
needed as well as research assessing biomedical health care worker knowledge on noma as this 





Study limitations include selection bias as we included caretakers of patients already accessing 
biomedical care through a convenience sampling approach.  They may not have been an 
accurate representation of all caretakers of noma patients, especially of those who might make 
more use of traditional healers than biomedical care.  There was also the potential for 
introducing social desirability bias as there could have been a reluctance to offer a wide range 
of opinions about traditional healers [237]. We were not able to interview traditional healers 
who had provided care for patients in the later stages of noma.  This limits our insights into the 
care provided for these stages.  We only included traditional healers who consented to being a 
part of the study, and there is the potential for the introduction of social desirability bias which 
may have meant we did not capture the full range of beliefs and treatments offered for the 
disease.  
 
Our research has identified several different actors involved along the pathway to care of noma 
patients, including traditional healers, who need to be included in intervention activities.  These 
findings show that traditional healers would be willing to attend trainings on the disease, and 
be a part of referral partnerships for noma patients.  This collaboration could expedite care 
provision from the community level, which would ultimately save lives and reduce the severity 
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7.1  Abstract 
7.1.1 Background 
Noma, a rapidly progressing infection of the oral cavity, mainly affects children.  The true 
burden is unknown.  We aimed to estimate noma prevalence in children in northwest Nigeria. 
 
7.1.2 Methods 
Oral screening was performed on all ≤15 year olds, with caretaker consent, in selected 
households during this cross-sectional survey.  Noma stages were classified using WHO 
criteria and caretakers answered survey questions.  The prevalence of noma was estimated 
stratified by age group (0-5 and 6-15 years).  Factors associated with noma were estimated 
using logistic regression. 
 
7.1.3 Results 
A total of 177 clusters, 3,499 households, and 7,122 children were included.  In this sample, 
4,239 (59.8%) were 0-5 years and 3,692 (52.1%) were female.  Simple gingivitis was identified 
in 3.1% (n=181; CI 2.6-3.8), acute necrotizing gingivitis in 0.1% (n=10; CI 0.1-0.3), and 
oedema in 0.05% (n=3; CI 0.02-0.2).  No cases of late-stage noma were detected.  Multivariable 
analysis in the 0-5 year age group showed having a well as the drinking water source (aOR 2.1; 
CI 12-3.6) and being aged three to five years (aOR 3.9; CI 2.1-7.8) was associated with being 
a noma case.  In six to 15 year olds, being male (aOR 1.5; CI 1.0-2.2) was associated with 
being a noma case and preparing pap once or more per week (aOR 0.4; CI 0.2-0.8) was 
associated with not having noma.  We estimated that 129,120 (CI 105,294-152,947) individuals 
<15 years of age would have any stage of noma at the time of the survey within the two states.  





Our study identified a high prevalence of children with simple and acute necrotizing gingivitis. 
Noma is important but neglected and therefore merits inclusion in the WHO Neglected Tropical 
Diseases (NTD) list.  
 
7.2  Introduction 
Noma, also known as cancrum oris, is a poorly understood, rapidly progressing infection of the 
oral cavity, with a reported 90% mortality rate [1].  If untreated, death usually occurs within 
weeks after the onset of symptoms [1, 2]. Treatment with antibiotics, wound debridement, and 
nutritional support in the early reversible stages of the disease greatly reduces mortality and 
morbidity [2].  Noma mostly affects children aged two to five years, and those who survive 
have severe facial disfigurements and multiple functional impairments including difficulties 
eating, seeing, and breathing, contributing towards stigmatization [2].   Noma starts as an 
inflammation of the gums leading to the rapid destruction of the hard and soft tissues of the 
face usually within one week [94]. The WHO has classified noma into stages [1]: Stage 0: 
simple gingivitis; Stage 1: acute necrotizing ulcerative gingivitis; Stage 2: oedema; Stage 3: 
gangrene; Stage 4: scarring; Stage 5: sequelae. Simple gingivitis (“Stage 0”) is a precursor to 
noma.  Acute necrotizing gingivitis is distinguished by orofacial necrosis and ulceration 
accompanied by severe halitosis. It is unknown what proportion of simple  or acute necrotizing 
gingivitis cases progress to the later stages of noma, but it is thought to be a small fraction [1].  
In the majority of later stage cases, infection causes the destruction of the cheek, while 
destruction of the jaw, lip, nose, and eye have also been reported [3].  Noma can become 
inactive with, and sometimes without, treatment.  Once this occurs, patients can survive into 




resulting defects and improve function [1].  The aetiology of noma is unknown but thought to 
be multifactorial [2].  Noma typifies the complex interactions between extreme poverty, 
malnutrition, poor oral hygiene, poor access to routine childhood vaccinations, limited access 
to quality health care and immunosuppression resulting from comorbidities such as HIV [2]. 
 
In the 1800s, noma was widely reported in Europe [238] but is currently thought to be most 
prevalent in low-resource settings in Africa and Asia [104].  The oldest estimate of the burden 
of this disease that we could locate was from Edinburgh, United Kingdom, which indicated 
that noma was diagnosed once out of every 5,000 cases of children with an illness between 
1860 and 1871 [65].  In 1998, the WHO estimated that 140,000 new cases of noma occur each 
year globally and that 770,000 patients were living with noma sequelae at that time, however 
the origin of this estimate and the stages included are unclear [19, 111]. Two 2003 Nigerian 
studies estimated the burden of disease ranged from seven cases per 1,000 children aged 
between one and 16 years (Denloye et al., 2003) [42] to 6.4 per 1,000 children (Fieger et al., 
2003) [7].  The most recent study from 2019 estimated the period prevalence of noma from 
2010-2018 was 1.6 per 100,000 population at risk in Nigeria [239]. These estimates are based 
on expert opinion, number of hospital admissions and retrospectively collected hospital-based 
data and it is unclear which stages of noma were included [49].   Our understanding of the 
current disease burden and epidemiology thus remains limited.  There are few studies not only 
on the burden of disease but also on the pathogenesis and mortality rate. Although these aspects 
highlight the neglected nature of the disease, noma is not currently on the WHO NTD list. 
 
Noma cases are frequently reported in Nigeria [6–8, 23, 37–39, 41–43, 50, 64, 71, 81, 89, 99, 
100, 102, 148].  The Nigerian Centre for Disease Control recorded 37,646 noma cases from 




limited surveillance data and the potential for under-reporting (low rates of diagnosis, patients 
not accessing health care, reported high and rapid mortality) [240].  The majority of noma cases 
are reported from the northwest and northeast of the country [241].  At the 2018 National Noma 
Day Workshop, the Nigerian Ministry of Health confirmed that noma was a national public 
health priority, and highlighted the urgent need to generate robust evidence on the country’s 
disease burden for programmatic planning [242]. This study contributes towards this need by 
estimating the prevalence of noma in northwest Nigeria using a robust cross-sectional 
population-based approach. 
 
7.3  Methods 
7.3.1 Study design and setting 
A two-stage cluster-based cross-sectional survey was conducted in Sokoto and Kebbi States in 
northwest Nigeria (Figure 7.1). 
 
7.3.2 Sampling  
Based on the 2006 Nigerian census data (with a 2.4% annual population increase), Sokoto and 
Kebbi States have an estimated population of 4,798,979 and 4,203,978, respectively (2,063,560 
and 1,807,710 aged under 15 years in Sokoto and Kebbi respectively) [243].  Sample size 
calculations indicated the need for inclusion of 3,615 households across 181 clusters with 20 
households per cluster in order to estimate noma prevalence with precision of 0.4%.  This 
calculation was based on the following assumptions: prior prevalence estimate, 1% [7]; design 
effect, 2; 1.98 children per household in the 0-4 year age group [244]; average household size, 






Figure 7.1 Clusters where data was collected (pale grey dots) within Sokoto and Kebbi 








The number of villages (clusters) per ward were selected proportional to the population size of 
each administrative ward.  A sampling frame of villages was created by ward in Sokoto and 
Kebbi using geo-sampling remote sensing methods.  The OpenStreetMap database was 
compared against freely available satellite imagery to identify and verify village geo-locations 
and add new village geo-locations to the list.  Villages were each assigned a number and a 
random selection was conducted.  Once the teams reached the villages, they first visited the 
village head to ask permission to conduct the study and if this was given, the team then asked 
the village head to identify what the residents of the village would define as the central point 
of the village.  Once at this central point, the adapted WHO EPI method of sampling was 
conducted to select the first compound [246].  At the central village point, the pen was spun 
and the team leader walked in the direction of the writing point of the pen to the edge of the 
village where the pen was spun again.  The team leader then walked in a straight line (following 
the direction of the pen) and counted all the compounds along the path. The number 1 and N 
(total number of compounds) were inputted into a random number generator, and the 
compound allocated to the number generated was the first compound selected.  When inside 
the selected compound, the number of households in each compound were counted (a 
household was defined as the children of one mother in the compound that lived in one hut). A 
random number was generated and the household allocated to that number was selected.  If the 
house was empty, the interviewers proceeded to the next household to the left.  If all households 
of a selected village were included in the study before completing the required number of 
households, the sampling was continued by selecting the geographically closest village. 
 
7.3.3 Study participants 
All children aged ≤15 years who lived in a selected household in sampled clusters were 




7.3.4 Data collection 
Five research teams, each with five team members, of whom one was a nurse or doctor, and 
one the team leader, carried out data collection.  To ensure standardisation of data collection 
methods, the teams were trained for one week prior to the commencement of data collection 
on the use of consistent measuring tools following the Standardised Monitoring and 
Assessment of Relief and Transitions (SMART) methodology which is an integrated method 
for assessing nutritional status in emergency situations [247]. Teams followed directions to 
selected clusters using a mobile mapping application (OsmAnd©) on data collection tablets 
(electronic mobile devices).   
 
Consenting caretakers answered a structured questionnaire, collected on tablets using 
KoBoCollect, which covered: sociodemographic characteristics, living conditions, child’s 
vaccination status, oral hygiene practices, food preparation, feeding practices and access to 
health care in the twelve months preceding the interview.  For the questions around feeding 
practices, pap was defined in this context as a type of porridge staple made from maize, 
sorghum, or millet.  Interviews were conducted in Hausa, and answers were coded 
automatically on the KoBoCollect tool into English. 
 
In the sampled households, all eligible children underwent oral screening, which involved 
visual examination by a medical team member for any noma stage, based on the WHO 
classification [1].  The caretakers of children with simple gingivitis were advised to follow a 
strict oral health regimen (gargle with salt water or use water to clean mouth twice or more a 
day) as were acute necrotizing gingivitis cases who were also referred to the closest health 
centre. If children were identified as having any later stage of noma, they were referred directly 




To assess the malnutrition status in children aged six months to five years, MUAC 
measurements were conducted using a flexible MUAC device with a precision of 1 mm. 
 
Medical data (oral screening and MUAC) was collected on paper and later entered into a 
password-protected database by the study team.  
 
Collected data were screened daily by the research team supervisors to identify inconsistencies 
and missing items and immediate feedback was given to the data collection teams.  
 
7.3.5 Statistical analysis 
We performed descriptive analyses of household characteristics in the study sample. 
Categorical variables are reported as frequencies and percentages.  Continuous variables are 
summarised using medians and IQR.  Missing data numbers are recorded in each table. 
 
Wealth scores were calculated by assigning a value of one to each of the following items owned 
by the family: a mobile phone, motorbike, tractor and camel (these items were chosen based 
on consultation with local researchers who were knowledgeable about the context). The 
minimum wealth score was zero and the maximum was four.  
 
Weighted prevalence and CI for all WHO noma stages were estimated, and stratified by age 
group (0-5 years and 6-15 years). The number of individuals with noma in Sokoto and Kebbi 
States was calculated by extrapolating the percentage prevalence from our study results to the 
total population in the 0-15 year age group for these states. This calculation took into 
consideration the cluster survey design and population age distribution of the two states.  Using 




MAM (between MUAC ≥115mm and <125 mm) and GAM (MUAC <125 mm) in children 
aged six months to five years. The standard errors of the estimates were adjusted using the 
linearization method (syvset suite of Stata commands) to reflect the two-stage clustered design 
of the survey [248].  The estimates and standard errors were weighted to account for the actual 
population distribution of the two states, as our survey sample was observed to have under-
represented participants aged six to 15 years when we compared our sample’s age distribution 
to the population age distribution.  The design effect (DEFF) was calculated to assess the ratio 
of variance under the sampling method used, in comparison to the variance of a simple random 
sample. This reflects the impact of the cluster sampling strategy.  DEFF is reported for each 
prevalence and malnutrition estimate. 
 
Univariable analysis with logistic regression was conducted to identify factors associated with 
noma Stages 1 and 2 in the total study sample, where the number of noma cases were too small 
to allow for multivariable analysis. 
 
Univariable and multivariable analysis were conducted using logistic regression, to estimate 
factors associated with any noma stage (Stage 0-2); stratified by age group (0-5 years and 6-15 
years).  Variables chosen for inclusion in the multivariable analysis were those with ten or more 
cases [249] and a univariable strength of association equivalent to a p-value <0.2, after 
assessing collinearity among variables.  To further understand the association with age, an age 
covariate with finer age categories (0-2 years, and three to five years, in the younger age group 
model; and six to ten years, and eleven to 15 years, in the older age group model, respectively) 






All data analysis was conducted with Stata 15 (StataCorp LP, College Station, TX, USA).  
 
7.3.6 Ethics 
Ethical approval was obtained from the MSF, UDUTH and the Sokoto and Kebbi States 
Ministry of Health ERBs.  Written informed consent was obtained from all literate caretakers; 
caretakers with insufficient literacy provided a thumbprint and a signature from a literate 
witness.  For individuals aged eight to 17 years, the child provided assent and a caretaker 
provided written consent. 
 
7.4  Results 
The survey was conducted from 17 September to 5 November 2018, and included 3,499 
households in 177 clusters, 92 clusters from Sokoto and 85 from Kebbi (four clusters were not 
accessible because of security issues), with 7,164 children aged <15 years.  As 42 children did 
not have oral examinations, they were excluded from the analysis and the remaining 7,122 were 
included.  The median caretaker age was 30 years (IQR 25-35); 3,423 caretakers (97.8%) were 
female; 2,194 (30.8%) were employed or self-employed, and the median household size was 
five people (IQR 4-7).  Most children (n=4,239; 59.5%) were aged 0-5 years, 3,692 (52.1%) 
were female, 5,875 (83.0%) had no education, and 6,686 (94.4%) had a primary caretaker that 









Table 7.1 Demographic characteristics of households in the noma prevalence survey 
population. 
 
Households  n=3,499 n (%) 
Caretaker age, years  median (IQR)   30 (25-35) 
Caretaker Sex 
Female 3,423 (97.8%) 
Male 76 (2.2%) 
Caretaker income source 
Employed or self-employed 2,194 (30.8%) 
Unemployed or other* 4,927 (69.2%) 
Total household members median (IQR)   5 (4-7) 
Drinking water source 
Bore hole in the village 644 (18.4%) 
River  91 (2.6%) 
Tap (running water) 578 (16.2%) 
Well in the compound 1,512 (43.2%) 
Other 674 (19.3%) 
Treat water before drinking (Yes) 1,026 (29.3%) 
Type of sanitation facility 
Flushing toilet 224 (6.4%) 
Pit latrine (with slab) 650 (18.6%) 
Pit latrine (no slab) 1,168 (33.4%) 
Other**  1,457 (41.6%) 
IQR- inter-quartile range 
*Other caretaker income source includes being a housewife or student 













Total n  
n=7,122 (%)* 
0-5 year olds n 
n= 4,239 (%) 
6-15 year olds n  
n= 2,841 (%) 
Age groups  (years) 
0-5 4,239 (59.8%)   
6-15 2,841 (40.1%)   
Missing 42*   
State 
Kebbi 3,291 (46.5%) 2,045 (48.2%) 1,246 (43.9%) 
Sokoto 3,789 (53.5%) 2,194 (51.8%) 1,595 (56.1%) 
Missing 42* 0 0 
Child sex 
Female 3,692 (52.1%) 2,119 (49.9%) 1,573 (55.4%) 
Male 3,388 (47.9%) 2,120 (50.0%) 1,268 (44.6%) 
Missing 42* 0 0 
Education of child    
None 5,875 (83.0%) 3,850 (90.8%) 2,025 (71.3%) 
Any education 1,204 (17.0%) 388 (9.2%) 816 (28.7%) 
Missing  42* 1 0 
Primary caretaker of the child interviewed 
Mother 6,686 (94.4%) 4,061 (95.8%) 2,625 (92.4%) 
Other (father,  grandmother, 
grandfather) 
394 (5.6%) 178 (4.2%) 216 (7.6%) 
Missing  42* 0 0 









Table 7.3 reports the prevalence of all stages of noma in the study population overall and by 
age group.  Any stage of noma was identified in 3.3% of sampled children (n=194; CI 2.7-4.0).  
Stage 0 noma was identified in 3.1% (n=181; CI 2.6-3.8), Stage 1 in 0.1% (n=10; CI 0.1-0.3), 
and Stage 2 in 0.05% (n=3; CI 0.02-0.2).  No children with Stages 3 to 5 noma were detected 
in our study population (Table 7.3). Based on these results 3,300 out of every 100,000 children 
in the 0-15 year age group would have any stage of noma (including simple gingivitis) and 150 
out of every 100,000 children would have Stage 1 or 2 noma in the study area. 
 
The prevalence of SAM in children aged six months to five years (n=3,993) was 3.7% (n=149; 
CI 3.2-4.4) and MAM 7.7% (n= 309; CI 6.7-8.7) (Table 7.3). 
 
7.4.2 Factors associated with noma  
Table 7.4 describes univariable analysis of risk factors for Stage 1 and 2 noma regardless of 
age category.  This analysis showed that having eaten pap in the last 24 hours (OR 0.2; CI 0.1-
0.9); the child eating pap once or more per week (OR 0.4; CI 0.1-0.9) and the caretaker 
preparing pap once or more per week compared to less frequent preparation of pap (OR 0.3; 
CI 0.1-0.8) were associated with not having Stage 1 and 2 noma.  The child experiencing an 
illness in the 12 months prior to the interview was associated with being a Stage 1 and 2 noma 





Table 7.3 Noma stage and malnutrition prevalence (overall and by age group). 
 
 
Total  (n=7,122)* 0-5 year olds  n=4,239* 6-15 year olds  n=2,841 * 
n (%) CI Deff n (%) CI Deff n (%) CI Deff 
P (age 
comparison) 
Any noma 194 (3.3%) 2.7, 4.0 1.9 63 (1.5%) 1.1, 2.0 1.3 129 (4.4%) 3.6, 5.4 1.6 <0.001 
Noma stages 








Stage 0: Simple gingivitis 181 (3.1%) 2.6, 3.8 1.8 56 (1.3%) 1.0, 1.8 1.3 123 (4.2%) 3.4, 5.2 1.5 




















Stage 2: Oedema 3 (0.05%) 0.02, 0.2 1.0 1 (0.02%) 0.0, 0.2 1.0 2 (0.1%) 0.02, 0.3 1.0 
Stage 3: Gangrene 0 (0%) NA NA 0 (0%) NA NA 0 (0%) NA NA 
Stage 4: Scarring 0 (0%) NA NA 0 (0%) NA NA 0 (0%) NA NA 
Stage 5: Sequelae 0 (0%) NA NA 0 (0%) NA NA 0 (0%) NA NA 
Malnutrition  6 month – 5 year olds (n = 3,993)  
Moderate acute malnutrition NA NA NA 309 (7.7%) 6.7, 8.7% 1.5 NA NA NA NA 
Severe acute malnutrition NA NA NA 149 (3.7%) 3.2, 4.4% 1.0 NA NA NA NA 
*42 missing age category 






Table 7.4 Univariable analysis for Stage 1 and 2 noma. 
 Study population Univariable analysis 
Proportion of all 
respondents; 
N=7,122; %(n/N*)  
Proportion respondents 
with Stage 1 and 2  












Other 5.6% (394/7,080) 7.7% (1/13)  Reference 0.561 
Mother 94.4% (6,686/7,080) 92.3% (12/13) 0.5 0.07, 4.18  
Pap eaten in the 24 hours before interview 
 
No 32.1% (2,271/ 7,080) 53.8% (7/13)  Reference 0.030 
Yes 67.9% (4,809/ 7,080) 46.2% (6/13) 0.2 0.07, 0.87  
Frequency of the child eating pap per week   
 
<1 or never 30.4% (2,151/7,080) 46.2% (6/13)  Reference 0.049 
1 or more 69.6% (4,929/7,080) 53.8% (7/13) 0.4 0.13, 0.99  
Frequency of the caretaker preparing pap per week 
 
<1 or never 29.9% (2,116/7,080) 53.8% (7/13)  Reference 0.018 
1 or more 70.1% (4,964/7,080) 46.2% (6/13) 0.3 0.11, 0.81  
Duration of breastfeeding at time of interview (months) 
 
12+ 89.4% (6,310/7,061) 84.6% (11/13)  Reference 0.782 
0-12 10.6% (751/7,061) 15.4% (2/13) 1.2 0.27, 5.63  
Colostrum given to the child at birth 
 
No 12.0% (843/7,047) 15.4% (2/13)  Reference 0.366 
Yes 88.0% (6,204/7,047) 84.6% (11/13) 0.5 0.10, 2.32  
Child sick during last 12 months 
 
No 30.0% (2,131/7,080) 7.7% (1/13)  Reference 0.041 
Yes 70.0% (4,949/7,080) 92.3% (12/13) 8.8 1.11, 69.49  
Did you seek health care for this child in the last year? 
 
No 48.4% (3,428/,7,080) 23.1% (3/13)  Reference 0.221 
Yes 51.6% (3,652/7,080) 76.9% (10/13) 2.5 0.58, 10.51  
Vegetables eaten in the 24 hours before interview 
 
No 68.2% (4,829/7,080) 76.9% (10/13)  Reference 0.461 




Wealth score (mobile phone, motorbike, tractor, camel) 0-1 63.5% (4,522/7,122) 84.6% (11/13)  Reference 0.106 
 2-4 36.5% (2,600/7,122) 15.4% (2/13) 0.3 0.08, 1.27  
*N = total number of respondents who answered the question (excluding missing) 




The risk factors associated with any stage of noma (including Stage 0) for the 0-5 year age 
group are shown in Table 7.5. The multivariable analysis shows that two factors remained 
associated with being a noma case in the 0-5 year age group, namely, having a well as the 
source of drinking water (aOR 2.09; CI 1.22-3.60), and being aged three to five years (aOR 
3.90; CI 2.04-7.47) (Table 7.5). 
 
In the six to 15 year age group, the risk factors associated with any stage of noma (including 
Stage 0) are shown in Table 7.6.  Multivariable analysis showed that males were more likely 
to be noma cases (aOR 1.52; CI 1.04-2.22), and that the caretaker preparing pap once or more  
per week was associated with not having noma (aOR 0.36; CI 0.16-0.82) in the six to 15 year 
old age group (Table 7.6). 
 
Vaccination coverage rates in both age groups were low (21% of 0-5 year olds and 12% of six 
to 15 year olds had any immunisations noted on the vaccination card seen by the interviewer).  
No association between vaccination status and noma was seen in our study. 
 
7.5  Discussion 
We have shown that the prevalence of any stage of noma in Kebbi and Sokoto States is 3.3%.   
Based on the study results, we therefore estimate that 129,120 (CI 105,294-152,947) 
individuals <15 years of age would have any stage of noma at the time of the survey within the 
two states.  Most of these cases (n=120,082, 94% of all cases) would be children with simple 
gingivitis (i.e. Stage 0) and approximately 7,101 (4% of all cases) and 1,937 (2% of all cases) 
of children would have Stage 1 and 2 noma, respectively.  Our estimates exceeded those from 
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Child age (years)   
  
0-2 46.2% (1,957/4,239) 17.5% (11/63)  Reference <0.001  Reference <0.001 
3-5 53.8% (2,282/4,239) 82.5% (52/63) 4.1 2.20, 7.62  3.90 2.04, 7.47  
Birth order 
 
1-2 39.9% (1,691/4,239) 30.2% (19/63)  Reference 0.174  Reference 0.398 
3 or more 60.1% (2,548/4,239) 69.8% (44/63) 1.5 0.83, 2.88  1.36 0.67, 2.79  
Feeding practices 
Duration of breastfeeding 
 
12+ months 84.4% (3,565/4,226) 95.2% (60/63)  Reference 0.020    
0-12 months 15.6% (661/4,226) 4.8% (3/63) 0.3 0.09, 0.81     
Colostrum given to baby 
 
No 11.9% (502/4,221) 11.1% (7/63)  Reference 0.899    
Yes 88.1% (3,719/4,221) 88.9% (56/63) 1.1 0.37, 3.09     
Frequency of the child eating pap per week   
 
<1 or never 31.6% (1,340/4,239) 34.9% (22/63)  Reference 0.597    
1 or more 68.4% (2,899/4,239) 65.1% (41/63) 0.9 0.47, 1.54     
Frequency of the caretaker preparing pap per week 
 
<1 or never 30.8% (1,307/4,239) 34.9% (22/63)  Reference 0.505    
1 or more 69.2% (2,932/4,239) 65.1% (41/63) 0.8 0.46, 1.46     
Animal products eaten in the 24 hours before 
interview 
No 91.5% (3,879/4,239) 95.2% (60/63)  Reference 0.274    




Grains eaten in the 24 hours before interview 
 
No 19.3% (819/4,239) 22.2% (14.63)  Reference 0.607    
Yes 80.7% (3,420/4,239) 77.8% (49/63) 0.8 0.45, 1.59     
Vegetables eaten in the 24 hours before interview 
 
No 69.6% (2,952/4,239) 69.8% (44/63)  Reference 0.963    
Yes 30.4% (1,287/4,239) 30.2% (19/63) 1.0 0.56, 1.73     
Health 
Are the teeth ever cleaned (self-reported) 
 
No 13.8% (508/3,679) 9.7% (6.62)  Reference 0.300    
Yes 86.2% (3,171/3,679) 90.3% (56/62) 1.5 0.69, 3.39     
Teeth cleaning frequency per day (self-reported) 
 
Once or twice 85.1% (3,132/3,679) 88.7 (55/62)  Reference 0.370    
Less than once 14.9% (547/3,679) 11.3% (7/62) 0.7 0.34, 1.50     
SAM, MAM  
 
 
Normal 88.5% (3,535/3,993) 91.1% (51/56)  Reference 0.199    
SAM 3.7% (149/3,993) 7.1% (4/56) 1.0 0.55, 6.85     
MAM 7.7% (309/3,993) 1.8% (1/56) 0.2 0.03, 1.71     
GAM  
 
Normal 88.5% (3,535/3,993) 91.1% (51/56)  Reference 0.666    
GAM 11.5% (458/3,993) 8.9% (5/56) 0.8 0.26, 2.36     
Was the child vaccinated (self-report)   
 
No 27.5% (1,165/4,239) 23.8% (15/63)  Reference 0.516    
Yes 72.5% (3,074/4,239) 76.2% (48/63) 1.2 0.67, 2.20     
Vaccinations listed on vaccination card:          
Diphtheria 
 
No 71.1% (635/893*) 75.0% (12/16)  Reference 0.688    
Yes 28.9% (258/893) 25.0% (4/16) 0.8 0.21, 2.81     
Pertussis 
 
No 73.7% (658/893) 75.0% (12/16)  Reference 0.840    
Yes 26.3% (235/893) 25.0% (4/16) 0.9 0.24, 3.21     
Tetanus 
No 82.1% (733/893) 75.0% (12/16)  Reference 0.584    






No 93.4% (834/893) 93.8% (15/16)  Reference 0.900    
Yes 6.6% (59/893) 6.3% (1/16) 0.9 0.11, 6.86     
Hepatitis B 
 
No 77.4% (691/893) 68.8% (11/16)  Reference 0.415    
Yes 22.6% (202/893) 31.3% (5/16) 1.6 0.52, 4.84     
Measles 
 
No 38.0% (339/893) 31.3% (5/16)  Reference 0.628    
Yes 62.0% (554/893) 68.8% (11/16) 1.3 0.43, 4.11     
Pneumococcal disease  
 
No 69.4% (620/893) 75.0% (12/16)  Reference 0.686    
Yes 30.6% (273/893) 25.0% (4/16) 0.8 0.19, 2.96     
Yellow fever 
 
No 64.7% (578/893) 68.8% (11/16)  Reference 0.745    
Yes 35.3% (315/893) 31.3% (5/16) 0.8 0.24, 2.75     
Meningitis 
 
No 87.6% (782/893) 75.0% (12/16)  Reference 0.150    
Yes 12.4% (111/893) 25.0% (4/16) 2.3 0.74, 7.26     
Polio 
 
No 21.8% (195/893) 12.5% (2/16)  Reference 0.351    
Yes 78.2% (698/893) 87.5% (14/16) 2.0 0.48, 8.12     
Any vaccination listed on vaccination card 
 
No 79.2% (3,356/4,239) 74.6% (47/63)  Reference 0.415    
Yes 20.8% (883/4,239) 25.4% (16/63) 1.3 0.70, 2.40     
Child sick during last 12 months 
 
No 29.7% (1,260/4,239) 23.8% (15/63)  Reference 0.235    
Yes 70.3% (2,979/4,239) 76.2% (48/63) 1.4 0.82, 2.28     
How often child was sick, last 12 months 
 
0-1 50.9% (2,156/4,239) 50.8% (32/63)  Reference 0.994    
2 or more 49.1% (2,083/4,239) 49.2% (31/63) 1.0 0.60, 1.68     
Did you seek health care for this child in the last year? 
 
 
No 47.3% (2,006/4,239) 50.8% (32/63)  Reference 0.634    




Difficulties accessing health care (cost, time, distance) 
 
 
Didn't seek care 47.3% (2,006/4,239) 50.8% (32/63)  Reference 0.765    
No difficulties 46.0% (1,949/4,239) 44.4% (28/63) 0.9      
Yes difficulties 6.7% (284/4,239) 4.8% (3/63) 0.7      
Caretaker and household information 
Caretaker age (years) 
 
Under 30 49.8% (2,109/4,239) 34.9% (22/63)  Reference 0.010  Reference 0.251 
30 or older 50.2% (2,130/4,239) 65.1% (41/63) 1.8 1.16, 2.94  1.38 0.80, 2.39  
Primary caretaker of the child interviewed 
 
Other 4.2% (178/4,239) 7.9% (5/63)  Reference 0.166    
Mother 95.8% (4,061/4,239) 92.1% (58/63) 0.5 0.18, 1.34     
Total number of household members 
 
0-6 71.7% (3,039/4,239) 74.6% (47/63)  Reference 0.591    
Above 6 28.3% (1,200/4,239) 25.4% (16/63) 0.9 0.48, 1.51     






















No 71.2% (3,020/4,239) 73.0% (46/63)  Reference 0.759    
Yes (strain through 














    
Wealth score (mobile phone, motorbike, tractor, 
camel) 
 
0-1 63.5% (2,693/4,239) 65.1% (41/63)  Reference 0.810    
2-4 36.5% (1,546/4,239) 
34.9% (22/63) 
0.9 0.55, 1.60     
OR = odds ratio; aOR = adjusted odds ratio; CI = 95% confidence interval; P = p-value from logistic regression model. Analysis adjusted for the survey design. 
Variables with ten or more cases and a p<0.2 in the univariable analysis included in the multivariable model (child age, birth order, caretaker age, drinking water source). 










Study population Univariable analysis Multivariable analysis 





any noma stage; 


























Child age (years)   
  
6-10 74.9% (2,127/2,841) 76.0% (98/129)  Reference 0.722    
11-15 25.1% (714/2,841) 24.0% (31/129) 0.93 0.64, 1.36     
Child gender 
  
Female 55.4% (1,573/2,841) 45.7% (59/129)  Reference 0.036  Reference 0.031 
Male 44.6% (1,268/2,841) 54.3% (70/129) 1.50 1.03, 2.20  1.52 1.04, 2.22  
Birth order 
  
1-2 50.2% (1,426/2,841) 55.8% (72/129)  Reference 0.186  Reference 0.613 
3 or more 49.8% (1,415/2,841) 44.2% (57/129) 0.79 0.56, 1.12  0.90 0.61, 1.34  
Feeding practices          
Colostrum given to baby 
  
No 12.1% (341/2,826) 11.7% (15/128)  Reference 0.856    
Yes 87.9% (2,485/2,826) 88.3% (113/128) 1.06 0.57, 1.98     
Frequency of the child eating pap per 
week   
  














1 or more 71.5% (2,030/2,841) 63.6% (82/129) 0.68 0.47, 0.98  1.87 0.83, 4.21  
Frequency of the caretaker preparing pap 
per week   
  














1 or more 71.5% (2,032/2,841) 61.2% (79/129) 0.61 0.42, 0.89  0.36 0.16, 0.82  
Animal products eaten in the 24 hours 















  Yes 9.0% (256/2,841) 5.4% (7/129) 0.57 0.22, 1.52     













   
Yes 81.8% (2,325/2,841) 84.5% (109/129) 1.22 0.73, 2.04     













   
Yes 33.9% (964/2,841) 28.7% (37/129) 0.78 0.50, 1.23     
Health 
Are the teeth ever cleaned (self-reported) 
 
No 3.1% (88/2,823) 4.7% (6/128)  Reference 0.372    
Yes 96.9% (2,735/2,823) 95.3% (122/128) 0.63 0.23, 1.73     





Toothbrush 23.8% (677/2,841) 18.6% (24/129)  Reference 0.654    
Ash or cloth 1.9% (55/2,841) 2.3% (3/129) 1.54 0.45, 5.32     










    
None or other 57.8% (1,643/2,841) 63.6% (82/129) 1.44 0.82, 2.52     
Teeth cleaning frequency per day (self-
reported) 
  










   
Less than once 4.8% (136/2,823) 7.0% (9/128) 1.53 0.72, 3.26     













   
Yes 11.5% (328/2,841) 14.0% (18/129) 1.24 0.71, 2.17     
Polio vaccination (self-report)   
  
No 29.8% (846/2,841) 24.0% (31/129)  Reference 0.131  Reference 0.113 
Yes 70.2% (1,995/2,841) 76.0% (98/129) 1.36 0.91, 2.01  1.40 0.92, 2.13  
Child sick last 12 months 
 
  



















How many times was child sick during 












   
2 or more 48.9% (1,390/2,841) 53.5% (69/129) 1.19 0.81, 1.74     
Did you seek health care for this child in 












   
Yes 49.9% (1,419/2,841) 52.7% (68/129) 1.10 0.75, 1.63     



















No difficulties 43.9% (1,247/2,841) 41.9% (54/129) 0.99 0.63, 1.55  0.78 0.45, 1.36  















Caretaker and household information 
Caretaker age (years) 
  
Under 30 21.5% (611/2,841) 20.2% (26/129)  Reference 0.731    
30 or older 78.5% (2,230/2,841) 79.8% (103/129) 1.08 0.69, 1.69     
Caretaker gender 
  
Female 97.5% (2,770/2,841) 99.2% (128/129)  Reference 0.271    
Male 2.5% (71/2,841) 0.8% (1/129) 0.32 0.04, 2.40     
Primary caretaker of the child  
interviewed 











    
Total number of household members 
 
0-6 58.1% (1,650/2,841) 67.4% (87/129)  Reference 0.025  Reference 0.145 
Above 6 41.9% (1,191/2,841) 32.6% (42/129)  0.46, 0.95  0.74 0.49, 1.11  















   








No 69.1% (1,964/2841) 65.1% (84/129)  Reference 0.376    
Yes (strain through 














    
Wealth score (mobile phone, motorbike, 
















2-4 37.1% (1,054/2,841) 29.5% (38/129) 0.70 0.48, 1.02  0.77 0.52, 1.14  
OR = odds ratio; aOR = adjusted odds ratio; CI = 95% confidence interval; P = p value from logistic regression model; Analysis adjusted for the survey design. 
Variables with ten or more cases and a p<0.2 in the univariable analysis included in the multivariable model (child gender, birth order, frequency of the child eating pap per 








Fieger et al. in 2003 (640 per 100,000 children) [7].  Differences between the two could be due 
to the inclusion of earlier noma stages including stage 0 in the estimates, geographical 
differences (Bello et al. is north central Nigeria vs our northwest Nigeria), or due to 
methodological differences (Bello et al. used patient record review of patients presenting at 
hospital and Fieger et al. based their estimates on the number of clefts and mathematical 
modelling vs our community-based cross-sectional survey).  
 
Despite only covering two states of one country, our prevalence estimates would account for 
17% of the current global WHO prevalence estimates [19].  Even though direct comparisons 
between the WHO and current study estimates are difficult as the stages included in the WHO 
estimates were not reported, our findings do suggest that the true burden of noma worldwide 
may be higher than previously thought.  
 
Results from this study highlight the under-reported and overlooked nature of noma.  Even 
though oral diseases, such as noma, are largely preventable, they impact over 3.5 billion people 
worldwide (untreated dental caries are the most prevalent of these oral health issues), 
disproportionally affecting marginalised groups [250].  Oral diseases are frequently more 
neglected than other diseases in low- and middle-income countries, which may be linked to the 
fact that modern dentistry focuses on high-technology solutions, which are unaffordable and 
not currently feasible in low-resource settings [251].  This overarching neglect of oral diseases 
is magnified in the case of noma, as patients live in underserved, often rural locations [32].  
Many cases will never seek care, and, even if they do, noma is unknown to many health care 
workers in endemic areas [21].  The condition may thus go undiagnosed, and rapid detection 
with opportunities for early treatment through improved oral hygiene, nutritional support and 




The presence of acute necrotizing gingivitis, which is rarely seen in healthy children, points to 
the need to assess and address risk factors at a community level with public health 
interventions.  Treatment with antibiotics, nutritional support and a search for underlying 
diseases including HIV, measles and chronic malnutrition is essential in preventing progression 
to the later stages of noma [252]. 
 
Strong surveillance systems have been the cornerstone of many successful NTD control 
programmes [253, 254].  The WHO has stated that robust surveillance helps to better 
understand the burden and distribution of disease, and to identify high risk populations so that 
evidence-based decision-making can be used to target interventions in resource-constrained 
contexts [255].  A further benefit of robust surveillance is an increase in the number of cases 
identified, diagnosed and treated [256].  Due to the neglected nature of noma, surveillance 
activities for active noma cases are hampered and it is unlikely that current surveillance 
mechanisms adequately identify deaths from noma at community level.  The mortality rate 
associated with noma is unknown, but estimated to be as high as 90% if the disease is left 
untreated [1].  Deaths may be primarily due to starvation, aspiration pneumonia, respiratory 
insufficiency or sepsis [25, 74], and not be attributed to noma, further reducing the potential 
for accurate reporting of disease burden.  Our findings suggest that improved efforts to 
enumerate the burden of disease are necessary.  
 
This study highlights the need for a single classification system for the differential diagnosis 
of each stage of noma, which would be beneficial in standardizing reporting of noma globally 
by the clinical and research noma community.  In published work, noma is often classified into 
two stages (acute and chronic noma [6, 8]) or with the Montandon system (classifies noma 




comparison between different studies. The WHO noma staging system [1] is the most 
comprehensive to date and includes an early-stage noma definition which is useful as it 
identifies those at risk of progressing to later-stage noma. However, it lacks specificity as it 
overlaps with commonly seen ailments such as simple gingivitis and acute necrotizing 
gingivitis and therefore may overestimate the burden of disease.  It is currently unknown what 
the risk factors are for progression, nor what proportion of patients do progress to the later 
stages of disease.  Explicit reference to which WHO stages of noma are included in prevalence 
and incidence estimates as well as improved detail of the method employed in these estimations 
would greatly improve our ability to compare findings across studies.  The lack of consistency 
of approach to assessing the incidence and prevalence of noma in the literature and the lack of 
real investment in assessing the true incidence and prevalence of this condition particularly in 
regions that bear the highest global burden, contributes to the ongoing neglect of this disease 
and the populations it affects. 
 
Study findings indicate that children aged between three and five years had a higher prevalence 
of noma in comparison to those aged two years or less, a finding corroborated by other studies 
[53, 67, 68, 71].  We hypothesise that this finding is likely due to the relationship between child 
feeding practices in Nigeria and malnutrition as a risk factor for noma.  Our study did not 
identify an association between malnutrition and noma.  However, other studies have shown 
that rural Nigerian children typically transition to a limited diet after being breastfeed until 24 
months of age [181, 257].  This has shown to result in higher levels of malnutrition and stunting 
[257] and therefore, a potentially higher risk of developing noma.  This discrepancy in our 
findings in comparison to other studies, could be due to the fact that our population had early-




and late-stage noma.  It is also possible that late-stage noma could cause malnutrition if the 
child was having difficulties eating due to the noma infection.  
 
Our findings showed that older (aged six to 15 years) male children were more likely to have 
any stage of noma in comparison to older female children.  We do not know what would explain 
this finding as we would not expect an inherent difference in gender in noma development.  
However, this association could point to risky behavioural traits that may be more common in 
males in this setting.  This finding warrants further research. 
 
We showed that various factors relating to pap preparation and consumption were linked to not 
having Stage 1 and 2 noma amongst the whole study sample and of any stage noma in the six 
to 15 year old age group.  It is difficult to explain this finding as it could be due to a lack of 
access to food or that pap made more frequently has less chance of becoming contaminated 
(thus causing less disease) as it is stored for shorter periods of time.  A Nigerian study showed 
that when mothers prepared food far in advance, contamination was more likely to occur [258].  
A further Nigerian study in Kebbi State showed that pap was contaminated with high levels of 
Salmonella in comparison to other commonly eaten foods [183].  This association with food 
preparation affected children in the older age group who are more reliant on this food source 
compared to the younger children. 
 
This study further indicated that having a well as the main water source in comparison to other 
water sources such as a borehole, river or tap, was associated with having noma in the 0-5 year 
age group.  Well water has a high risk of contamination from nearby pit latrines or livestock 
[56], and the consumption of contaminated well water is a risk factor for diarrhoea [118], which 




Vaccination coverage in all eligible children included in the study was low.  Even though this 
result prevented us from exploring whether vaccination is associated with noma prevention, it 
does confirm findings from other studies in rural Sokoto State, where up to 70% of children 
were not vaccinated against measles and other common childhood diseases [8]. Low 
immunisation coverage is an important indicator of struggling societal systems in need of 
multi-sectoral improvements, including access to quality timely health care, access to safe 
drinking water, improved nutrition, and security.  Prevention efforts should also include early 
detection training with health care workers, and setting up effective referral pathways.  These 
initiatives are resource-intensive and require large-scale investment of time, money and human 
resources. 
 
This study had a large sample size and robust approach to sampling and analysis, and we are 
confident that prevalence estimates are broadly representative of the study area.  However, a 
few limitations should be considered.  This cross-sectional study was conducted on a disease 
with an extremely rapid clinical progression with onset to death taking as little as two weeks 
[1].  Thus, it is possible that Neyman bias was present and we only identified a fraction of noma 
cases that occur.  The research team did come across Stage 5 noma patients in study villages, 
but not in households included in the study.  These patients were referred to the NCH for care.  
The sample size was calculated using the only available, but nonetheless, relatively out-of-date 
data with the household size used only representing Sokoto and not Kebbi, this could have 
influenced the findings of the study.  It is possible that if we had reached the calculated number 
of clusters (181) or had a study with a larger sample size, we could have identified children 
with the later stages of disease.  Some of the answers were self-reported by caretakers, which 
could have introduced social desirability bias that either inflated or deflated the risk factor 




trying to phrase questions in contextually acceptable ways. Data on some risk factors, such as 
comorbidities, water quality, and malnutrition in older children was not collected, limiting our 
ability to identify associations with these factors.  It is difficult to interpret the results of 
questions asking about consumption of any food and specific foodstuffs in the 24 hours prior 
to the interview and associations with noma as respondents with noma could have difficulty 
eating in general and would thus have been less likely to report eating at all.  The measurement 
of malnutrition using only the MUAC was a limitation as this tool is useful to diagnose severe 
acute malnutrition but noma is reported to be associated with chronic malnutrition often 
accompanied by stunting.  Finally, the challenging security situation limited the areas the 
research teams could access. This may have introduced selection bias, and an under-estimation 
of noma and malnutrition prevalence, as we did not visit the hardest to reach communities who 
were likely most vulnerable to noma infection. Future research on the burden of noma should 
be combined with existing surveillance systems for other disease and research activities such 
as malnutrition and vaccination surveys. 
 
Noma meets the criteria of a NTD as defined by the WHO: it is a preventable disease that 
affects children in low-resource contexts; children that survive will have life-long physical and 
mental health sequelae; and there is a poor understanding of the disease, its pathogenesis and 
global burden [259].   
 
This study has shown that the prevalence of any stage of noma is higher than previous 
estimates.  While we did not find any later stages of the disease, the high rates of simple 
gingivitis and the presence of known risk factors for noma (low vaccination rates, malnutrition 
and poor access to health care) suggest the need for improved coverage of preventative 




than those for snakebite in Nigeria (497 per 100,000 people), which the WHO recently 
recognised as a NTD [260].  Noma prevention and control will require a concerted health 
systems approach.  Adding noma to the WHO’s list of NTDs will facilitate global attention for 
noma and the allocation of much needed resources to those countries where noma continues to 





Chapter 8  Discussion and recommendations 
This chapter presents a synopsis of the key findings of the thesis in relation to the initial aims 
and objectives, the overarching themes and the recommendations for policy, practice and future 
research. 
 
8.1  Synopsis  
The main aim of this thesis was to refine our understanding of the biopsychosocial features of 
noma, its epidemiology and treatment in northwest Nigeria.  Through the various studies 
included in the thesis, we were able to address the three key objectives: 
1. Assess the distribution of noma among children in Sokoto and Kebbi States, northwest 
Nigeria. 
2. Identify factors associated with noma in this setting, including factors influencing 
health-seeking behaviour and risk factors for the development of noma. 
3. Gain an understanding of the biomedical and non-biomedical care provided to noma 
patients in this setting. 
 
Firstly, we examined the literature on noma (Chapter 2) which clearly demonstrates the paucity 
of knowledge on the distribution of noma globally and in Nigeria. The literature review further 
illustrated the changing distribution of noma from the 1800’s to 2019.  Crude estimates of 
global prevalence and incidence found in this review have not been updated since 1998 [19].  
Secondly, recognising the need to update and expand on current prevalence data for noma in 
Nigeria, we conducted a community-based cross-sectional prevalence study in the two 
northwest Nigerian states of Sokoto and Kebbi (Chapter 7).  The study included 177 clusters, 
3,499 households, and 7,122 children.  The prevalence of noma for 0-15 year olds in this area 




of simple gingivitis (3.1%) demonstrates that this remains a population at risk for developing 
late stage noma. Most prevalence and incidence data reported from Nigeria prior to this study 
arose from hospital-based surveillance systems, which are likely to only detect more serious 
cases that have successfully sought care [7, 42, 239].  Our study represents the first population-
based noma prevalence study in Nigeria and provides a more comprehensive view of disease 
distribution in these states.   
 
Thirdly, we identified factors associated with noma in this setting, including factors influencing 
health-seeking behaviour.  Chapter 3, a qualitative study showed the varied beliefs about noma 
causes including birds and insects, interference from the spirit world and preceding cases of 
disease (measles was specifically mentioned).  These beliefs impacted the health-seeking 
decisions of caretakers, with several seeking care at traditional healers who treat not only the 
physical but also the spiritual manifestations and causes of disease.  Reasons for traditional 
healer use were also noted by caretakers in Chapter 6 and include issues surrounding trust, 
affordability and distance to care when compared to biomedical services.  Even though 
biomedical care was free for patients at the NCH, other costs such as childcare and a loss of 
income posed additional barriers to this type of care.  
 
Fourth, risk factors for the development of noma were explored in both the case control study 
(Chapter 4) and the prevalence study (Chapter 7).  Notable risk factors centred on food, water 
and caretakers and child demographics.  These included: pap being consumed more than once 
per week, pap being prepared less than once a week, a well point as the main water source, the 
mother not being the primary caretaker, the caretaker being unmarried and the child being aged 
between three and five years.  The differences in risk factors identified in these chapters is 




control study were hospital-based, compared to the community-based identification of cases in 
the prevalence study. 
 
Fifth, we explored the biomedical surgical care available at the NCH as well as the care 
provided by traditional healers living in the villages of the patients in Sokoto State.  The 
literature review (Chapter 2) showed the importance of seeking care in the early reversible 
stages of disease and the positive impact receiving antibiotic treatment, nutritional support and 
wound debridement had on noma mortality and morbidity.  The review also highlighted the 
limitations of biomedical care for noma patients. These included the lack of outreach to 
communities at risk, health care workers’ low levels of knowledge about the disease, and the 
inadequate amount of follow-up conducted after surgical treatment to provide care such as 
physiotherapy and assess longer-term outcomes. These limitations were echoed in the 
outcomes study (Chapter 5) which showed that surgical care reportedly improved patients’ 
quality of life, but had limited improvements in patients’ functional outcomes.  
 
In Chapter 6, traditional healers reported that they believed the different stages of noma were 
different diseases.  Treatment of noma in the oedema phase included herbs, ointments and the 
creation of bleedings marks.  However, several healers noted they had not treated the later 
stages of the disease.  Traditional healers also reported referring these patients to biomedical 
health care centres, reflecting their recognition and acceptance of biomedical care alongside 
traditional interventions.  Qualitative studies in Chapters 3 and 6 highlight the importance of 
traditional healers as a first point of call for noma patients.  However, this can result in delayed 
access to biomedical care at a crucial point in the patient pathway when progression of the 








pathways to care for noma patients in northwest Nigeria, the factors associated with the disease 
in this setting and the care options available to patients. 
 
8.2 Noma:  an invisible and neglected disease 
Noma is a disfiguring disease that affects vulnerable populations who live in underserved 
communities.  A pervasive theme across this thesis is that noma patients and the disease itself 
remain invisible within the communities they reside, the health systems that are supposed to 
serve them and the global health community.  These layers of invisibility are all interwoven 
and exercise influence upon one another (Figure 8.2).   If a disease is invisible, it will likely be 
neglected.  
 
At the United Nations Human Rights Council in 2011, Jean Ziegler stated that “Noma is a 
neglected disease: neglected by the medical community, by governmental authorities, by major 
private donors and by public opinion.  The persistence of noma in today’s world raises doubts 
not only about our morality, but it comes to prove that the human rights of children, the most 
vulnerable members of the international community are being severely ignored and violated” 
[261].  Noma has been labelled a neglected disease by several other authors for many decades 
as indicated by the titles below: 
- Noma : a neglected scourge of children in sub-Saharan Africa (1995) [238] 
- Noma: a neglected enigma (2013) [209] 
- Noma: neglected, forgotten and a human rights issue (2015) [58] 






Figure 8.2 Invisible noma: depiction of the levels of invisibility of noma as shown in the 
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Despite these pleas over many decades and the evidence generated that indicates the neglected 
nature of noma, the disease remains neglected on several fronts discussed in more detail below. 
 
At the first layer are the individuals experiencing the direct consequences of noma.  Our 
research has shown that noma affects children aged between three and five years who are 
predominantly cared for by someone other than their mothers.  These children were shown to 
have a poor variety in their diet and a recent history of illness.  Such factors highlight the 
vulnerable and marginalised nature of noma patients who predominantly live in areas of 
socioeconomic need and have limited voices of their own. Our studies further showed that 
caretakers of noma patients were frequently unmarried and often female.  Movements of 
females in this setting are limited to their residential compounds due to cultural and religious 
norms [136].  This heightens the invisibility and neglect of noma patients who rely on female 
caregivers to access care.   
 
Our findings showed an additional layer of invisibility is added to noma patients and caretakers 
due to the significant stigma associated with the disease.  Caretakers and patients are ostracised 
by family and friends, resulting in mental health strain, a finding corroborated by others [162–
164].  The outcomes study in Chapter 5 demonstrated that when noma patients are provided 
with surgical care, stigma and social isolation are reduced.  Patients reported less invisibility 
and greater societal inclusion by attending school, having friends and perceiving marriage as a 
possibility after their surgery showing that access to timely care can reduce stigma and the 




A third layer of invisibility occurs at the population level.  Noma cases are frequently reported 
in low socioeconomic populations such as those found in northwest Nigeria [11, 32, 38, 41, 70, 
262, 263].  Our community-based prevalence study showed that there is a large population at 
risk of developing later stage noma.  Populations living in poverty are at times ignored, and as 
such, the diseases affecting these marginalized populations are also ignored by the governments 
and health systems that serve them [58, 70].  
 
In northwest Nigeria, our studies showed that participants had limited access to biomedical 
health services and low vaccination coverage rates.  These factors add weight to previous 
studies which found that a lack of access to quality care and vaccine preventable comorbidities 
were associated with increased risk of noma [2, 8, 147].  In the absence of a functional and 
accessible health system infrastructure, noma precursor conditions and cases cannot be 
detected or timeously managed, further compounding the political and social invisibility of this 
disease.  
 
This invisibility in the biomedical health system was mirrored in Chapter 6 where traditional 
healers noted that many of them had not seen cases of the later stages of disease.  As traditional 
healers are frequently the first port of call for any health issues, this could indicate noma 
patients are either kept at home or, due to the rapid progression of the disease, die before 
seeking care.  Thus ensuring patients remain unseen and unnoticed by traditional and 
biomedical healthcare providers.   
 
The thesis literature review has shown that despite the major developments in healthcare and 
health research since noma was first identified, noma remains a poorly understood disease in 




10, 17, 20, 22, 23, 34, 40–43, 56, 107, 117] making comparison between our study results and 
others difficult.  The invisibility of noma within the global health community could be 
explained by the reported relative rarity of the condition and the fact that geographic clustering 
of cases has tended to occur in hard-to-reach communities such as northwest Nigeria.  This 
means that even for those who do want to study the disease, conditions are challenging.  A 
further reason could be the limited presence of noma in international health dialogues.  This 
limits the amount of resources allocated to researching noma, adding to the circular nature of 
the invisibility of noma within the global health community. 
 
Based on the invisibility and neglect of noma, we offer several recommendations for policy, 
practice and further research. 
 
8.3 Recommendations for policy 
The strongest policy recommendation from this thesis is to further support the advocacy of the 
addition of noma to the WHO NTD list [57, 58, 113, 209, 238, 261].  NTDs are characterised 
as diseases that do not have a strong political voice, affecting people with a low status in public 
health priorities, living in remote, rural areas, in conditions of poverty [259]. Noma meets all 
of these criteria.  
 
However, the WHO have stated that there are two main reasons for the deliberations over 
including noma on the WHO NTD list.  Firstly, there have been discussions over whether to 
classify noma as an infectious disease or as a dermatological condition [264].  This difficulty 
in classification should not however cause a delay as there are NTDs that are infectious diseases 
(leishmaniasis), and others that are not infectious (snake bite), and there are others that are 




strictly a tropical disease [264].  Tropical diseases are labelled as those found in the areas 
around the equator between the lines of the Tropic of Capricorn and the Tropic of Cancer  [265].   
This point is valid, the maps in Chapter 2 have shown the global distribution of noma. However, 
several diseases on the WHO NTD list including snakebite [266], scabies [267], dengue [268], 
rabies [269], leprosy [270] and Chagas [271] are present in non-tropical regions but are still 
included on the list.  Therefore, geographical distribution should not stop noma from being 
added to the WHO NTD list.  It is also possible that the non-inclusion on the WHO NTD list 
is linked with the fact that acute noma can be treated with relatively inexpensive and widely 
available antibiotics meaning it is not a target for pharmaceutical companies which contrasts 
with other diseases on the list which have significant interest for these companies, including 
snake bite. 
 
The addition of noma to the WHO NTD list could raise awareness about the disease and boost 
much needed funding for prevention, treatment and research.  For example, since the inclusion 
of snakebite onto the WHO NTD list, this cause has received several large scale donations such 
as USD$102 million from the Wellcome Trust [272].  Many funders rely on the WHO NTD 
list to make donation decisions, including the Bill and Melinda Gates Foundation, USAID and 
UK Aid.   In 2014, diseases on the WHO’s NTD list received an estimated USD$300 million 
in donations [259].  Furthermore, the addition of noma to the WHO NTD list could boost 
national awareness and funding.  In Nigeria, there have been successful eradication campaigns 
for other diseases such as Guinea-worm in 2009 [273].  This cost the Nigerian Ministry of 
Health USD$2 million [273].  This figure far outweighs the 2018 available budget for noma 





8.4 Recommendations for practice   
The thesis provides recommendations for practice including health system strengthening, 
training initiatives and the adoption of a singular noma classification system. 
 
8.4.1  Health system strengthening 
To decrease the number of noma cases, three main areas of improvement to the health system 
have been identified: increasing access to care, preventative activities and the creation of a 
robust surveillance network.  As these are broad health systems initiatives, they would be 
beneficial in curbing the incidence of noma and other childhood diseases simultaneously. 
 
8.4.1.1 Access to care 
Our findings identified several barriers to care in the northwest Nigerian setting including time, 
money and distance.  These challenges lead to the need for several improvements in health care 
access. The number of health centres and health care workers needs to be increased, as does 
their distribution into rural areas [129, 274].  Whilst noma does occur in urban settings, the risk 
factors for noma are more frequently found in rural areas.  Increased rural health services would 
need to be paired with health financing programmes which would aim to remove the 
catastrophic health expenditure faced by many families of noma patients. A further area of 
focus should be the creation of effective and efficient referral mechanisms. This would mean 
that noma patients could access the type of care they need in the crucial early stages of the 
disease.  Improving access to healthcare would not only reduce the incidence of noma but also 







8.4.1.2 Preventative activities 
This thesis has shown that noma has devastating consequences, and even for those who survive 
and are able to access surgical treatment, outcomes in terms of functionality are limited.  As 
such, focus should be placed on preventing noma.  By removing the main risk factors associated 
with noma development (low vaccination rates, malnutrition and poor oral hygiene) there 
would be a reduction in the incidence of noma and other childhood diseases. 
 
The creation of a functioning vaccination system that reaches even the most rural communities 
is an important first step in the prevention of noma.  This system would need to be adequately 
resourced and provide continual high coverage.  Due to mistrust in vaccines in this setting, this 
system would need to be paired with an awareness campaign about the safety and efficacy of 
vaccines which should involve community and religious leaders [275–277]. 
 
Programmes focussing on improving the nutritional status of children could be a further 
effective mechanism in the prevention of noma. This would yield numerous other health 
benefits to this population.  As stated in this thesis, most acute noma cases occur in children 
aged between two and five years and so interventions should focus on caretakers of young 
children.  These should include providing prenatal care and nutritional assistance for mothers 
as the first one thousand days of a child’s life (including time spent in utero) have been shown 
to be instrumental in the health outcomes of children [278].  Infants born with a low birth 
weight are also at higher risk of contracting noma [239]. 
 
Oral health care is a major public health issue in Nigeria where there is a high prevalence of 
dental caries and periodontal diseases [145].  Poor oral health is a recognised risk factor for 




estimated 1.2 dentists per 100,000 population members [145].  A school- and community- 
based oral health programme would provide access to dental care.  This has proven to be an 
effective option in Ibadan, Nigeria [279] and could be an effective means of diagnosing and 
treating the early reversible stages of noma in other Nigerian states.  However, interventions 
within dental health programs alone may limit the health care system’s ability to help these 
children most effectively and so system wide interventions are needed. 
 
These three preventative activities could be achieved through the deployment of mobile health 
care workers.  Such workers could provide immunization services, monitor nutritional and oral 
health status, identify cases that need referral and deliver health education talks.  These efforts 
could build trust in the health system and offer protection from a host of childhood diseases 
[184, 280].   Moreover, these mobile healthcare workers could improve the functioning and 
geographical reach of other routine healthcare services.  
 
8.4.1.3 Surveillance 
A strong recommendation from this thesis would be the strengthening of the surveillance 
system for noma in Nigeria in particular, but also in other endemic countries.  An improved 
surveillance system would assist in gaining a better understanding of the incidence, spatio-
temporal distribution and burden of diseases, which, in turn, is essential for prevention, control 
and elimination [281, 282].  The smallpox and polio eradication programmes provide 
convincing examples of the critical role played by a globally organised approach in linking 
surveillance data to targeted, swift and effective public health responses [281].  
 
Noma is a notifiable disease in Nigeria, however, the Nigerian Centre for Disease Control 




disease [240].  There is a need to strengthen the national noma surveillance system.  At this 
point, the most effective form of surveillance would likely be a combination of active health 
facility-based (new cases detected in health facilities by health care professionals) and 
population-based surveillance (cases identified in a defined population or at a community level 
who are not presenting at a health centre).  In 2017, the Nigerian Centre for Disease Control 
adopted the Surveillance and Outbreak Review Management System, a digital surveillance tool 
which is now functional in 15 health facilities across 11 states [283].  This could be a useful 
tool (once fully rolled out) for the rapid surveillance of noma at a health facility level.  To 
ensure the effectiveness of this surveillance system, large scale training for health care workers 
and surveillance officers would be required (discussed below). 
 
One unique method of surveillance which has been effective in the mapping of onchocerciasis 
(river blindness) is the use of rapid screening in high risk areas [282].  This could be useful in 
terms of noma in that active community-based surveillance initiatives could first target 
communities with high levels of known noma risk factors.  These could include areas with low 
vaccination rates or areas with recent measles outbreaks, high levels of malnutrition or food 
insecurity, areas where most citizens use well water or in water scare settings and areas where 
government clinics or non-governmental organisation partners (such as Operation Smile, 
Mercy Ships, Smile Train or MSF) have identified noma cases. 
 
8.4.2  Training initiatives 
The MSF and Nigerian Ministry of Health outreach team train community members and health 
care workers on the stages of noma and appropriate treatment protocols for each stage. This 
team visits approximately 30 villages each month training approximately 500 community 




knowledge gap that further training could fill. The main focus areas should include community 
awareness raising and health care worker trainings.  
 
8.4.2.1 Healthcare worker training 
Wide scale healthcare worker trainings with biomedical and non-biomedical care providers 
(nurses, doctors, dentists, pharmacists, traditional healers and traditional birth attendants) could 
facilitate better surveillance initiatives, more efficient treatment and referrals to the correct 
points of care and assist with generating interest in noma.  These trainings should focus on 
educating health care workers on the early signs and symptoms of the disease, identification of 
the different stages of disease and the timeframes for progression between stages, the risk 
factors for the disease (to encourage discussions around prevention), the language used to 
describe the disease (to enable improved patient interaction) and the appropriate treatment 
regimens for each stage.  These trainings should be paired with the creation of efficient referral 
pathways between biomedical health centres and from non-biomedical health care providers to 
biomedical health centres.  In other African settings, traditional healers have been recruited to 
serve as community health workers through training and support by nearby health facilities 
[284].  This could be a strategy for the effective inclusion of traditional healers in noma 
interventions.  
 
8.4.2.2 Community-based awareness raising and training 
Awareness about the biomedical causes and treatment protocols for noma in northwest 
Nigerian communities is limited, indicating a need to improve awareness about the disease. 
Awareness raising campaigns should focus on educating community members looking after 
children who are at risk of developing noma.  These awareness campaigns should include the 




boiling well water, healthy oral hygiene practices, the early signs and symptoms of noma and 
the urgency with which health care should be sought.  The various names for noma identified 
in this thesis should be included in these awareness campaigns to ensure community members 
know which disease the campaigns are targeting.  The beliefs about the causes of disease should 
also be discussed in face to face trainings and included in other messaging methods.  Radio 
adverts, fliers handed out at village events and posters hung in prominent positions in the 
villages (mosque, shop, health centre) could be effective means of alternative communication.  
These would need to be well illustrated to accommodate for the low levels of literacy in noma 
endemic countries.  Public messaging tools should be paired with a hotline number which 
allows for speedy referrals. Testing the success of each awareness raising approach will be 
important to determine the most affordable and effective methods for scaling programmes. 
 
Including community leaders (religious leaders, village chiefs, village elders and school 
teachers) will assist in gaining community trust and acceptance for all initiatives (prevention, 
treatment and research).  Community leaders are frequently the first port of call for patients if 
they are seeking advice or financial assistance to take their children to health care facilities. 
Tailor-made trainings for this group should include information on the importance of 
supporting unmarried mothers and caretakers of children who are not the biological mother in 
raising their children specifically at times when the child is sick.  Information should also be 
given about the causes and treatment options available for noma, the early signs and symptoms, 
the speed with which care needs to be sought and the best referral options for patients from 







8.4.3  Single noma classification system 
There are numerous classification systems and descriptions of the staging of noma in the 
literature, making comparisons of study results difficult.  These include classifying noma into 
two stages, acute and chronic noma [10, 31, 32], the Montandon system which focuses 
classification on the area of the face implicated [55], the WHO noma classification system 
which classifies noma according to distinct stages of clinical progression [1] and the NOITULP 
grading tool which classifies noma cases based on the percentage loss of each anatomical unit 
[38].  This thesis has utilised two of these tools, namely the WHO noma classification tool and 
the NOITULP grading tool.  However, these tools have limitations. The WHO classification 
system is useful as a surveillance tool; it is sensitive but not adequately specific. It is intended 
to assist surveillance staff and affected communities in identifying the stages of noma.  As the 
tool includes the more commonly seen ailments of simple gingivitis and acute necrotizing 
ulcerative gingivitis to ensure populations at risk are identified, and the fraction of patients with 
these conditions who go on to develop the later stages of noma is unknown, the tool may 
overestimate the true burden of disease.  This tool also classifies the later stages of disease as 
inactive which is not necessarily true as the defect created by noma heals with contracture and 
as the child grows the scar contracts and this can cause further damage including the exposure 
of teeth or the opacification of the exposed eye leading to blindness of the affected eye.  The 
NOITULP scale is not a classification of noma stage, but a classification of anatomical loss of 
the nose, the outer cheek and the inner lining of the cheek, the upper lip and lower lip, and the 
degree of trismus [38].  This is a useful tool to determine priorities for surgical reconstruction 
and understanding the outcomes of surgical care of later stage noma patients, but cannot be 
used as a diagnostic tool.  Further research is needed to assess the most appropriate tools to 
use, but even with these limitations, the adoption of the WHO tool for surveillance along with 




reporting for each stage of the disease as well as the clinical outcomes.  This could lead to 
clearer estimates of each stage of noma being identified and allow for easier comparison of 
study results.  The WHO tool should also be embedded in training materials such as 
information booklets and educational messaging. 
 
8.5 Recommendations for further research 
Future research should be paired with education and training for respondents and in areas where 
the research is conducted.  Topics covered should be based on the needs identified for the target 
populations.  These may include the naming of the disease, risk factors and appropriate referral 
practices.  This would mean that research initiatives have a positive impact for the respondents 
and communities in which the research tasks place. 
 
Further robust studies need to be undertaken to examine the associations found in this thesis. 
Along with these studies, based on the findings of the thesis, the main recommendations for 
future research are to better enumerate the burden and distribution of noma, gain an 
understanding of the proportion of cases that progress from one stage to the next, and the risk 
factors for this progression, create evidence around the main gaps in biomedical health care 
workers knowledge about the disease, conduct an economic evaluation of the impact of noma 
and to validate a Hausa quality of life tool. 
 
8.5.1   Distribution and burden of noma   
The thesis assessed the prevalence of noma in two states in Nigeria.  One of the main gaps in 
knowledge remains the national distribution and burden of disease. Specifically, the incidence 
of noma is unknown.  A prospective cohort study would enable an assessment of the incidence 




number of randomly selected villages could be included, and all children in those villages could 
undergo oral examinations once a month over a year long period.  This would enable the 
detection of all stages of noma.  This study would however, be resource- and time- intensive, 
especially considering the rare nature of noma. 
 
We recognize that there are many other issues these communities face. Cross-cutting initiatives 
that address more than one disease, strengthen reporting structures and upskill human resources 
may be more beneficial than vertical noma initiatives.  Future initiatives to gain a better 
understanding of the distribution and burden of noma could be incorporated into vaccine 
coverage surveys, surveillance initiatives for other diseases listed as high priorities in the 
country (lassa fever, yellow fever, cholera and measles [283]) or malnutrition surveys. Nigeria 
conducts SMART nutrition surveys twice a year in the areas most prone to malnutrition 
(northern Nigeria) and nationally once every two years [285].  The 2018 national SMART 
survey included 19,471 children aged between 0 and 59 months across all 36 states in Nigeria 
[285]. If oral health screening was included in these surveys, this would provide national 
estimates for the prevalence of any stage of noma and would provide the largest data source on 
noma prevalence in Nigeria (and globally). 
 
8.5.2  Progression to later stage noma and death 
This thesis has shown there is a lack of evidence around the proportion of cases who move 
from each stage of noma to the next, as well as the risk factors for this progression.  This 
knowledge would offer useful information to identify opportunities for interventions.  A cohort 
of patients with simple gingivitis could be followed and offered the WHO prescribed standard 
of care [1].  This would allow for an assessment of the number of cases that develop to the later 




randomised trial could be conducted with one arm receiving the standard of care, and another 
arm receiving interventions specifically designed for noma treatment (mouth wash etc.).  This 
study would also offer information on the most effective treatment protocols to stop cases from 
developing the later stages of disease.  If specific risk factors are found for progression during 
this crucial time, intervention options could be taught during health care worker and 
community awareness campaigns.  There are several ethical issues, particularly around what 
treatments are offered to each arm of the trail (the use of placebos would not be ethical in this 
instance as there are known effective treatments).  It is also possible that providing the standard 
of care would prevent cases from developing to later stage noma, which would lead to an under-
estimation of the proportion of cases that progress. These studies are also logistically complex 
and the sample size would be very large which could prove difficult in this context.  
 
An alternate idea would be to conduct a modelling study to assess the contribution of specific 
factors to the progression of the disease.  Factors such as immunosuppression, malnutrition, 
child and caretaker demographics and feeding practices could be included in these models 
which may offer predictions on the roles each factor plays in the progression of the disease 
which could then provide evidence for prevention programmes.  
 
As this thesis has shown, the true mortality rate of noma is unknown.  Ascertaining noma 
mortality in the absence of intervention using a prospective study design is not ethical, but a 
retrospective mortality survey at a community level or paired with a malnutrition survey may 
provide this information.  Using a structured verbal autopsy, with questions focussing on 
assessing if the cause of death was from noma, it would be possible to ascertain how many 





8.5.3  Knowledge, attitudes and perceptions of health care workers 
This thesis has elucidated gaps in knowledge of traditional healers, and the literature review 
revealed that biomedical knowledge on noma was sub-optimal. A cross-sectional study 
assessing biomedical health care workers’ knowledge, attitudes and perceptions of noma in 
Nigeria could yield useful information which highlights the gaps in knowledge of health care 
workers.  These points could be the main items covered in health care worker trainings.  
Tailoring these trainings around the identified gaps in knowledge could increase the 
effectiveness of this intervention. 
 
A further approach to determining health care workers’ knowledge of noma would be to assess 
which medical school and tropical medicine curricula include sections on noma.  This would 
be useful to assess both in Nigeria and other noma-afflicted countries but also more broadly 
among international tropical medicine programs which attract students from regions across the 
globe. These include the Liverpool School of Tropical Medicine (UK); London School of 
Hygiene and Tropical Medicine (UK); Institute of Tropical Medicine (Peru); Royal Tropical 
Institute (Amsterdam) and the Kenya Institute of Tropical Medicine and Infectious Diseases 
(Kenya). 
 
8.5.4   Economic evaluation  
The thesis has shown the impact the disease has on both the patient and the caretaker in terms 
of the emotional toll as well as the impact on quality of life.  In 2013, the Swiss Tropical Public 
Health Institute group calculated that 1-10 million disability adjusted life years were lost due 
to noma, the estimate is wide due to uncertainties about incidence, mortality, and surgical 
rehabilitation [57].  This estimate is similar to the 2010 Global Burden of Disease study for 




[286], highlighting the comparable nature of the economic burden of noma.  Further studies 
assessing the economic impact of noma may highlight the significant costs of this disease for 
both the patient, the health system and society.  This would provide useful information for 
advocacy, funding and policy efforts. 
 
8.5.5  Quality of life scale in Hausa   
As indicated in the outcomes study, there is currently no validated quality of life scale in Hausa 
(the predominantly spoken language in northwest Nigeria).  This makes it difficult to robustly 
measure the improvement in noma patient’s quality of life.  This measure should be the focus 
of treatment programmes and needs to be incorporated in initiatives set up to monitor the 
efficacy of surgical treatments.  Designing and validating such a tool would provide an 
opportunity to minimize the neglect of this aspect of noma care and would be useful for a range 
of other assessments in this setting.  A previous study assessing quality of life changes for noma 
patients in Ethiopia utilised a semi-structured interview [111] which provided useful insights 
into the noma specific changes to this metric and could be used as a basis for the standardised 
noma assessment tool. 
 
8.6 Conclusion 
In conclusion, this thesis provides a unique view of the biopsychosocial features, epidemiology 
and treatment options for noma in northwest Nigeria.  Noma is a disease which is indicative of 
a weak health system and socio-economic environments of extreme deprivation. 
 
Intervention programmes should include wide-spread health system improvements which 
could address a host of risk factors for noma, and simultaneously other childhood diseases. 




mechanisms, predominantly in rural areas, and the creation of a robust surveillance network. 
Health financing initiatives would need to be paired with these improvements.  Nutritional 
programs aimed at caretakers of young children and community based oral health initiatives 
could also be effective mechanisms to curb the number of noma cases.  Trainings with 
healthcare workers and community members are necessary to ensure awareness of noma is 
improved in endemic settings. 
 
The combined findings of this thesis highlight the neglected nature of noma and make a strong 
case for placing noma on the WHO NTD list.  This addition could garner awareness and open 
up much needed funding streams which would allow for further research, sufficient 
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Appendix 3 Scoping literature review documents 
3.1 PRISMA checklist for scoping literature review 
Section Item PRISMA-scar checklist item Reported 
TITLE 




2 Provide a structured summary that includes (as applicable): 
background, objectives, eligibility criteria, sources of 
evidence, charting methods, results, and conclusions that 
relate to the review questions and objectives. 
NA 
INTRODUCTION 
Rationale 3 Describe the rationale for the review in the context of what 
is already known. Explain why the review 
questions/objectives lend themselves to a scoping review 
approach. 
Yes 
Objectives 4 Provide an explicit statement of the questions and objectives 
being addressed with reference to their key elements (e.g., 
population or participants, concepts, and context) or other 
relevant key elements used to conceptualize the review 





5 Indicate whether a review protocol exists; state if and where 
it can be accessed (e.g., a Web address); and if available, 
provide registration information, including the registration 
number. 
NA 
Eligibility criteria 6 Specify characteristics of the sources of evidence used as 
eligibility criteria (e.g., years considered, language, and 
publication status), and provide a rationale. 
Yes 
Information sources 7 Describe all information sources in the search (e.g., 
databases with dates of coverage and contact with authors to 
identify additional sources), as well as the date the most 
recent search was executed. 
Yes 
Search 8 Present the full electronic search strategy for at least 1 




Section Item PRISMA-scar checklist item Reported 
Selection of sources 
of evidence 
9 State the process for selecting sources of evidence (i.e., 




10 Describe the methods of charting data from the included 
sources of evidence (e.g., calibrated forms or forms that 
have been tested by the team before their use, and whether 
data charting was done independently or in duplicate) and 
any processes for obtaining and confirming data from 
investigators. 
Yes 
Data items 11 List and define all variables for which data were sought and 
any assumptions and simplifications made. 
Yes 
Critical appraisal of 
individual sources 
of evidence 
12 If done, provide a rationale for conducting a critical 
appraisal of included sources of evidence; describe the 
methods used and how this information was used in any data 
synthesis (if appropriate). 
Yes 
Synthesis of results 13 Describe the methods of handling and summarizing the data 
that were charted. 
Yes 
RESULTS 
Selection of sources 
of evidence 
14 Give numbers of sources of evidence screened, assessed for 
eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally using a flow diagram. 
Yes 
Characteristics of 
sources of evidence 
15 For each source of evidence, present characteristics for 
which data were charted and provide the citations. 
Yes 
Critical appraisal 
within sources of 
evidence 
16 If done, present data on critical appraisal of included sources 





17 For each included source of evidence, present the relevant 
data that were charted that relate to the review questions and 
objectives. 
Yes 
Synthesis of results 18 Summarize and/or present the charting results as they relate 





19 Summarize the main results (including an overview of 
concepts, themes, and types of evidence available), link to 
the review questions and objectives, and consider the 
relevance to key groups. 
Yes 
Limitations 20 Discuss the limitations of the scoping review process. Yes 
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Section Item PRISMA-scar checklist item Reported 
Conclusion 21 
Provide a general interpretation of the results with respect to 
the review questions and objectives, as well as potential 
implications and/or next steps. 
Yes 
FUNDING 
Funding 22 Describe sources of funding for the included sources of 
evidence, as well as sources of funding for the scoping 




3.2 Scoping literature review data extraction tool 
Noma scoping review extraction tool 
Notes on using a data extraction form: 
 Be concise
 If you cannot find information, note down 'Cannot Find'
Include or exclude 
Include Exclude 




Year of publication: 
Study type: RCT Yes / No 
Cross-sectional Yes / No 
Cohort Yes / No 
Case control Yes / No 
Qualitative Yes / No 
Case series Yes / No 
Case report Yes / No 
Meets research goal: Yes / No / Unclear 
Geographical location first author: 
Setting: 
253 
(including location and social context) 
Population description: 














Appendix 4 WHO classified noma stages 
*All pictures included are from the WHO noma information booklet  [1]
Appendix 5 Published Manuscripts 
Stage 1: Acute necrotizing gingivitis 
Stage 0: Simple gingivitis 
Stage 5: Sequela 
Stage 4: Scarring 
Stage 3: Gangrene Stage 2: Oedema 
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Appendix 5 Published manuscripts 

























































































































































































Appendix 6 Questionnaires or question guides 
6.1  Language and beliefs question guides  
6.1.1  In-depth interview guide 
Background:  The key informant interviews will be conducted in a setting that minimises the 
influence of the researcher and encourages the interviewee to discuss noma, and their role in 
the project.   
 
Introduction (5 mins max):  • Thank the participant for agreeing to take part in this research. 
• Introductions - explain who you are and share some of your experience. 
• Create a relaxed atmosphere; offer the participant something to drink when this is 
possible. 
• Tell each participant:  
 “I (We) would like to talk to you about your experiences of noma and your role at the 
hospital.  We would like to hear your stories, what you think about the disease, what 
works well for treatment and the challenges you face.  This interview will contribute to 
a better understanding of noma and the work occurring at the Noma Children’s Hospital 
in Sokoto.  The interview will take approximately 30 minutes and can be stopped by you 
at any time without any consequences.  If you would like to continue there is a form we 
have to complete to check that you have all the information you need before we start.  
Would you like to continue? Would you be happy for us to record this conversation for 
our records? 
• Make sure the participant has been informed and has consented verbally to participate 
in the research study.  




Questions should be adapted where necessary, but can follow the below themes: 
1. Discuss patient flow thorough the noma surgical program. 
2. What noma stage patients are at when they are included in to the program? 
3. How long on average after onset do patients come to hospital?  
4. What would the best terms be to use in the questionnaire to describe noma, as there is 
no official Hausa word for noma? 
5. What beliefs staff have about noma? 






6.1.2  Focus group discussion question guide 
Introduction (5 mins max):   
• Thank the participants for agreeing to take part in this research. 
• Introduce yourself. 
• Create a relaxed atmosphere; offer the participants something to drink when this is 
possible. 
• Tell the group: 
 “I (We) would like to talk to you about noma, your beliefs about this disease and the 
words you use to describe it.   This discussion will contribute to a better understanding 
of how people living with noma experience the disease.  
 The interview will take approximately 45 - 60 minutes with anyone in the group deciding 
to leave at any time if they no longer want to contribute at any time without any 
consequences". 
• Make sure the group participants have been informed about the study and have 












**TURN ON the recorder and test it is recording** 
Topic Specific Questions Prompts and Notes 
Introduction - Study aim
- Why invited to participate
- Consent and respect within the group
Answer any questions group 
has about study 
Language used to 
describe noma 
- Show picture of noma patient and ask
group - if this person was walking in
your village, what name would you use
to describe the disease they had?
- Ask what their community would call
the disease?
- What the names mean?
- Where the names come from?
Specific names, ask about 
origins of names, ask each 
group member what name it is 
called in their village, try and 
see if there are variations 
Perception of 
noma 
- Ask caretakers what other people say
about this disease?
- What do community members know
about disease?
- Is it a common disease?
Ask about community and 
personal perceptions of the 
disease.  
Beliefs - Where does the disease come from?
- What causes the disease?
- Risk factors for disease?
- How best to treat disease?





6.2 Risk factors questionnaire  
Study Number: _________________________________________________________  
Date :  _________________________________________________________ 
 
INTERVIEWER PLEASE READ INTRODUCTION:  
 Thank you for agreeing to participate in this study!  
 This study is important as it will help us to develop programmes to prevent noma 
in Nigeria. 
 I will ask you questions about yourself, your lifestyle, and about the child of interest 
(case).  
 All of your responses are confidential, and I will not write your name on this form.  
 There are no right or wrong answers. 
 This interview will take about 45 minutes.  
 Please answer all questions honestly.   
 Do you have any questions before we begin?  
 
 
A. SOCIODEMOGRAPHIC CHARACTERISTICS 
1. How old is your child (the case)? ___________ years  OR __________ months 
2. How old are you (parent/guardian)? ___________ years 







h) Other, please specify:  
 ______________________________ 
4. How many wives do you have (if 
husband)? (Skip to 6) 
 How many wives does your husband 
have (if wife)? 
 
 __________________  (number) 




e) Other, please specify:  
 ______________________________ 
 
6. What is the highest level of education 
you have completed? 
a) None 
b) Arabic studies 




d) Secondary school 
e) University 
f) Other, please specify:  
 ______________________________ 
 
7. What is your primary business/money 
making activity? 
a) Livestock (own cattle, sheep, goats etc.) 
b) Agriculture (grow and sell food products  
 from own land) 
c) Trading/shop (owner of business) 
d) Seasonal labour/daily 
e) Regular work (work in shop, drive bus, 
 regular  job etc.) 
f) No business/housewife 
g) Student 
h) Don's know 
i) Other, please specify:  
 ______________________________ 
 
8. What is your husband's/wife's primary  
 business/money making activity? 
a) Livestock (own cattle, sheep, goats etc.) 
b) Agriculture (grow and sell food products  
 from own land) 
c) Trading/shop (owner of business) 
d) Seasonal labour/daily 
e) Regular work (work in shop, drive bus, 
 regular  job etc.) 
f) No business/housewife 
g) Student 
h) Don's know 
i) Other, please specify:  
 ______________________________ 
 
9. Does any member of your compound 
own: (circle all appropriate) 
a) A watch 
b) A motorbike 
c) A radio 
d) A phone 
e) A generator to make electricity 
f) A car 
10. What level of education has your child 
 completed (the case)? 
a) None 
b) Arabic studies 
c) Primary school 
d) Secondary school 












h) Other, please specify:  
 ______________________________ 
 
B. LIVING CONDITIONS 
12. How many people live in your  
 compound and of what sex?  
 Male Female Total 
Children 0-4 yrs    
Children 5-17 yrs    
Adults 18 & older    
Total    
13. How many houses are there in your 
 Compound? 
 
 __________________  (number) 
 
14. What is the main material of the  
 external walls of your house? 
a) Improvised/temporary (e.g. plastic) 
b) Wood, mud, bamboo 
c) Stone, brick, cement 
d) Other, please specify:  
 ______________________________ 
 
15. Do you  have running water (a tap) in 
 your compound? 
a) Yes 
b) No 
16. Where do you get your drinking water 
 from? 
a) Bore hole in the village 
b) Well in the compound 
c) Tap (running water) 
d) River/stream 
e) Other, please specify:  
 ______________________________ 
 
17. Do you treat your drinking water? a) Yes 
b) No 
18. If you do treat your drinking water, how 
 do you treat it? 
a) Boil 
b) Add bleach/chlorine tabs 
c) Add floculant and strain through a cloth 
d) Strain it through a cloth 
e) Use water filter (ceramic/sand) 
f) Let it stand and settle 
g) Other, please specify:  
 ______________________________ 
h) Don't know 
19. Does your compound have electricity? a) Yes 
b) No 
20. Do you have cows living in your  







21. Do you have donkeys living in your 
 compound?  
a) Yes 
b) No 
















26. Do you have any other animals living in 
your compound? 
a) Yes 
b) No.   
What kind: ____________________________ 
 
27. How many meals did the family eat 
yesterday (at the hospital)? 
 
 __________________  (number) 
 
28. How many meals does your family eat 
when you are in your village 
 
 __________________  (number) 
 
29. Does your child eat cassava every day 
when you are living in the village? 
a) Yes 
b) No 
30. Does your child eat pap every day when 
you are living in the village? 
a) Yes 
b) No 
31. What food does your child normally eat 
in the day?  (Please list contents of all 
meals) 
 
Breakfast:  ____________________________ 
_____________________________________ 
Lunch:   ______________________________ 
_____________________________________ 
Dinner:    _____________________________ 
_____________________________________ 
Other:    ______________________________ 
 
32. What food does your family normally 
eat in the day?  (Please list contents of 
all meals if different from above) 
a) Same as child (above) 
b) Different from child (details below) 
 
Breakfast:  ____________________________ 
_____________________________________ 
Lunch:   ______________________________ 
_____________________________________ 
Dinner:    _____________________________ 
_____________________________________ 







33. Does your child have a health card? a) Yes 
b) No 
34. Was your child vaccinated?  a) Yes 
b) No 




36. Interviewer:  Ask to see vaccination 
card, if the caretaker has one, circle all 




 Add number of doses based on dates 












Vaccination Number of doses 
a) Diphtheria  
b) Hepatitis A  
c) Hepatitis B  
d) Poliomyelitis  
e) Measles  
f) Mumps  
g) Pertussis  
h) Pneumococcal  
i) Rotavirus  
j) Rubella  
k) Tetanus  
l) Typhoid  




o) Rabies  
p) Chicken pox  
37. Self-reported vaccines.  Ask caretaker 
which vaccinations child received.  
Vaccination Self-reported (tick) 
a) Diphtheria  
b) Hepatitis A  
c) Hepatitis B  
d) Poliomyelitis  
e) Measles  
f) Mumps  
g) Pertussis  
h) Pneumococcal  
i) Rotavirus  
j) Rubella  
k) Tetanus  
l) Typhoid  




o) Rabies  






D. BREASTFEEDING PRATICES AND CHILDREN 
38. How many children did you/your wife 
give birth to? 
 
 __________________  (number) 
 
39. How many of these children are still 
alive?  
 
 __________________  (number) 
 
40. How many boy children do you have 
(including those who died)?  
  
 __________________  (number) 
 
41. How many girl children do you have 
(including those who died)? 
 
 __________________  (number) 
 
42. What number in the birth order of your 
children, is the case?  
 
 __________________  (number) 
 
43. How much did  your child (case) weigh 
when they were born? 
a) Light 
b) Heavy  
44. Birthweight in grams (if known)  
 __________________  (grams) 
 
45. How long did you breast feed for the 
child/case? 
a) Less than 2 months 
b) 3-6 months 
c) 7-12 months 
d) 1-2 years 
e) Other, please specify:  
 _________________________________ 
 
46. Did you give colostrum (first mild) to 
the case?  
a) Yes 
b) No 
c) Don't know 
47. Do you give the baby/case breast milk 
and other food simultaneously? 




48. When did you first begin giving the case 
water when they were a baby?  
a)  ________________ (age in months/years) 
b) Don't know 
49. When did you first begin giving the 
baby/case solid foods?  
a) ________________ (age in months/years) 
b) Don't know 
50 What are the first foods you gave the 
baby/case?  
____________________________________ 
____________________________ (list items) 
 
51. Does your child have any traditional 















E. CHILD HEALTH AND ACCESS TO CARE 12 MONTHS BEFORE INTERVIEW 
54. Has your child been sick (in addition to 




55. If yes, how many times during the last 
12 months?  
 
 __________________  (number) 
 












Did the child 






















     
List of diseases to choose from - Malaria - Respiratory infections 
  - Measles - Intestinal infections 
  - HIV - Rash 
  - Bronchial infections - Diarrhoea 
  - Other (specify) 
56. Has your child taken medication in the 
last 12 months?  
a) Yes 
b) No 
If yes, what medicine 
______________________________________ 
F. ACCESS TO CARE - GENERAL 
57. For any of the times that your child was 
sick in the last 12 months (apart from 








58. Which of the following health care 




c) Traditional healer 
d) Village elder 
e) Other, please specify:  
______________________________________ 
 
59. Did the doctor/nurse ever do a home 
visit when your child was sick? 
a) Yes 
b) No 
60. Where would you go when your child is sick in general? (tick the appropriate one) 






a) 1st place I would visit      
b) 2nd place I would visit      
c) 3rd place I would visit      
d) 4th place I would visit      
61. How do you get to the point of care? 






a) Taxi      
b) Bus      
c) Walking      
d) Bicycle taxi      
e) Hitchhiking      
f) Motorbike      
g) Other, please specify? 
 ____________________ 
 
     
62. How long does it take to get to the point of care 






a) 0-14 minutes      
b) 15-44 minutes      
c) 45 minutes - 1.5 hours      
d) 1.5 hours - 2.5 hours      
e) Half a day      
f) Full day      
g) 2 days      
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G. CHILD ORAL HEALTH
63. Does your child brush their teeth? a) Yes
b) No
64. If yes, how many times a day?
__________________  (number) 
65. Can I see your child's toothbrush and
toothpaste?
a) Yes (interviewer visually confirms
toothbrush + toothpaste)
b) Yes (interviewer visually confirms only
toothbrush)
c) Yes (interviewer visually confirms only
toothpaste)
d) No (interviewer does not have visual
confirmation)
H. MUAC MEASUREMENT AT THE TIME OF THE INTERVIEW
66. INTERVIEWER to test nutritional status
by using mid upper arm circumference
(MUAC) tool




a) Number of MAUC measurements:
_________________________________
b) Nutritional status upon admission from
medical file:
_________________________________
I. OPEN ENDED INTRODUCTORY NOMA QUESTIONS
67. What disease do you believe your child has?
68. What do you think caused this problem?
69. What do you think is the best way to fix it?
70. Are there any beliefs in your culture about this disease?
J. NOMA DISEASE IN THE CHILD
71. What do you call this disease before you




















74. What do you think is the best way to fix it? a) Traditional medicine - herbs/powder to
drink 
b) Traditional medicine - to put on wound
c) Cutting cheek with sharp blade (after
placing blade in fire)
d) Medicine from hospital
e) Operation
f) Other ____________________________
75. When did you first notice the signs and
symptoms of Noma?
a) Rainy season (May - September)
b) Dry season (Harmattan, October - April)
76. How long from first signs and symptoms
(mouth ulcer/bleeding gums) did it take
for the noma to develop to Stage 2?






f) More than one month
77. How long from first signs and symptoms
(mouth ulcer/ble3eding gums) did it take
for noma to develop to Stage 3?  (Skin on






f) More than one month
78. What age was the child when they
developed noma? __________________  (years/months) 
79. What were the initial signs and symptoms
of the disease?
a) Mouth ulcer
b) Soft tissue damage
c) Problems feeding
d) Problems breathing
e) Other, please specify:
_________________________________
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80. Which symptoms did you seed care for? a) Mouth ulcer
b) Soft tissue damage
c) Problems feeding
d) Problems breathing
e) Other, please specify:
_________________________________
81. Why did you seek care for your child? a) Cosmetic reasons
b) Soft tissue damage
c) Problems feeding
d) Problems breathing
e) Other, please specify:
_________________________________
82. Do you feel your child/you has been
stigmatised in any way due to the disease?
a) Yes
b) No (skip to 85)
83. If yes, how? (choose all that apply) a) Not allowed to go to school
b) Gets teased by community members
c) I am not allowed to socialise with other
parents
d) My family has disowned me
e) My husband/wife left me
f) I cannot go to pray
g) My friends no longer talk to me
h) My village elders told me to leave my
village
i) My community members said I had a spell
on me
j) Other, please specify:
_________________________________
84. If yes, how often is the child/caretaker
affected by the stigmatisation?
a) Every day
b) Three times a week
c) Once a week
d) Once every 2 weeks
e) Once a month
f) Once every 6 months
g) Once a year
h) Less than once a year
85. Where did you seed care for your child?








a) 1st place visited
b) 2nd place visited
c) 3rd place visited
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d) 4th place visited















g) Other, please specify











c) 45 minutes - 1.5 hours
d) 1.5 hours - 2.5 hours
e) Half a day
f) Full day
g) 2 days
h) Other, please specify
88. How much did it cost to get to the point of care (in Naira)?
Amount 
a) 1st place visited
b) 2nd place visited
c) 3rd place visited
d) 4th place visited
89. How long after you noticed the initial






f) Other, please specify:
_________________________________
90. Did any of the healthcare providers that






What was the diagnosis:
_________________________________
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i) Other, please specify:
_________________________________




94. If yes, do you know what tests they were
and what the results were? ____________________________________ 
95. Have you had previous surgeries for
noma?
a) Yes. How many: ___________________
b) No
96. In your own words, can you describe to me
what noma is?
97. What impact has noma had on your child's
life?  (prompts:  school, eating, breathing)
98. What impact has noma had on your life?
99. Do you have any questions about noma?
END OF SURVEY 
Thank you very much for your time and for agreeing to participate in our study.  Do you 
have any questions for me?  
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6.3  Outcomes questionnaire 
Patient hospital ID 
Date of assessment 
Date of patient's final surgery 
Assessment 6 months 12 months 
Name of assessor 
Is the patient still alive Yes No 
**  If No, complete Verbal Autopsy Form Consent and if given, Verbal Autopsy Form ** 
Metrics (to measure WHZ, weight for height and weight for age) 
Weight (kg) 
Height (cm) 
Age (round to closest year) 





Maximum mouth opening 
Mouth open (mm) 
Mouth closed (mm) 
Maximum Mouth Opening (mm) 
Mouth opening comments (Note here if measurement was taken from alveolar ridges and not 
incisors) 
Has the surgery improved your quality of life? Yes No 
In what way: 
I can go to school now Yes No 
I have friends now Yes No 
I am included in the community Yes No 
I am now getting married Yes No 
I can eat more easily Yes No 
I can drink more easily Yes No 
People can now understand what I am saying more easily than before Yes No 
I feel more happy with the way I look than before the surgery Yes No 
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6.4 Traditional healer study question guides 
6.4.1  Interview guide caretakers 
Introduction (5 mins max): 
• Thank the participant for agreeing to take part in this research.
• Introduce yourself.
• Create a relaxed atmosphere; find a quiet, private place to sit, offer the participant
something to drink when this is possible.
• Make sure the interviewee have been informed about the study and has consented to
participate in the research.
• Tell the participant:
"I would like to talk to you about your perceptions of traditional healing, your
relationship with traditional healers and the experiences you may have had visiting
them. This discussion will contribute to a better understanding of how people interact
with traditional healers, especially in regards to seeking treatment for noma.
The interview will take approximately 30 - 60 minutes and you can decide to end the 
interview at any time without any consequences". 
**DO NOT RECORD** 







- Family setting (married etc.)
- Relationship between caretaker and patient (mother,
grandmother, uncle)
- Number of children
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Introduction - Study aim
- Why invited to participate
- Consent
- Answer any questions participant has about study
** TURN ON the recorder and test it is recording** 
Topic Specific questions Prompts/Probe 
Caretakers perceptions 
of traditional healing 
Can you tell me about the 
different health care options 
available to  you in your 
village? 
Probes:  Clinic, Hospital, 
Traditional Healer, Mobile health 
such as vaccination campaigns 
Which of these health options 
do you usually prefer and 
why? 
Probe:  Any negative views on 
any kind of health care, or 
vaccinations?  
Different health care options for 
different diseases? 
Can you tell me what you 
have heard about traditional 
healing in your community? 
How do  your 
neighbours/village members 
view community healing? 
Probe:  If person is not able to 
discuss their own experiences, 
ask them to discuss if their 
neighbours/local community 
members consult healers.  Probe 
for what kind of healers and 
services are offered.  Trust?  
Scared?  
Have you ever visited a 
traditional healer?  If yes, can 
you describe this experience 
to me?  
Can you describe how long 
you stayed with the healer and 
what the experience was like?  
Probes:  Ask about non-noma 
experiences.  Why did you go, 
what kind of care was provided, 
who accompanied you, treatment 
received, how many times you 
visited? 
Can you explain to me why 
you decided to visit the 
traditional healer? 
Probes:  Trust, knowledge of the 
healer, recommendation, cost, 
proximity, type of illness visited 
for. 
Can you describe what your 
relationship is like with the 
traditional healer? 
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Can you tell me about the 
kind of treatment you received 
from the healer?  How did you 
feel about it? 
Probes:  Understanding of 
disease and treatment, 
satisfaction, consulted someone 
else after? 
Can you tell me about how 
long after the first symptoms 
started, you decided to access 
care?  
Were there any reasons you 
waited to access care? 
Probes:  Too far, cost, prefer 
traditional healer, others in my 
family told me not to, child was 
too ill to travel 
Noma specific 
diagnoses and care 
provided by the 
traditional healers 
I'd now like to ask you some 
questions related to noma [use 
Hausa terms].  
How long ago did the disease 
begin? 
Can be a month, or season 
Can you tell me what has 
happened since you first 
noticed the symptoms of the 
disease? 
Were there any issues along 
the way?  
How did you come to the 
decision to seek health care? 
How long did it take to make 
this decision?   
Can you explain why it took 
that length of time?  
Can you describe who made 
the decision and how the 
decision was made? 
Describe:  Pathway to care. 
Link to measles. 
Did you receive any diagnosis 
or treatment before coming to 
the Noma Hospital? 
Probes:  Consulted other 
healthcare facilities/traditional 
healer 
What kind of diagnosis were 
you given? 
Probes:  Previous mention of 
noma, names of other diseases 
(measles)/conditions diagnosed, 
difference in diagnosis from 
different people 
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If you saw a traditional healer, 
what did they say about 
noma?  Please be as specific 
as you can, even if you can't 
remember all the details.  
What kind of treatment did 
the traditional healer offer 
you? 
Probes:  Did they offer more 
than one treatment option?  
Which ones? 
Link to measles? 
Which kind of treatment was 
given to your child?  Can you 
tell me why this kind of 
treatment was given? 
Probe:  Choice:  did the 
caretaker feel there was a choice 
in the treatment, who is part of 
the decision-making process 
If you did not visit a 
traditional healer for noma, 
can you tell me why?  Who 
did you go to for treatment 
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6.4.2 Interview guide - traditional healers 
Introduction (5 mins max): 
• Thank the participant for agreeing to take part in this research.
• Introduce yourself, and tell the participant you are not there as a health provider.
• Create a relaxed atmosphere; offer the participant something to drink when this is
possible.
• Make sure the interviewee has been informed about the study and has consented to
participate in the research.
• Tell the participant:
"I would like to talk to you about your perceptions of noma, your relationship with
community members and your experiences of the disease. This discussion will contribute
to a better understanding of how people interact with traditional healers in regards to
seeking treatment for noma.
The interview will take approximately 30 - 45 minutes and you can decide to end the 
interview at any time without any consequences". 
**DO NOT RECORD** 





- Length of time being a traditional healer
- Type of healer (broad overview of role)
Introduction - Study aim
- Why invited to participate
- Consent
- Answer any questions participant has about study
** TURN ON the recorder and test it is recording** 
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Can you tell me more about the role 
you play in the community?  What 
does your work involve? 
Why do people come to you?  
When do people come to you? 
Trust 
What kind of treatments do 
you prescribe? 
Do you ever offer multiple 
treatments for one ailment? 
Can you provide an example? 
Could you tell me how you learned 
your craft? 
How do you keep your 
knowledge up to date? 
How would you feel about 
attending a training on noma? 
What are some of the most common 
things people come to see you for? 
For common illnesses 
For prevention 
Other reasons? 
Can you describe the kind of 
relationship you have with your 
patients? 
Probes: Trust, any issues, 
status in community 
Traditional healer 
perceptions of 
noma and noma 
treatment?  
Show picture of different noma stages 
and ask: 
 What do you know about this 
disease? 
What treatment would you prescribe 
for the different stages of the disease? 
Is it a common disease?   
Do you have a name for it? 
Where does the disease come 
from? 
What causes the disease?   
Any way that can be 
prevented? 
How best to treat disease? 
When best to treat disease? 
Link with measles? 
Have you ever treated a case of this 
disease? 
If yes: 
Can you tell me more about what 
happened while treating this disease? 
Who brought the patient? 
How long after first symptoms 
did patient come? (Can show 
pictures of different stages of 
the disease) 
Had they visited other health 
providers before coming to 
you? 
What symptoms did the patient 
have? 
What treatment regimen did 
you suggest? 
Did you have any follow up 
visits? If so, what happened? 
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How do you feel about the disease? Where does it come from? 
Do others in the village know 
about it? 
Do people in the village fear 
it? 
Stigma? 
What other forms of health care are 





What do you think about other forms 
of health care? 
Trust  
Barriers to care 
How do you feel about referring 
patients to other forms of health care? 
Trust  
Barriers to care 
Would you refer a noma patient to the 
NCH?  Can you explain why/why not? 
If so, when would you refer a 
noma patient? 
Do/could you think of the 





6.5  Prevalence questionnaire 
 
Family ID: _________________________________________________________  
Date of Interview :  _________________________________________________________ 
Name of interviewer: _________________________________________________________ 
 
HOUSEHOLD QUESTIONS ANSWERED BY CARETAKER 
Do you have running water 
(a tap) in your compound? 
Yes 
No  
Where do you get your 
drinking water from? 
a) Bore hole in the village 
b) Well in the compound 
c) Tap (running water) 
d) River/stream 
e) Other, please specify:  
 _______________________________________________ 
 




If you do treat your drinking 
water, how do you treat it? 
a) Boil 
b) Add bleach/chlorine tabs 
c) Strain it through a cloth 
d) Use water filter (ceramic/sand) 
e) Let it stand and settle 
f) Other, please specify: 
 _______________________________________________ 
g) Don’t know 
How old are you (parent/ 
guardian)? (years) 
_________  (years) 
Respondents/ caretakers 














CHILD SPECIFIC QUESTIONS 
 Child 1 Child 2 Child 3 Child 4 Child 5 Child 6 
How old is your child? 
(round to closest year, 
can use events calendar) 
 
 
    
 
 
What number is this child 
in the bird order of your 
family? 
      
Does your child have any 
teeth? 
      
If yes, how many teeth?        
Does your child brush or 
clean their teeth? 
      
If yes, what do they use 









































e) Salt and water 
Other: 
_______________ 
If yes, how often do they 
brush their teeth? 
      
If child has rotten teeth, 
what do you use to clean? 
      
Has your child eaten pap 













How often does your 
child eat pap?  
a) >once a day 
b) 4–6 days/wk 
c) 2-3 days/wk 
d) < once a week 
a) >once a day 
b) 4–6 days/wk 
c) 2-3 days/wk 
d) < once a week 
a) >once a day 
b) 4–6 days/wk 
c) 2-3 days/wk 
d) < once a week 
a) >once a day 
b) 4–6 days/wk 
c) 2-3 days/wk 
d) < once a week 
a) >once a day 
b) 4–6 days/wk 
c) 2-3 days/wk 
d) < once a week 
a) >once a day 
b) 4–6 days/wk 
c) 2-3 days/wk 
d) < once a week 
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How often do you 
prepare  the pap  
 
a) >once a day 
b) 4–6 days/wk 
c) 2-3 days/wk 
d) < once a week 
a) >once a day 
b) 4–6 days/wk 
c) 2-3 days/wk 
d) < once a week 
a) >once a day 
b) 4–6 days/wk 
c) 2-3 days/wk 
d) < once a week 
a) >once a day 
b) 4–6 days/wk 
c) 2-3 days/wk 
d) < once a week 
a) >once a day 
b) 4–6 days/wk 
c) 2-3 days/wk 
d) < once a week 
a) >once a day 
b) 4–6 days/wk 
c) 2-3 days/wk 
d) < once a week 
Did you give colostrum 




















What is your most used 
sanitation facility  
a) Flushing toilet  
b) Latrine with 
slab  




a) Flushing toilet  
b) Latrine with 
slab  




a) Flushing toilet  
b) Latrine with 
slab  




a) Flushing toilet  
b) Latrine with 
slab  




a) Flushing toilet  
b) Latrine with 
slab  




a) Flushing toilet  
b) Latrine with 
slab  
























Do you have your child’s 













Interviewer: Ask to see 
vaccination card, if the 
caretaker has one, write 
all vaccinations that are 
recorded in book (date 
and name of vaccination) 
      
Has your child been sick 
in the last 12 months 

















If yes, how many times 
during the last 12 
months? (put number) 
      
For any of the times that 
your child was sick in the 
last 12 months, did you 




















Which of the following 









































PHYSICAL EXAMINATIONS (BY NURSE OR CLINICIAN) 
Weight in kg       
Height in cm       
MUAC mm       
























Anaemia eye test a) Anaemic 
b) Not anaemic 
a) Anaemic 
b) Not anaemic 
a) Anaemic 
b) Not anaemic 
a) Anaemic 
b) Not anaemic 
a) Anaemic 
b) Not anaemic 
a) Anaemic 

















































If yes to any stage of 
noma, how many days ago 
did the child first show 
any signs of this disease? 




Stage 0:  Simple Gingivitis 
Stage 1:  Haemorrhagic or Necrotizing Gingivitis/ Stomatitis 
Stage 2:  Oedema (early acute) 
Stage 3:  Necrosis and tissue loss (late acute) 
Stage 4:  Tissue and bone loss and wound healing process  
Stage 5:  Sequelae lesion 
 
 
END OF SURVEY 
Thank you very much for your time and for agreeing to participate in our study. Do you have any questions for me?
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Appendix 7 Informed consent and assent forms 
7.1  Language and beliefs informed consent forms 
7.1.1  Focus group discussion informed consent form 
Project Title:  Risk factors for diagnosed noma in North Western Nigeria, a sequential mixed 
methods study - 2017.  
 
Organization:  Médecins sans Frontières (MSF) and the Ministry of Health. 
 
This informed consent has two parts: 
 The information sheet – which gives you information about the study; 
 Certificate of consent study participation – which you will sign to demonstrate that you 
agree to participate with the interview for this study. 
 
Introduction:  We are conducting this study for Médecins Sans Frontières (MSF) and the 
Ministry of Health in Sokoto to find out more about the risk factors of a disease called noma, 
which affects mostly children in this part of Nigeria.  MSF has been running a program to assist 
noma patients in Sokoto Nigeria, and in order to better understand the disease and improve 
these services, we would like to ask patients and community members some questions.  
 
What is the study about? Very little is understood about the disease noma, what causes it and 
why some children develop the disease and others do not.  We are wanting to run focus group 
discussions with caretakers to discuss the names used to describe disease, and their beliefs 




Who will participate in the study? Caretakers of noma patients at the Noma Children’s 
Hospital. 
 
What does the participation in the study request from me? We will ask a group of noma patient 
caretakers to spend between 45 - 60 minutes answering the questions we have.  This will be a 
group discussion led by the researcher. 
 
We would like to ask you some questions about the names used to describe the disease, and 
their beliefs about the disease.  We would like to record your answers on a tape recorder, so 
that we can have an accurate record of what is said during the discussions. 
 
If you do not understand a question, please ask me to explain it to you.   If you do not want to 
answer a question or if you would like to stop at any time, please tell me.  
 
Do we have to participate? Whether you choose to be in the study or not is up to you.  There 
will be no effect on your family if you decide you do not want to be in the study. 
 
What will happen with the information that you collect? We will collect the information from 
everyone in the group, and we will then collate all information to see if there are patterns in the 
names noma is called, and the beliefs about the disease.  This information could assist us in 
gaining and understanding about the disease.  We may use some of the stories and experiences 
you share with us to write reports or press releases to draw attention to noma, if we do so, we 




Where will the study take place? We can conduct the interview anywhere where the group feels 
comfortable. 
 
Will I or my family receive anything to participate? You will not get anything, such as money 
or extra food, for taking part in this survey. 
 
Is it dangerous to participate? You may find some questions upsetting.  If a question makes 
you uncomfortable, we can skip this question and go on to the next question.  
 
What might we get from this study? You are free to stop at any time during the interview.  Once 
we have the results of this study, we will send an announcement to the health clinics and you 
will be able to find out what our conclusions are.  We hope that the results will help us better 
understand noma and contribute to finding better ways to prevent and treat this disease in your 
community. 
 
Confidentiality:  The recordings from this study are private.  Only the people who are doing 
the study can see the answers you give to the questions.  We do not ask for your name so there 
will be no record that you participated in the study.  I will not repeat what you have told me to 
anyone else.  We cannot assure confidentiality as others in the group will know what you have 
said, but we will ask all group members to respect confidentiality.  
 
Approvals: The ethical aspects of this research have been approved by Médecins sans 
Frontières Ethics  
Review Committee and by the Usman Danfodiyo University Teaching Hospital (UDUTH) 
Health Research and Ethics Committee. 
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Queries and Concerns:  You can call and speak to us at any time if you want to find out more 
about this project.  
 
Study coordinator name and phone number [to be inserted] 
Local Ethics Committee Details for questions regarding rights as research participants:  
Dr. Nma Jiya, Address: UDUTH; Phone: +234 805 038 1688. 
 




Consent Certificate Adult Study Participant – Copy Study Team 
Please administer the information sheet before seeking consent! 
I have understood the information sheet and my questions have been answered to my 
satisfaction.  I give voluntary consent to answer all the questions in the discussion about the 
child in my care.  I understand that I can stop the interview at any time. 
I hereby declare that I consent to the above. 
Date (insert day/month/year of study):     ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦ 
Name of study participant (≥18 years):   __________________________________________ 
Study participant signature/thumb print: __________________________________________ 
Interviewer's name:  __________________________________________________________ 
Interviewer's signature:  _______________________________________________________ 
If the person is illiterate (to be completed by the survey team): 
I have accurately read out the information sheet to the potential participant, and to the best of 
my ability made sure that the participant understands that we will conduct an interview with 
him/her about the child under his/her care. 
I confirm that the participant was given an opportunity to ask questions about the study, and 
all the questions asked by the participant have been answered correctly and to the best of my 
ability.  I confirm that the individual has not been coerced into giving consent, and the consent 
has been given freely and voluntarily.  
 A copy of this Consent Certificate has been provided to the participant. 
Date (insert day/month/year of study):     ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦  
Interviewer's name:  __________________________________________________________ 
Interviewer's signature:  _______________________________________________________ 
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Consent Certificate Adult Study Participant – Copy Study Participant 
Please administer the information sheet before seeking consent! 
I have understood the information sheet and my questions have been answered to my 
satisfaction.  I give voluntary consent to answer all the questions in the discussion about the 
child in my care.  I understand that I can stop the interview at any time. 
I hereby declare that I consent to the above. 
Date (insert day/month/year of study):     ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦ 
Name of study participant (≥18 years):   __________________________________________ 
Study participant signature/thumb print: __________________________________________ 
Interviewer's name:  __________________________________________________________ 
Interviewer's signature:  _______________________________________________________ 
If the person is illiterate (to be completed by the survey team): 
I have accurately read out the information sheet to the potential participant, and to the best of 
my ability made sure that the participant understands that we will conduct an interview with 
him about the child under his/her care. 
I confirm that the participant was given an opportunity to ask questions about the study, and 
all the questions asked by the participant have been answered correctly and to the best of my 
ability.  I confirm that the individual has not been coerced into giving consent, and the consent 
has been given freely and voluntarily.  
 A copy of this Consent Certificate has been provided to the participant. 
Date (insert day/month/year of study):     ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦  
Interviewer's name:  __________________________________________________________ 
Interviewer's signature:  _______________________________________________________ 
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7.1.2  In-depth interview informed consent forms 
Project Title:  Risk factors for diagnosed noma in North Western Nigeria, a sequential mixed 
methods study - 2017.  
Organization:   Médecins sans Frontières (MSF) and the Ministry of Health. 
This informed consent has two parts: 
 The information sheet – which gives you information about the study;
 Certificate of consent study participation – which you will sign to demonstrate that you
agree to participate with the interview for this study.
Introduction:  We are conducting this study for Médecins Sans Frontières (MSF) and the 
Ministry of Health in Sokoto to find out more about the risk factors of a disease called noma, 
which affects mostly children in this part of Nigeria.  
What is the study about?  Very little is understood about the disease noma, what causes it and 
why some children develop the disease and others do not.  We are wanting to hold key 
informant interviews with staff at the Noma Children’s Hospital to discuss the names used to 
describe disease, and their beliefs about the disease. 
Who will participate in the study?  Staff at the Noma Children’s Hospital. 
What does the participation in the study request from me?  The interview should take 
approximately 30 minutes during your working hours.  We would like to ask you some 
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questions about noma and your role in the project.  We would like to record your answers, so 
that we can have an accurate record of what is said during the interview. 
If you do not understand a question, please ask me to explain it to you.   If you do not want to 
answer a question or if you would like to stop at any time, please tell me.  
Do we have to participate?  Whether you choose to be in the study or not is up to you.  There will be 
no effect on you if you decide you do not want to be in the study.  Participation in the study and whatever 
you say during the interview, will not affect your employment in any way.  
What will happen with the information that you collect?  We will collect the information from 
the interviews, and we will then collate all information to see if there are patterns in the 
information.   This information could assist us in gaining an understanding about the disease. 
We may use some of the stories and experiences you share with us to write reports or press 
releases to draw attention to noma, if we do so, we will always ensure to anonymize your name 
and any places you mention. 
Where will the study take place?  We can conduct the interview anywhere which is convenient 
for you. 
Will I or my family receive anything to participate?  You will not get anything, such as money 
or extra food, for taking part in this survey. 
Is it dangerous to participate?  You may find some questions upsetting.   If a question makes 
you uncomfortable, we can skip this question and go on to the next question.  
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What might we get from this study?  You are free to stop at any time during the interview.   
Once we have the results of this study, we will send an announcement to the health clinics and 
you will be able to find out what our conclusions are.  We hope that the results will help us 
better understand noma and contribute to finding better ways to prevent and treat this disease 
in your community. 
 
Confidentiality:  The recordings from this study are private.  Only the people who are doing 
the study can see the answers you give to the questions.  We do not ask for your name so there 
will be no record that you participated in the study.  I will not repeat what you have told me to 
anyone else.  
 
Approvals:  The ethical aspects of this research have been approved by Médecins sans 
Frontières Ethics Review Committee and by the Usman Danfodiyo University Teaching 
Hospital (UDUTH) Health Research and Ethics Committee. 
 
Queries and Concerns:  You can call and speak to us at any time if you want to find out more 
about this research project.  
 
Study coordinator name and phone number [to be inserted] 
Project coordinator name and phone number [to be inserted] 
Local Ethics Committee Details for questions regarding rights as research participants:  
Dr. Nma Jiya, Address: UDUTH; Phone: +234 805 038 1688. 
 




Consent Certificate Adult Study Participant – Copy Study Team 
Please administer the information sheet before seeking consent! 
I have understood the information sheet and my questions have been answered to my 
satisfaction. I give voluntary consent to answer all the questions in the interview.  I understand 
that I can stop the interview at any time. 
 
I hereby declare that I consent to the above. 
Date (insert day/month/year of study):     ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦  
Name of study participant (≥18 years):   __________________________________________ 
Study participant signature/thumb print: __________________________________________ 
Interviewer's name:  __________________________________________________________ 
Interviewer's signature:  _______________________________________________________ 
 
If the person is illiterate (to be completed by the survey team): 
I have accurately read out the information sheet to the potential participant, and to the best of 
my ability made sure that the participant understands that we will conduct an interview with 
him/her. 
 
I confirm that the participant was given an opportunity to ask questions about the study, and 
all the questions asked by the participant have been answered correctly and to the best of my 
ability.  I confirm that the individual has not been coerced into giving consent, and the consent 
has been given freely and voluntarily.  
 
 A copy of this Consent Certificate has been provided to the participant. 
Date (insert day/month/year of study):     ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦  
Interviewer's name:  __________________________________________________________ 
Interviewer's signature:  _______________________________________________________ 
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Consent Certificate Adult Study Participant – Copy Study Participant 
Please administer the information sheet before seeking consent! 
I have understood the information sheet and my questions have been answered to my 
satisfaction. I give voluntary consent to answer all the questions in the interview.  I understand 
that I can stop the interview at any time. 
 
I hereby declare that I consent to the above. 
Date (insert day/month/year of study):     ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦  
Name of study participant (≥18 years):   __________________________________________ 
Study participant signature/thumb print: __________________________________________ 
Interviewer's name:  __________________________________________________________ 
Interviewer's signature:  _______________________________________________________ 
 
If the person is illiterate (to be completed by the survey team): 
I have accurately read out the information sheet to the potential participant, and to the best of 
my ability made sure that the participant understands that we will conduct an interview with 
him/her. 
 
I confirm that the participant was given an opportunity to ask questions about the study, and 
all the questions asked by the participant have been answered correctly and to the best of my 
ability.  I confirm that the individual has not been coerced into giving consent, and the consent 
has been given freely and voluntarily.  
  
A copy of this Consent Certificate has been provided to the participant. 
Date: ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦ [insert day/month/year of the study] 
Interviewer’s name: __________________________________________________________ 




7.2  Risk factors informed consent forms 
7.2.1  Cases informed consent form 
Project Title:   Risk factors for diagnosed noma in North Western Nigeria, a sequential mixed 
methodology study - 2017.  
 
Organization:  Médecins sans Frontières (MSF) and the Ministry of Health. 
 
This informed consent has two parts: 
 The information sheet – which gives you information about the study; 
 Certificate of consent study participation – which you will sign to demonstrate that you 
agree to participate with the interview for this study. 
 
Introduction:  We are conducting this study for Médecins Sans Frontières (MSF) and the 
Ministry of Health in Sokoto to find out more about the risk factors of a disease called noma, 
which affects mostly children in this part of Nigeria.  MSF has been running a program to assist 
noma patients in Sokoto Nigeria, and in order to better understand the disease and improve 
these services, we would like to ask patients and community members some questions.  
 
What is the study about?  Very little is understood about the disease noma, what causes it and 
why some children develop the disease and others do not.  We are trying to understand what 
factors put some children more at risk of developing noma compared to other children.  This 
information might help MSF and the Ministry of Health to implement programmes to prevent 




First, we will ask the parents or caretakers of parents of noma patients in the MSF project in 
the Noma Children’s Hospital some questions.  We will ask the same questions to caretakers 
or parents of children from the same village without noma who are the same ages and sex as 
the patients.  This will allow us to identify specific risk factors in patients of noma to help us 
design ways to avoid more children getting this disease in the future.  
 
Who will participate in the study?  We will be asking the parents/caretakers of all the patients 
that are 16 years and younger at the noma project at Noma Children’s Hospital in Sokoto to 
participate in the study, as well as the parents/caretakers of children that are similar to the 
patients in their home village. 
 
What does the participation in the study request from me?  As you are a parent/caretaker of a 
child who is a noma patient in the Sokoto hospital, we will ask you to spend between 45 minutes 
to one hour answering the questions we have.  
 
We would like to ask you some questions about things in your life such as the food you eat, 
where you live, your lifestyle, your health and the health care facilities in your village.  
 
We will ask you questions about the following things:  
 People that live in the same house as the participant. 
 Living conditions of your household. 
 Vaccination status of the child in question at the time of the interview. 
 Breastfeeding practices of the mother for the child in question. 
 Child’s health and access to care for disease in the child in question in the 12 months 
prior to the interview (apart from noma). 
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 Access to health care in a general way for your family. 
 Child’s oral health. 
 
We would also like to measure the circumference of your child’s upper arm using this 
measurement tool (show the MUAC). 
 
If you do not understand a question, please ask me to explain it to you.   If you do not want to 
answer a question or if you would like to stop the survey at any time, please tell me.  Also, if 
you do not want us to measure your child’s arm, please tell us and we will not. 
 
Do we have to participate?  Whether you choose to be in the study or not is up to you.  There 
will be no effect on your family or your treatment at the hospital if you decide you do not want 
to be in the study. 
 
What will happen with the information that you collect?  We will collect the information from 
everyone in the study through the interviews like the interview we are conducting with you.  
We will then compare the answers that parents/caretakers of noma patients gave to the 
questions to those given by the parents/caretakers of the other children.  This will give us some 
information on understanding what might be contributing to making specific children sick of 
noma. 
 
The records from this study are private.  Only the people who are doing the study can see the 
answers you give to the questions.  We do not ask for your name so there will be no record that 




Once we have the results of this study, we will send an announcement to the health clinics and 
you will be able to find out what our conclusions are. 
 
Where will the study take place?  We can conduct the interview anywhere where you feel 
comfortable: in your house, at the clinic, anywhere else in the village. 
 
Will I or my family receive anything to participate?  You will not get anything, such as money 
or extra food, for taking part in this survey. 
 
What are the risks of participating in the study?  You may find some questions upsetting.  If a 
question makes you uncomfortable, we can skip this question and go on to the next question.  
Stopping the questionnaire does not impact on the medical care that MSF was providing for 
you.  
 
What might we get from this study?  You are free to stop at any time during the interview.  Once 
we have the results of this study, we will send an announcement to the health clinics and you 
will be able to find out what our conclusions are.  We hope that the results will help us better 
understand noma and contribute to finding better ways to prevent and treat this disease in your 
community. 
 
Confidentiality: The records from this study are private.  Only the people who are doing the 
study can see the answers you give to the questions.  We do not ask for your name so there will 
be no record that you participated in the study.  I will not repeat what you have told me to 
anyone else. Answers from everyone who participates in the study will be grouped together 
and looked at and it is these findings that will be published, not your specific answers. 
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Approvals:  The ethical aspects of this research have been approved by Médecins sans 
Frontières Ethics Review Committee and by the Usman Danfodiyo University Teaching 
Hospital (UDUTH) Health Research and Ethics Committee. 
 
Queries and Concerns:  You can call and speak to us at any time if you want to find out more 
about this research project.  
 
Study coordinator name and phone number [to be inserted] 
Project coordinator name and phone number [to be inserted] 
Local Ethics Committee Details for questions regarding rights as research participants:  
Dr. Nma Jiya, Address: Usman Danfodiyo University Teaching Hospital. 
 Phone: +234 805 038 1688. 
 




Consent Certificate Adult Study Participant – Copy Study Team 
Please administer the information sheet before seeking consent! 
I have understood the information sheet and my questions have been answered to my 
satisfaction.  I give voluntary consent to answer all the questions in the questionnaire about the 
child in my care.  I understand that I can stop the interview at any time. 
I hereby declare that I consent to the above. 
Date (insert day/month/year of study):     ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦ 
Name of study participant (≥18 years):   __________________________________________ 
Study participant signature/thumb print: __________________________________________ 
Interviewer's name:  __________________________________________________________ 
Interviewer's signature:  _______________________________________________________ 
If the person is illiterate (to be completed by the survey team): 
I have accurately read out the information sheet to the potential participant, and to the best of 
my ability made sure that the participant understands that we will conduct an interview with 
him about the child under his/her care. 
I confirm that the participant was given an opportunity to ask questions about the study, and 
all the questions asked by the participant have been answered correctly and to the best of my 
ability.  I confirm that the individual has not been coerced into giving consent, and the consent 
has been given freely and voluntarily.  
A copy of this Consent Certificate has been provided to the participant. 
Date: ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦ [insert day/month/year of the study] 
Interviewer’s name: __________________________________________________________ 
Interviewer’s signature: _______________________________________________________ 
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Consent Certificate Adult Study Participant – Copy Study Participant 
Please administer the information sheet before seeking consent! 
I have understood the information sheet and my questions have been answered to my 
satisfaction.  I give voluntary consent to answer all the questions in the questionnaire about the 
child in my care.   I understand that I can stop the interview at any time. 
I hereby declare that I consent to the above. 
Date (insert day/month/year of study):     ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦ 
Name of study participant (≥18 years):   __________________________________________ 
Study participant signature/thumb print: __________________________________________ 
Interviewer's name:  __________________________________________________________ 
Interviewer's signature:  _______________________________________________________ 
If the person is illiterate (to be completed by the survey team): 
I have accurately read out the information sheet to the potential participant, and to the best of 
my ability made sure that the participant understands that we will conduct an interview with 
him about the child under his/her care. 
I confirm that the participant was given an opportunity to ask questions about the study, and 
all the questions asked by the participant have been answered correctly and to the best of my 
ability.  I confirm that the individual has not been coerced into giving consent, and the consent 
has been given freely and voluntarily.  
A copy of this Consent Certificate has been provided to the participant. 
Date: ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦ [insert day/month/year of the study] 
Interviewer’s name: __________________________________________________________ 
Interviewer’s signature: _______________________________________________________ 
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7.2.2  Controls informed consent form 
Project Title:   Risk factors for diagnosed noma in North Western Nigeria, a sequential mixed 
methodology study - 2017.  
Organization:  Médecins sans Frontières (MSF) and the Ministry of Health. 
This informed consent has two parts: 
 The information sheet – which gives you information about the study;
 Certificate of consent study participation – which you will sign to demonstrate that you
agree to participate with the interview for this study.
Introduction:  We are conducting this study for Médecins Sans Frontières (MSF) and the 
Ministry of Health in Sokoto to find out more about the risk factors of a disease called noma, 
which affects mostly children in this part of Nigeria.  MSF has been running a program to assist 
noma patients in Sokoto Nigeria, and in order to better understand the disease and improve 
these services, we would like to ask patients and community members some questions.  
What is the study about?  Very little is understood about the disease noma, what causes it and 
why some children develop the disease and others do not.  We are trying to understand what 
factors put some children more at risk of developing noma compared to other children.  This 
information might help MSF and the Ministry of Health to implement programmes to prevent 
children from developing noma in the future.  
First, we will ask the parents and caretakers or parents of noma patients in the MSF project in 
the Noma Children’s Hospital some questions.  We will ask the same questions to caretakers 
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or parents of children from the same village without noma who are the same ages and sex as 
the patients.  This will allow us to identify specific risk factors in patients of noma to help us 
design ways to avoid more children getting this disease in the future.  
Who will participate in the study?  We will be asking the parents/caretakers of all the patients 
that are 16 years and younger at the noma project at Noma Children’s Hospital in Sokoto to 
participate in the study, as well as the parents/caretakers of children that are similar to the 
patients in their home village. 
What does the participation in the study request from me?  As you are a parent/caretaker of a 
child close to the age of a noma patient, we will ask you to spend between 45 - 60 minutes 
answering the questions we have.  
We would like to ask you some questions about things in your life such as the food you eat, 
where you live, your lifestyle, your health and the health care facilities in your village.  
We will ask you questions about the following things: 
 People that live in the same house as the participant.
 Living conditions of your household.
 Vaccination status of the child in question at the time of the interview.
 Breastfeeding practices of the mother for the child in question.
 Child’s health and access to care for disease in the child in question in the 12 months
prior to the interview.
 Access to health care in a general way for your family.
 Child’s oral health.
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We would also like to measure the circumference of your child’s upper arm using this 
measurement tool (show the MUAC). 
If you do not understand a question, please ask me to explain it to you.  If you do not want to 
answer a question or if you would like to stop the survey at any time, please tell me.  Also, if 
you do not want us to measure your child’s arm, please tell us and we will not. 
Do we have to participate?  Whether you choose to be in the study or not is up to you.  There 
will be no effect on your family if you decide you do not want to be in the study. 
What will happen with the information that you collect?  We will collect the information from 
everyone in the study through the interviews like the interview we are conducting with you. 
We will then compare the answers that parents/caretakers of noma patients gave to the 
questions to those given by the parents/caretakers of the other children.  This will give us some 
information on understanding what might be contributing to making specific children sick of 
noma. 
The records from this study are private.  Only the people who are doing the study can see the 
answers you give to the questions.  We do not ask for your name so there will be no record that 
you participated in the study.  I will not repeat what you have told me to anyone else.  
Once we have the results of this study, we will send an announcement to the health clinics and 
you will be able to find out what our conclusions are. 
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Where will the study take place?  We can conduct the interview anywhere where you feel 
comfortable: in your house, at the clinic, anywhere else in the village. 
Will I or my family receive anything to participate?  You will not get anything, such as money 
or extra food, for taking part in this survey. 
What are the risks of participating in the study?  You may find some questions upsetting.  If a 
question makes you uncomfortable, we can skip this question and go on to the next question.  
What might we get from this study?  You are free to stop at any time during the interview.  Once 
we have the results of this study, we will send an announcement to the health clinics and you 
will be able to find out what our conclusions are.  We hope that the results will help us better 
understand noma and contribute to finding better ways to prevent and treat this disease in your 
community. 
Confidentiality:  The records from this study are private.  Only the people who are doing the 
study can see the answers you give to the questions.  We do not ask for your name so there will 
be no record that you participated in the study.  I will not repeat what you have told me to 
anyone else. Answers from everyone who participates in the study will be grouped together 
and looked at and it is these findings that will be published, not your specific answers.  
Approvals:  The ethical aspects of this research have been approved by Médecins sans 
Frontières Ethics Review Committee and by the Usman Danfodiyo University Teaching 
Hospital (UDUTH) Health Research and Ethics Committee. 
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Queries and Concerns:  You can call and speak to us at any time if you want to find out more 
about this research project.  
Study coordinator name and phone number [to be inserted] 
Project coordinator name and phone number [to be inserted] 
Local Ethics Committee Details for questions regarding rights as research participants: 
Dr. Nma Jiya, Address: Usman Danfodiyo University Teaching Hospital. 
 Phone: +234 805 038 1688. 
Thank you very much for your time and participation. 
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Consent Certificate Adult Study Participant – Copy Study Team 
Please administer the information sheet before seeking consent! 
I have understood the information sheet and my questions have been answered to my 
satisfaction.  I give voluntary consent to answer all the questions in the questionnaire about the 
child in my care.  I understand that I can stop the interview at any time. 
 
I hereby declare that I consent to the above. 
Date (insert day/month/year of study):     ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦  
Name of study participant (≥18 years):   __________________________________________ 
Study participant signature/thumb print: __________________________________________ 
Interviewer's name:  __________________________________________________________ 
Interviewer's signature:  _______________________________________________________ 
 
If the person is illiterate (to be completed by the survey team): 
I have accurately read out the information sheet to the potential participant, and to the best of 
my ability made sure that the participant understands that we will conduct an interview with 
him/her about the child under his/her care. 
 
I confirm that the participant was given an opportunity to ask questions about the study, and 
all the questions asked by the participant have been answered correctly and to the best of my 
ability.  I confirm that the individual has not been coerced into giving consent, and the consent 
has been given freely and voluntarily.  
 
 A copy of this Consent Certificate has been provided to the participant. 
Date: ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦ [insert day/month/year of the study] 
Interviewer’s name: __________________________________________________________ 
Interviewer’s signature: _______________________________________________________ 
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Consent Certificate Adult Study Participant – Copy Study Participant 
Please administer the information sheet before seeking consent! 
I have understood the information sheet and my questions have been answered to my 
satisfaction.  I give voluntary consent to answer all the questions in the questionnaire about the 
child in my care.  I understand that I can stop the interview at any time. 
 
I hereby declare that I consent to the above. 
Date (insert day/month/year of study):     ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦  
Name of study participant (≥18 years):   __________________________________________ 
Study participant signature/thumb print: __________________________________________ 
Interviewer's name:  __________________________________________________________ 
Interviewer's signature:  _______________________________________________________ 
 
 
If the person is illiterate (to be completed by the survey team): 
I have accurately read out the information sheet to the potential participant, and to the best of 
my ability made sure that the participant understands that we will conduct an interview with 
him/her about the child under his/her care. 
 
I confirm that the participant was given an opportunity to ask questions about the study, and 
all the questions asked by the participant have been answered correctly and to the best of my 
ability.  I confirm that the individual has not been coerced into giving consent, and the consent 
has been given freely and voluntarily.  
 
 A copy of this Consent Certificate has been provided to the participant. 
Date: ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦ [insert day/month/year of the study] 
Interviewer’s name: __________________________________________________________ 
Interviewer’s signature: _______________________________________________________ 
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7.3  Outcomes informed consent and assent forms 
7.3.1  Information sheet and informed consent for retrospective outcome measurement 
Project Title:   Long-term followup of noma patients after surgical, nutritional and mental 
health interventions at the Noma Children’s Hospital in northwest Nigeria, 2018 - 2020. 
 
Organization:   Médecins sans Frontières (MSF) and the Ministry of Health. 
 
This informed consent has two parts: 
 The information sheet – which gives you information about the study; 
 Certificate of consent study participation – which you will sign to demonstrate that you 
agree to participate in the assessment for this study. 
 
Introduction:  We are conducting this study for Médecins Sans Frontières (MSF) and the 
Ministry of Health in Sokoto to find out more about the complications after medical treatment 
for noma at the Noma Children’s Hospital.  MSF has been running a program to assist noma 
patients in Sokoto Nigeria, and in order to better understand the disease and improve these 
services, we would like to ask patients and community members some questions.  
 
What is the study about?  Very little is understood about the disease noma.  We are trying to 
understand what complications arise after treatment for noma, and what the factors are that 
favour survival.  This information might help MSF and the Ministry of Health to implement 
programmes to more efficiently and effectively treat noma patients in the future.  During this 





Who will participate in the study?  We will be asking noma patients who were cared for at the 
Noma Children’s Hospital since 2015 and are not scheduled for follow up surgery to participate 
in the study. 
 
What does the participation in the study request from me?  As you are a parent/caretaker of a 
noma patient or a noma patient in the Sokoto hospital, we will ask to examine you/your child.  
This should take between 10 – 15 minutes.   
 
We will conduct a physical exam to see how you/your child is/are healing. 
 
We would like to take some photographs of you/your child to show to some doctors who will 
then be able to assess how you are healing.  If you do not want us to take any photographs, 
please tell us and we will not take any.  We may use these photographs in presentation, reports 
or in published articles.  If you are not wanting your photograph to be taken, this will not in 
any way impact the care you receive. 
 
If you do not want to answer a question or if you would like to stop the exam at any time, please 
tell me as we can stop at any time.  
 
We would also like permission to access your medical files which are stored at the Noma 
Children’s Hospital.  This is voluntary and if you would not like us to access your files, this 
will not in any way impact the care you receive. 
 
I consent to participate in this study (circle) Yes No 
I consent to grant the research team access to my 





Do we have to participate?  Whether you choose to be in the study or not is up to you.  There 
will be no effect on your family or your future treatment at the hospital if you decide you do 
not want to be in the study. 
 
What will happen with the information that you collect?  The records from this study are 
private.  Only the people who are doing the study can see the answers you give to the questions.  
I will not repeat what you have told me to anyone else.  Once we have the results of this study, 
we will send an announcement to the health clinics and you will be able to find out what our 
conclusions are.  The pictures we are taking will be stored in a secure folder and only the 
surgeons assessing the pictures and selected research staff will have access to these. It may be 
necessary to use your picture in a publication, if you consent to this use.  You are free to say 
no.  
 
Where will the study take place?  We can conduct the assessment anywhere where you feel 
comfortable: in your house, at the clinic, anywhere else in the village. 
 
What are the risks of participating in the study?  You may find the physical exam 
uncomfortable.  Stopping the assessment does not impact on the future medical care that MSF 
may provide for you.  
 
Will I or my family receive anything to participate?  There are no direct benefits to the 





Will I be told about the results of the study?  Once we have the results of this study, we will 
send an announcement to the health clinics and you will be able to find out what our 
conclusions are.  We hope that the results will help us better understand noma and contribute 
to finding better ways to prevent and treat this disease in your community. 
 
Confidentiality:  The records from this study are private.  Only the people who are doing the 
study can see the assessment results.  I will not repeat what you have told me to anyone else.  
Answers from everyone who participates in the study will be grouped together and looked at 
and it is these findings that will be published, not your specific answers. 
 
Approvals:  The ethical aspects of this research have been approved by Médecins Sans 
Frontières Ethics Review Committee and by the Usman Danfodiyo University Teaching 
Hospital (UDUTH) Health Research and Ethics Committee. 
 




Consent Certificate Adult Study Participant - Copy for Study Team 
Please administer the information sheet before seeking consent! 
I have understood the information sheet and my questions have been answered to my 
satisfaction. I give voluntary consent to be a part of the assessment.  I understand that I can 
stop the assessment at any time. 
I hereby declare that I consent to the above. 
Date (insert day/month/year of study):     ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦  
Name of study participant (≥18 years):   __________________________________________ 
Study participant signature/thumb print: __________________________________________ 
If necessary, name and signature of witness: _______________________________________ 
Assessor's name:  __________________________________________________________ 
Assessor's signature:  _______________________________________________________ 
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Consent Certificate Adult Study Participant - Copy Study Participant 
Please administer the information sheet before seeking consent! 
I have understood the information sheet and my questions have been answered to my 
satisfaction. I give voluntary consent to be a part of the assessment. I understand that I can stop 
the assessment at any time. 
I hereby declare that I consent to the above. 
Date (insert day/month/year of study):     ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦  
Name of study participant (≥18 years):   __________________________________________ 
Study participant signature/thumb print: __________________________________________ 
If necessary, name and signature of witness: _______________________________________ 
Assessor's name:  __________________________________________________________ 
Assessor's signature:  _______________________________________________________ 
Queries and Concerns:  You can call and speak to us at any time if you want to find out more 
about this research project.  
Principal Investigator: Elise Farley, email: noma-research@oca.msf.org; 
Phone: 08025737703 
Local Ethics Committee Details for questions regarding rights as research participants: 
Dr. Nma Jiya, Address: Usman Danfodiyo University Teaching Hospital. 
Phone: +234 805 038 1688. 
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7.3.2 Assent Form for any Under 18’s 
Project Title:  Outcomes of noma patients following surgical, nutritional and mental health 
interventions at the Noma Children’s Hospital in northwest Nigeria, 2018 - 2020. 
Organization:   Médecins sans Frontières (MSF) and the Ministry of Health. 
This informed assent has two parts: 
 The information sheet – which gives you information about the study;
 Certificate of assent study participation – which you will sign to demonstrate that you
agree for you to participate in this study.
Introduction:  My name is ________________________________ and I work for the 
organization Médecins sans Frontières (MSF) here in Nigeria.   We are working hard to reduce 
the number of cases of noma in your community and are now doing a study to help us better 
understand how we can best treat those people who do have noma.  
We have already spoken to the head of your household and have also asked your parents for 
their approval to speak to you and ask you to help us in this study.  We will now give you some 
information about the study and what it would mean for you to participate.  You do not have 
to agree to participate if you do not want to, even if your parents agreed. 
You may discuss anything in this form with your parents or friends or anyone else you feel 
comfortable talking to.  You can decide whether to participate or not after you have talked it 
over.   You do not have to decide immediately. 
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There may be some words you don't understand or things that you want me to explain more 
about because you are interested or concerned.   Please ask me to stop at any time and I will 
take time to explain). 
 
What is the study about?  Very little is understood about the disease noma.  We are trying to 
understand what problems arise after treatment for noma, and what the things help keep people 
alive.  This information might help MSF and the Ministry of Health to implement programmes 
to more efficiently and effectively treat noma patients in the future.  During this study, exams 
will be conducted on patients who have been treated at the Noma Children’s Hospital.  
 
Who will participate in the study?  We will be asking noma patients who were cared for at the 
Noma Children’s Hospital to participate in the study. 
 
Do I have to do this?  Whether you choose to be in the study or not is up to you. There will be 
no effect on your treatment at the hospital if you decide you do not want to be in the study. 
 
Check that the child understands what you are telling them by asking: “Do you have any 
questions at this point? Do you understand that you do not have to participate in the study if 
you do not want to? 
 
I have checked with the child and they understand that participation is voluntary: 





What is going to happen to me?  As you are a patient who was cared for at the Noma Children’s 
Hospital we would like to conduct some examinations and also ask you/your caretaker some 
questions.  We would also like to take some photographs of you. 
 
We will conduct the following examinations: 
 Physical exam to see how you are healing. 
 We would also like to measure how much you weight and how tall you are (show the 
scale and measuring tape).  
 We would like to take some photographs of you to show to some doctors who will then 
be able to assess how you are healing.  If you do not want us to take any photographs, 
please tell us and we will not take any.  We may use these photographs in presentation, 
reports or in published articles.  If you are not wanting your photograph to be taken, 
this will not in any way impact the care you receive. 
 
We will ask you questions about the following things:  
 Eating and drinking. 
 Social interaction and inclusion. 
 
If you do not understand a question, please ask me to explain it to you.  If you do not want to 
answer a question or if you do want us to conduct a physical exam or if you would like to stop 
the exam at any time, please tell me.  
 
Check that the child understands what you are telling them by asking: “Can you repeat to 




I have checked with the child and they understand that procedures of the study: 
_________________________ (initial of study interviewer) 
 
Is it bad or dangerous for me or will it hurt?  You may find some questions upsetting and the 
physical exam uncomfortable.  If a question makes you uncomfortable, we can skip this 
question and go on to the next question, of if you want to stop the physical exam, we can at 
any time.  Stopping the questionnaire does not impact on the medical care that MSF will 
provide for you.  
 
Check that the child understands what you are telling them by asking: “Do you understand 
what could be uncomfortable today when we examine you? Can you repeat it back to me?  
 
I have checked with the child and they understand that risks and discomforts of the study: 
_________________________ (initial of study interviewer) 
 
Is there anything good that I might happen to me from this study?  You will not get anything 
extra like food or money for participating in this study.  You are free to stop at any time during 
the interview.  
 
I have checked with the child and they understand the benefits of the study: 
__________________________ (initial of study interviewer) 
 
Is everyone going to know about this and will you tell me the results? The records from this 
study are private.  Only the people who are doing the study can see the answers you give to the 
questions.  I will not repeat what you have told me to anyone else.  Answers from everyone 
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who participates in the study will be grouped together and looked at and it is these findings that 
will be published, not your specific answers. 
 
Once we have the results of this study, we will send an announcement to the health clinics and 
you will be able to find out what our conclusions are.  We hope that the results will help us 
better understand noma and contribute to finding better ways to prevent and treat this disease 
in your community. 
 
I have checked with the child and they understand that that there is no remuneration for 
participating in the study and that their information will be kept confidential: 
_________________________ (initial of study interviewer) 
 
What happens if I get hurt?  We do not think that you will get hurt today, but in case you don’t 
feel well today or later, you can always ask to be referred and we will try and take care of you 
as best as possible. 
 
Can I withdraw or refuse to participate?  Whether you choose to be in the study or not is up to 
you.  There will be no effect on your family if you decide you do not want to be in the study. 
 
Who can I talk to if I have a question?  I will give you copy of the information we have talked 
about today and this has my information on it, so you can always come and find me or contact 
me in case you have other questions. 
 
I have checked with the child and they understand what to do if they are hurt, that they can 
withdraw/refuse to participate at any time and how to contact us if they have more questions: 
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__________________________ (initial of study interviewer) 
 
Queries and Concerns:  You can call and speak to us at any time if you want to find out more 
about this research project.  
 
Local Ethics Committee Details for questions regarding rights as research participants:  
Dr. Nma Jiya, Address: Usman Danfodiyo University Teaching Hospital (UDUTH). 
Phone: +234 805 038 1688. 
 
The ethical aspects of this research have been approved by Médecins Sans Frontières Ethics 
Review Committee and by the Usman Danfodiyo University Teaching Hospital (UDUTH) 
Health Research and Ethics Committee. 
 





Assent Certificate Child Study Participant – Copy Study Team 
I have read this information (or had the information read to me) and I have had my questions 





Only if child assents: 
Date: ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦ [insert day/month/year of the study] 
Print name of child: __________________________________________________________ 
Signature of child: ___________________________________________________________ 
 
If the child is illiterate: 
A literate witness must sign (if possible, this person should be selected by the participant, 
not be a parent, and should have no connection to the research team). Participants who are 
illiterate should include their thumb print as well.   
I have witnessed the accurate reading of the assent form to the child, and the individual has had 
the opportunity to ask questions. I confirm that the individual has given consent freely.  
 
Date: ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦ [insert day/month/year of the study] 
Print name of witness (not a parent): _____________________________________________ 
Signature of witness: _________________________________________________________ 
 




 I agree to take part in the research 
 I do not wish to take part in the research and have not signed the assent below – 
Initials of the child _____________________ 
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I have accurately read or witnessed the accurate reading of the assent form to the potential 
participant, and the individual has had the opportunity to ask questions. I confirm that the 
individual has given assent freely.  





Assent Certificate Child Study Participant – Copy Study Participant 
I have read this information (or had the information read to me) and I have had my questions 
answered and know that I can ask questions later if I have them.  
Only if child assents: 
Date: ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦ [insert day/month/year of the study] 
Print name of child: __________________________________________________________ 
Signature of child: ___________________________________________________________ 
If the child is illiterate: 
A literate witness must sign (if possible, this person should be selected by the participant, 
not be a parent, and should have no connection to the research team). Participants who are 
illiterate should include their thumb print as well.   
I have witnessed the accurate reading of the assent form to the child, and the individual has had 
the opportunity to ask questions. I confirm that the individual has given consent freely.  
Date: ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦ [insert day/month/year of the study] 
Print name of witness (not a parent): _____________________________________________ 
Signature of witness: _________________________________________________________ 
AND    Thumb print of participant 
 I agree to take part in the research
 I do not wish to take part in the research and have not signed the assent below –
Initials of the child __________ 
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I have accurately read or witnessed the accurate reading of the assent form to the potential 
participant, and the individual has had the opportunity to ask questions. I confirm that the 
individual has given assent freely.  
Print name of researcher:  ____________________________________________________ 
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7.4 Traditional healer study informed consent forms 
7.4.1   Information sheet and informed consent – caretakers 
Project Title:  Noma and traditional healing in northwest Nigeria, 2018. 
Organization: Médecins Sans Frontières (MSF) and the Ministry of Health 
This informed consent has two parts: 
 The information sheet – which gives you information about the study;
 Certificate of consent study participation – which you will sign/give your thumbprint
to demonstrate that you agree to participate in an interview for this study.
Introduction:  We are working with Médecins Sans Frontières (MSF) and the Ministry of 
Health in Sokoto to find out more about a disease called noma, which you may know as ciwon 
daji or ciwon iska, this disease mostly affects children in this part of Nigeria.  
What is the study about?  We want to talk with mothers and other caretakers of noma patients 
admitted at the Noma Children’s Hospital to help us understand more about traditional healing 
and noma.  With your agreement, we would like to ask you some questions on how you feel 
about traditional healing, your relationships with traditional healers, and if you have visited 
traditional healers for help with your child’s current noma condition.  
Who will participate in the study?  Caretakers of noma patients admitted at the Noma Children’s 
Hospital and traditional healers will be invited to take part.  You were chosen as you are the caretaker 
of a noma patient who is admitted at the Noma Children’s Hospital at the time we are conducting the 
study.  We are hoping to include 40 people in the study. 
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What does the participation in the study mean for me? The interview should take approximately 
30 - 60 minutes.  We would like to ask you some questions about traditional healing and the 
health care you tried for noma.  With your permission we would like to audio-record your 
answers, so that we can have an accurate record of what is said during the interview.  
If you do not understand a question, please ask me to explain it to you.  If you do not want to 
answer a question or if you would like to stop at any time, please tell me.  
Do we have to participate?  Whether you choose to be in the study or not is up to you. There will be 
no effect on you if you decide you do not want to be in the study.  Participation in the study and whatever 
you say during the interview, will not affect the health care you or your family receive in any way.   You 
are free to stop the interview at any time. 
What will happen with the information that you collect?  We will collect the information from 
the interviews to learn as much as we can about traditional healing and noma in this area.  This 
information could assist us in gaining an understanding about the disease.  We may use some 
of the stories and experiences you share with us to write reports or news stories to draw 
attention to noma, or give presentations.   If we do this, we will make sure not to include your 
name and any places you mention so that no-one will know it is you. 
Where will the study take place?  We can conduct the interview anywhere which is convenient 
for you. 
Will I or my family receive anything to participate?  You will not get anything, such as money 
or extra food, for taking part in this study. 
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Is it dangerous to participate?  There will be no danger to you in this study. You may find 
some questions upsetting.  If a question makes you uncomfortable, we can skip this question 
and go on to the next question.  If you would like to see one of the mental health officers we 
can arrange an appointment.  
What might we get from this study?  Once we have the results of this study, we will send an 
announcement to the health clinics and with the outreach team and you will be able to find out 
more about what we have learned. We hope that the results will help us better understand noma 
so we can find better ways to prevent and treat this disease in your community. 
Confidentiality: The recordings from this study are private.  Only the people who are doing the 
study can see the answers you give to the questions.  We do not ask for your name while 
conducting the interview, only on the consent form.  I might repeat what you tell me to other 
people in the research team, but I will never link it to you directly or use your name.  
Approvals:  This study has been approved by Médecins Sans Frontières Ethics Review Board 
and by the Usman Danfodiyo University Teaching Hospital (UDUTH) Health Research and 
Ethics Committee. [reference numbers to be added once approved].  If you have questions 
about the study you can contact [details of ERB] and [details of PI]. 
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Consent Certificate Adult Study Participant – Copy Study Team 
Please administer the information sheet before seeking consent! 
I have understood the information sheet and my questions have been answered to my 
satisfaction.  I give voluntary consent to answer all the questions in the interview and for my 
answers to be recorded.  I understand that I can stop the interview at any time. 
 
I hereby declare that I consent to the above. 
Date (insert day/month/year of study):     ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦  
Name of study participant (≥18 years):   __________________________________________ 
Study participant signature/thumb print: __________________________________________ 
Study participant agrees to the audio recording 
of interview signature/thumb print: ____________________________________________ 
Interviewer's name:  __________________________________________________________ 
Interviewer's signature:  _______________________________________________________ 
 
 
If the person is illiterate (to be completed by the research team): 
I have accurately read out the information sheet to the potential participant, and to the best of 
my ability made sure that the participant understands that we will conduct an interview with 
him/her. 
 
I confirm that the participant was given an opportunity to ask questions about the study, and 
all the questions asked by the participant have been answered correctly and to the best of my 
ability.  I confirm that the individual has not been coerced into giving consent, and the consent 




A copy of this Consent Certificate has been provided to the participant. 
Date: ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦ [insert day/month/year of the study] 
Interviewer’s name: __________________________________________________________ 
Interviewer’s signature: _______________________________________________________ 
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Consent Certificate Adult Study Participant – Copy Study Participant 
Please administer the information sheet before seeking consent! 
I have understood the information sheet and my questions have been answered to my 
satisfaction.  I give voluntary consent to answer all the questions in the interview and for my 
answer to be recorded.  I understand that I can stop the interview at any time. 
I hereby declare that I consent to the above. 
Date (insert day/month/year of study):     ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦  
Name of study participant (≥18 years):   __________________________________________ 
Study participant signature/thumb print: __________________________________________ 
Study participant agrees to the audio recording 
of interview signature/thumb print: ____________________________________________ 
Interviewer's name:  __________________________________________________________ 
Interviewer's signature:  _______________________________________________________ 
If the person is illiterate (to be completed by the research team): 
I have accurately read out the information sheet to the potential participant, and to the best of 
my ability made sure that the participant understands that we will conduct an interview with 
him/her. 
I confirm that the participant was given an opportunity to ask questions about the study, and 
all the questions asked by the participant have been answered correctly and to the best of my 
ability. I confirm that the individual has not been coerced into giving consent, and the consent 
has been given freely and voluntarily.  
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A copy of this Consent Certificate has been provided to the participant. 
Date: ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦ [insert day/month/year of the study] 
Interviewer’s name: __________________________________________________________ 
Interviewer’s signature: _______________________________________________________ 
Queries and Concerns:  You can call and speak to us at any time if you want to find out more 
about this research project.  For questions around the ongoing research you should contact the 
study investigator.  For any concerns around ethical implications of the research, you should 
contact the ERB. 
Study coordinator name and phone number [to be inserted] 
Local Ethics Committee Details for questions regarding rights as research participants: 
Dr. Nma Jiya, Address: Usman Danfodiyo University Teaching Hospital. 
 Phone: +234 805 038 1688. 
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7.4.2 Information sheet and informed consent – traditional healers 
Project Title:  Noma and traditional healing in northwest Nigeria, 2018. 
 
Organization:  Médecins sans Frontières (MSF) and the Ministry of Health 
 
This informed consent has two parts: 
 The information sheet – which gives you information about the study; 
 Certificate of consent study participation – which you will sign to demonstrate that you 
agree to participate with the interview for this study. 
 
Introduction:  We are conducting this study for Médecins Sans Frontières (MSF) and the 
Ministry of Health in Sokoto to find out more about a disease called noma, which you may 
know as ciwon daji or ciwon iska, this disease mostly affects children in this part of Nigeria.  
 
What is the study about?  We want to ask some questions to traditional healers in Sokoto State 
to understand what they think of noma, their relationship with community members and to 
understand more about the treatments offered for noma patients. 
 
Who will participate in the study? 
Caretakers of noma patients admitted at the Noma Children’s Hospital and traditional healers 
will be invited to take part.  You were invited to participate in the study as you are known in 
the community as someone who provides health care to the population.  We are hoping to 




What does the participation in the study mean for me?  The interview should take 
approximately 30 - 60 minutes.  We would like to ask you some questions about your work 
and noma disease.  We would like to audio-record your answers, so that we can have an 
accurate record of what is said during the interview. 
 
If you do not understand a question, please ask me to explain it to you.  If you do not want to 
answer a question or if you would like to stop at any time, please tell me.  
 
Do we have to participate?  Whether you choose to be in the study or not is up to you.  There will be 
no effect on you if you decide you do not want to be in the study.  You are free to stop the interview at 
any time. 
What will happen with the information that you collect?  We will collect the information from 
the interviews to learn as much as we can about traditional healing and noma in this area.  This 
information could assist us in gaining an understanding about the disease.  We may use some 
of the stories and experiences you share with us to write reports or news stories to draw 
attention to noma, or give presentations.   If we do this, we will make sure not to include your 
name and any places you mention so that no-one will know it is you. 
 
Where will the study take place?  We can conduct the interview anywhere which is convenient 
for you. 
 
Will I or my family receive anything to participate?  You will not get anything, such as money 




Is it dangerous to participate?  There will be no danger to you in this study. You may find 
some questions upsetting.  If a question makes you uncomfortable, we can skip this question 
and go on to the next question or we can stop the interview at any time.  
 
We are not trying to test your knowledge on any subject, and we do not want to learn your 
healing techniques so that we can use them ourselves.  We are trying to understand what you 
think about the disease, and how we can work together to help the people who suffer from this 
disease. 
 
What might we get from this study?  Once we have the results of this study, we will send an 
announcement to the health clinics and with the outreach team and you will be able to find out 
more about what we have learned.  We hope that the results will help us better understand noma 
so we can find better ways to prevent and treat this disease in your community and we may 
find better ways to work together. 
 
Confidentiality:  The recordings from this study are private.  Only the people who are doing 
the study can see the answers you give to the questions.  We do not ask for your name while 
conducting the interview, only on the consent form.  I might repeat what you tell me, but I will 
never link it to you directly. 
 
Approvals:  This study has been approved by Médecins Sans Frontières Ethics Review Board 
and by the Usman Danfodiyo University Teaching Hospital (UDUTH) Health Research and 
Ethics Committee. [reference numbers to be added once approved].  If you have questions 




Consent Certificate Adult Study Participant – Copy Study Team 
Please administer the information sheet before seeking consent! 
I have understood the information sheet and my questions have been answered to my 
satisfaction. I give voluntary consent to answer the questions in the interview and for my 
answers to be recorded. I understand that I can stop the interview at any time. 
 
I hereby declare that I consent to the above. 
Date (insert day/month/year of study):     ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦  
Name of study participant (≥18 years):   __________________________________________ 
Study participant signature/thumb print: __________________________________________ 
Study participant agrees to the audio recording 
of interview signature/thumb print: ____________________________________________ 
Interviewer's name:  __________________________________________________________ 
Interviewer's signature:  _______________________________________________________ 
 
 
If the person is illiterate (to be completed by the research team): 
I have accurately read out the information sheet to the potential participant, and to the best of 
my ability made sure that the participant understands that we will conduct an interview with 
him/her. 
 
I confirm that the participant was given an opportunity to ask questions about the study, and 
all the questions asked by the participant have been answered correctly and to the best of my 
ability.  I confirm that the individual has not been coerced into giving consent, and the consent 






 A copy of this Consent Certificate has been provided to the participant. 
Date: ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦ [insert day/month/year of the study] 
Interviewer’s name: __________________________________________________________ 





Consent Certificate Adult Study Participant – Copy Study Participant 
Please administer the information sheet before seeking consent! 
I have understood the information sheet and my questions have been answered to my 
satisfaction.  I give voluntary consent to answer all the questions in the interview and for my 
answer to be recorded.  I understand that I can stop the interview at any time. 
 
I hereby declare that I consent to the above. 
Date (insert day/month/year of study):     ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦  
Name of study participant (≥18 years):   __________________________________________ 
Study participant signature/thumb print: __________________________________________ 
Study participant agrees to the audio recording 
of interview signature/thumb print: ____________________________________________ 
Interviewer's name:  __________________________________________________________ 
Interviewer's signature:  _______________________________________________________ 
 
If the person is illiterate (to be completed by the research team): 
I have accurately read out the information sheet to the potential participant, and to the best of 
my ability made sure that the participant understands that we will conduct an interview with 
him/her. 
 
I confirm that the participant was given an opportunity to ask questions about the study, and 
all the questions asked by the participant have been answered correctly and to the best of my 
ability.  I confirm that the individual has not been coerced into giving consent, and the consent 





A copy of this Consent Certificate has been provided to the participant. 
Date: ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦ [insert day/month/year of the study] 
Interviewer’s name: __________________________________________________________ 
Interviewer’s signature: _______________________________________________________ 
Queries and Concerns:   You can call and speak to us at any time if you want to find out more 
about this research project.  For questions around the ongoing research you should contact the 
study investigator. For any concerns around the ethical implications of the research, you should 
contact the ethics review board. 
Study coordinator name and phone number [to be inserted] 
Local Ethics Committee Details for questions regarding rights as research participants: 
Dr. Nma Jiya, Address: Usman Danfodiyo University Teaching Hospital. 
 Phone: +234 805 038 1688. 
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7.5  Prevalence informed consent and assent forms 
7.5.1  Information sheet and informed consent 
Project Title: Determining the prevalence of all stages of noma and n0ma in northwest Nigeria. 
 
Organization:  Médecins sans Frontières (MSF) and the Ministry of Health. 
 
This informed consent has two parts: 
 The information sheet – which gives you information about the study; 
 Certificate of consent study participation – which you will sign to demonstrate that you 
agree to participate with the interview for this study. 
Introduction:  We are conducting this study for Médecins Sans Frontières (MSF) and the 
Ministry of Health in Sokoto to find out how many people have noma in northwest Nigeria. 
MSF has been running a program to assist noma patients in Sokoto Nigeria, and in order to 
better understand the disease and improve these services, we would like to ask community 
members some questions.  
 
What is the study about?  Very little is understood about the disease noma.  We are trying to 
find out how many people have noma in northwest Nigeria. This information might help MSF 
and the Ministry of Health to implement programmes to more efficiently and effectively treat 
noma patients in the future.  
 
Who will participate in the study?  During this study, questions will be asked to community 
members who live in either Sokoto or Kebbi states.  Your village and household was chosen at 
random by the research team. 
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What does the participation in the study request from me? As you are a parent/caretaker of a 
child who lives in either Sokoto or Kebbi States, we will ask you to spend between 15 - 30 
minutes answering some questions and being examined.  
We will conduct the following examinations: 
 Physical oral health exam.
 We would also like to measure the circumference of you/ your child’s upper arm using
this measurement tool (show the MUAC).
 Weight.
 Height.
We will ask you questions about the following things: 
 Vaccinations.
 Previous illness.
 Health seeking practices.
 Feeding practices.
 Water source.
We will also ask if any children under the age of 15 years who live in your household have 
died in the year preceding data collection, and if so, we would like to assess the cause of death 
and so will request to ask you some questions about the signs and symptoms that occurred 
before death.  You do not have to answer any of these questions if you do not wish to. 
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If you do not understand a question, please ask me to explain it to you. If you do not want to 
answer a question or if you would like to stop the survey at any time, please tell me.  Also, if 
you do not want us to conduct any of the measurements, please tell us and we will stop.  
What will happen if the exam shows that my child may have noma?  If the research team think 
your child may have noma, then if it is at a very early stage, the team will give you advice on 
the best things you can do to look after your child.  If the team think your child is at a later 
stage of the sickness, then they will either refer you to your closest health centre or to the Noma 
Children’s Hospital (NCH) in Sokoto, where you will be taken care of by the Ministry of Health 
and MSF.  If the team advises you to go to the NCH, transportation will be provided for you.  
Do we have to participate?  Whether you choose to be in the study or not is up to you.  There 
will be no effect on your family if you decide you do not want to be in the study. 
What will happen with the information that you collect?  The records from this study are 
private.  Only the people who are doing the study can see the answers you give to the questions. 
I will not repeat what you have told me to anyone else. Once we have the results of this study, 
we will send an announcement to the health clinics and you will be able to find out what our 
conclusions are. 
Where will the study take place?  We can conduct the interview anywhere where you feel 
comfortable: in your house, at the clinic, anywhere else in the village. 
Will I or my family receive anything to participate?  You will not get anything, such as money 
or extra food, for taking part in this survey. 
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What are the risks of participating in the study?  You may find some questions upsetting or the 
physical measurements and exams uncomfortable.  If you are uncomfortable at any time, tell 
us and we can stop and skip this question and go on to the next question.   
What might we get from this study?  You are free to stop at any time during the interview.  Once 
we have the results of this study, we will send an announcement to the health clinics and you 
will be able to find out what our conclusions are.  We hope that the results will help us better 
understand noma and contribute to finding better ways to prevent and treat this disease in your 
community. 
Confidentiality:  The records from this study are private.  Only the people who are doing the 
study can see the answers you give to the questions.  I will not repeat what you have told me 
to anyone else.  Answers from everyone who participates in the study will be grouped together 
and looked at and it is these findings that will be published, not your specific answers. 
Approvals:  The ethical aspects of this research have been approved by Médecins Sans 
Frontières Ethics Review Committee and by the Usman Danfodiyo University Teaching 
Hospital (UDUTH) Health Research and Ethics Committee. 
Thank you very much for your time and participation. 
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Consent Certificate Adult Study Participant – Copy Study Team 
Please administer the information sheet before seeking consent! 
I have understood the information sheet and my questions have been answered to my 
satisfaction.  I give voluntary consent to answer all the questions in the questionnaire about the 
child in my care. I understand that I can stop the interview at any time. 
I hereby declare that I consent to the above. 
Date (insert day/month/year of study):     ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦ 
Name of study participant (≥18 years):   __________________________________________ 
Study participant signature/thumb print: __________________________________________ 
Interviewer's name:  __________________________________________________________ 
Interviewer's signature:  _______________________________________________________ 
If the person is illiterate (to be completed by the survey team): 
I have accurately read out the information sheet to the potential participant, and to the best of 
my ability made sure that the participant understands that we will conduct an interview with 
him/her about the child under his/her care. 
I confirm that the participant was given an opportunity to ask questions about the study, and 
all the questions asked by the participant have been answered correctly and to the best of my 
ability. I confirm that the individual has not been coerced into giving consent, and the consent 
has been given freely and voluntarily.  
 A copy of this Consent Certificate has been provided to the participant. 
Date: ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦ [insert day/month/year of the study] 
Interviewer’s name: __________________________________________________________ 
Interviewer’s signature: _______________________________________________________ 
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Consent Certificate Adult Study Participant – Copy Study Participant 
Please administer the information sheet before seeking consent! 
I have understood the information sheet and my questions have been answered to my 
satisfaction. I give voluntary consent to answer all the questions in the questionnaire about the 
child in my care. I understand that I can stop the interview at any time. 
I hereby declare that I consent to the above. 
Date (insert day/month/year of study):     ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦ 
Name of study participant (≥18 years):   __________________________________________ 
Study participant signature/thumb print: __________________________________________ 
Interviewer's name:  __________________________________________________________ 
Interviewer's signature:  _______________________________________________________ 
If the person is illiterate (to be completed by the survey team): 
I have accurately read out the information sheet to the potential participant, and to the best of 
my ability made sure that the participant understands that we will conduct an interview with 
him/her about the child under his/her care. 
I confirm that the participant was given an opportunity to ask questions about the study, and 
all the questions asked by the participant have been answered correctly and to the best of my 
ability. I confirm that the individual has not been coerced into giving consent, and the consent 
has been given freely and voluntarily.  
A copy of this Consent Certificate has been provided to the participant. 
Date: ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦ [insert day/month/year of the study] 
Interviewer’s name: __________________________________________________________ 
Interviewer’s signature: _______________________________________________________ 
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Queries and Concerns:  You can call and speak to us at any time if you want to find out more 
about this research project.  
Local Ethics Committee Details for questions regarding rights as research participants: 
Dr. Nma Jiya, Address: Usman Danfodiyo University Teaching Hospital. 
 Phone: +234 805 038 1688. 
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7.5.2 Information sheet and verbal assent for study participation by child from 8 to 15 
years of age (following informed consent of parent/caretaker). 
Project Title:  Determining the prevalence of all stages of noma and noma in northwest 
Nigeria. 
Organization:  Médecins sans Frontières (MSF) and the Ministry of Health. 
This informed consent has two parts: 
 The information sheet – which gives you information about the study;
 Certificate of consent study participation – which you will sign to demonstrate that you
agree to participate with the interview for this study.
Information Sheet Child Assent  
Introduction:  My name is _______________________________ and I work for the 
organization Médecins sans Frontières (MSF) here in Nigeria.  We are working hard to reduce 
the number of cases of noma in your community and are now doing a study to help us better 
understand how many people are getting sick in Nigeria from this disease and what else we can 
do to help stop new cases from occurring.  
We have already spoken to the head of your household and have also asked your parents for 
their approval to speak to you and ask you to help us in this study.  We will now give you some 
information about the study and what it would mean for you to participate.  You do not have 
to agree to participate if you do not want to, even if your parents agreed. 
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You may discuss anything in this form with your parents or friends or anyone else you feel 
comfortable talking to.  You can decide whether to participate or not after you have talked it 
over.  You do not have to decide immediately. 
There may be some words you don't understand or things that you want me to explain more 
about because you are interested or concerned.  Please ask me to stop at any time and I will 
take time to explain). 
What is the study about?  Very little is understood about the disease noma.  We are trying to 
find out how many people have noma in northwest Nigeria. This information might help MSF 
and the Ministry of Health to implement programmes to more efficiently and effectively treat 
noma patients in the future.  
Who will participate in the study?  During this study, questions will be asked to community 
members who live in either Sokoto or Kebbi States.  Your village and household was chosen 
at random by the research team. 
Do I have to do this?  You can choose if you want to participate in the study or not.  It is 
completely up to you.  If you decide not to participate in this study, that is ok and nothing 
changes.  You and your family can still come to our hospital when you are sick.  If you say yes 
now, but change your mind later to not participate, that is also ok! 
Check that the child understands what you are telling them by asking: “Do you have any 
questions at this point? Do you understand that you do not have to participate in the study if 
you do not want to? 
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I have checked with the child and they understand that participation is voluntary: 
_______________ (initial of study interviewer) 
What is going to happen to me?  As you are a child who lives in either Sokoto or Kebbi States, 
we will ask you to spend between 15 - 30 minutes answering some questions and being 
examined.  
We will conduct the following examinations: 
 Physical oral health exam.
 We would also like to measure the circumference of you/ your child’s upper arm using
this measurement tool (show the MUAC).
 Weight.
 Height.
We will ask you questions about the following things: 
 Vaccinations.
 Previous illness.
 Health seeking practices.
 Feeding practices.
 Water source.
If you do not understand a question, please ask me to explain it to you. If you do not want to 
answer a question or if you would like to stop the survey at any time, please tell me. Also, if 
you do not want us to conduct any of the measurements, please tell us and we will stop.  
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Check that the child understands what you are telling them by asking: “Can you repeat to 
me what you remember from me telling you about what will happen to you as part of this 
study?  
I have checked with the child and they understand that procedures of the study: 
_____________  (initial of study interviewer) 
Is it bad or dangerous for me or will it hurt?  You may find some questions upsetting or the 
physical measurements and exams uncomfortable.  If you are uncomfortable at any time, tell 
us and we can stop and skip this question and go on to the next question.   
Check that the child understands what you are telling them by asking: “Do you understand 
what could be uncomfortable today when we examine you? Can you repeat it back to me?  
I have checked with the child and they understand that risks and discomforts of the study: 
____________  (initial of study interviewer) 
Is there anything good that I might happen to me from this study? 
You will not get anything extra like food or money for participating in this study.  You are free 
to stop at any time during the interview.  
I have checked with the child and they understand that benefits the study: 
_____________  (initial of study interviewer) 
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Is everyone going to know about this and will you tell me the results?  The records from this 
study are private.  Only the people who are doing the study can see the answers you give to the 
questions.  I will not repeat what you have told me to anyone else. Answers from everyone 
who participates in the study will be grouped together and looked at and it is these findings that 
will be published, not your specific answers. 
Once we have the results of this study, we will send an announcement to the health clinics and 
you will be able to find out what our conclusions are.  We hope that the results will help us 
better understand noma and contribute to finding better ways to prevent and treat this disease 
in your community. 
I have checked with the child and they understand that that there is no remuneration for 
participating in the study and that their information will be kept confidential: 
________________  (initial of study interviewer) 
What happens if I get hurt?  We do not think that you will get hurt today, but in case you don’t 
feel well today or later, you can always ask to be referred and we will try and take care of you 
as best as possible. 
Can I withdraw or refuse to participate?  Whether you choose to be in the study or not is up to 
you.  There will be no effect on your family if you decide you do not want to be in the study. 
Who can I talk to if I have a question?  I will give you copy of the information we have talked 
about today and this has my information on it, so you can always come and find me or contact 
me in case you have other questions. 
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I have checked with the child and they understand what to do if they are hurt, that they 
can withdraw/refuse to participate at any time and how to contact us if they have more 
questions: 
_______________  (initial of study interviewer) 
Queries and Concerns:  You can call and speak to us at any time if you want to find out more 
about this research project.  
Local Ethics Committee Details for questions regarding rights as research participants: 
Dr. Nma Jiya, Address: Usman Danfodiyo University Teaching Hospital. 
 Phone: +234 805 038 1688. 
The ethical aspects of this research have been approved by Médecins Sans Frontières Ethics 
Review Committee and by the Usman Danfodiyo University Teaching Hospital (UDUTH) 
Health Research and Ethics Committee. 
Thank you very much for your time and participation. 
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Assent Certificate Child Study Participant – Copy Study Team 
I have read this information (or had the information read to me) and I have had my questions 
answered and know that I can ask questions later if I have them.  
Only if child assents: 
Date: ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦ [insert day/month/year of the study] 
Print name of child: __________________________________________________________ 
Researcher confirms that child offers verbal assent__________________________________ 
Print name of researcher: ______________________________________________________ 
Assent Certificate Child Study Participant – Copy Study Participant 
I have read this information (or had the information read to me) and I have had my questions 
answered and know that I can ask questions later if I have them.  
Only if child assents: 
Date: ¦__¦¦__¦ / ¦__¦¦__¦ / ¦__¦¦__¦ [insert day/month/year of the study] 
Print name of child: __________________________________________________________ 
Researcher confirms that child offers verbal assent__________________________________ 
Print name of researcher: ______________________________________________________ 
 I agree to take part in the research
 I do not wish to take part in the research and have not signed the assent below –
Initials of the child ____________________ 
 I agree to take part in the research
 I do not wish to take part in the research and have not signed the assent below –
Initials of the child __________ 
